sign in sign up
<<
Home , Hydroxynefazodone

HANDBOOK OF

BIOANALYTICALEdition: METHODS January 2015at LAMBDA THERAPEUTIC RESEARCH

Edition: FEBRUARY 2020 Bio-analytical Lambda is one of the most experienced Bioanalytical service providers in India. We provide these services from two different strategic locations - India and Canada. Our highly qualified and experienced scientists work 24x7 and have an accumulated global catalogue of more than 1200 validated methods. Our vast expertise and in-depth understanding of the stringent regulatory demands ensures each project is accomplished in rapid turn-around times.

qualified (Ph. D, M. Pharm, M.Sc, B.Pharm) and experience team comprising of 150+ research professionals

GLP certified Bioanalytical labs in India and Canada

Capabilities of analyzing 90,000+ samples per month on 50+ LC-MS/MS

7-8 new methods in development/month with expertise in handling different matrices such as plasma, serum, urine, whole blood, milk, food, bone, stool and animal tissues

Infrastructure

Separate well equipped extraction labs and chromatography labs.

Separate lab for photosensitive drug. Separate room for storage of standards / balance room.

Low temperature storage (-22 ± 5 °C, -65 ± 10 °C)

Biolyte (Chromatographic Data review and data printing software)

Different types of 50+ LC-MS/MS systems (including API 6500 and Waters Xevo TQ-S)

Regulatory Track Record

Table of Contents

Title Page

Large Molecules / Therapeutic Proteins / Biosimilars ...... 1

Small Molecules ...... 2

New Chemical Entities ...... 71

In‐Vitro Studies ...... 72

Immunogenicity Assesment ...... 73

PD Markers ...... 74

Evaluation Of Effectiveness Of Healthcare Hygiene Products ...... 76

Lambda Therapeutic Research

LARGE MOLECULES / THERAPEUTIC PROTEINS / BIOSIMILARS Instrument/Method of Sr. No. Drug Name Matrix Range Anticoagulant Dose Analysis Location : India Human 1 Bevacizumab Sandwich ELISA 150 to 6000 ng / mL NA NA Serum Human 2 *Bevacizumab LC-MS/MS (6500 QTRAP) 5 to 500 µg / mL NA NA Serum Human 3 Darbepoetin Sandwich ELISA 0.075 to 2.6 ng / mL NA 0.45µg/kg Serum Human 4 Denosumab Sandwich ELISA 160 to 10000 ng / mL NA 60 mg Serum Human 5 Erythropoietin Sandwich ELISA 5.005 to 200 mIU / mL NA 50IU/kg Serum Human 6 Etanercept Sandwich ELISA 39.063 to 5000 ng / mL NA 50mg Serum Human 7Glucagon LC-MS/MS (Waters XEVO TQ-S) 0.2 to 10 ng / mL K EDTA 1 mg/vial Plasma 2 Human 8 PEG G-CSF Sandwich ELISA 0.150 to 10 ng / mL NA 6mg /0.6 mL SC Serum Electrochemiluminescence Human 0.156 to 20 mIU/mL 9 rHu-FSH NA 300 IU Immunoassay Serum Human 10 Rituximab Competitive ELISA 50 to 1502 ng / mL K EDTA 100mg/10mL Plasma 2 Human 11 *Romiplostim Sandwich ELISA 0.040 to 5.000 ng/mL NA 250 µg/0.5 mL Serum

12 *Teriparatide LC-MS/MS (6500 QTRAP) Human 5 to 500 pg / mL NA NA Serum Human 13 Teriparatide Sandwich ELISA 10 to 400 pg / mL NA NA Serum Human 14 Trastuzumab LC-MS/MS (6500 QTRAP) 5 to 500 µg / mL NA 8 mg / Kg Serum Human 15 *Trastuzumab Competitive ELISA 9.7 to 625 ng / mL NA NA Serum *: Developed method available

Page 1 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method A Location : Canada

LC-MS/MS Human 1 Acetaminophen 0.1 to 13 µg / mL K EDTA - (API 300 or 3000) Plasma 2 LC-MS/MS Human 2 Acetaminophen 0.1 to 13 µg / mL K EDTA 320 mg (Waters QPXE) Plasma 2 Human 3 Acyclovir HPLC-UV 5 to 1280 ng / mL Heparin - Plasma HPLC Human Sodium 4 Acyclovir 10 to 2560 ng / mL - - Flurosence Plasma heparin HPLC Human Sodium 5 Acyclovir 20 to 2560 ng / mL - Flurosence Plasma heparin LC-MS/MS Human 6 Acyclovir 5 to 1600 ng / mL K EDTA 200 mg (Thermo) Plasma 2 LC-MS/MS Human 7 Alverine 0.05 to 10 ng / mL K EDTA 120 mg (Thermo) Plasma 2 LC-MS/MS Human 8 Allopurinol 10 to 5000 ng/mL K EDTA 200 mg (Thermo) Plasma 2 LC-MS/MS Human 9Amantadine 2 to 1500 ng / mL K EDTA 300mg (Waters QPXE) Plasma 2 LC-MS/MS Human Not 10 Amantadine 20 to 3000 ng / mL 160 mg (Thermo) Urine applicable LC-MS/MS Human 0.4 to 51 ng / mL K EDTA - (API 3000) Plasma 2 11 LC-MS/MS Human 0.4 to 51 ng / mL K EDTA - (API 3000) Plasma 2 LC-MS/MS Human 12 Amlodipine 0.1 to 13 ng / mL K EDTA 10 mg (API 3000) Plasma 3 LC-MS/MS Human D- 0.5 to 100 ng / mL K EDTA (API 6500) Plasma 2 13 30 mg LC-MS/MS Human L-Amphetamine 0.15 to 30 ng/mL K EDTA (API 6500) Plasma 2 C A N D LC-MS/MS Human 14 Amphotericin B 5 to 5000 ng / mL K EDTA 200 to 400 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 15 Alectinib 1 to 600 ng/mL K EDTA 50mg (Thermo) Plasma 2 LC-MS/MS Human 16 Alectinib 1 to 600 ng/mL K EDTA 150 mg (Thermo) Plasma 2 LC-MS/MS Human Not 17 Alendronate 1 to 256 ng / mL - (API 3000) Urine applicable LC-MS/MS Human 18 Anastrozole 0.1 to 26 ng / mL K EDTA 1 mg (API 3000) Plasma 2 LC-MS/MS Human 19 0.500 to 500 ng/mL K EDTA 10 mg (Thermo) Plasma 2 LC-MS/MS Human 20 Atomoxetine 2.5 to 2500 ng/mL K EDTA 60 mg (Thermo) Plasma 2 LC-MS/MS Human Atomoxetine 2 to 512 ng / mL K EDTA 40 mg (Thermo) Plasma 2 LC-MS/MS Human 21 4-Hydroxyatomoxetine 2 to 512 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human N-Desmethylatomoxetine 2 to 512 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human Sodium 22 Atorvastatin 0.3 to 300 ng/mL 80 mg (Thermo) Plasma heparin LC-MS/MS Human Atorvastatin 0.4 to 102 ng / mL K EDTA 80 mg (Thermo) Plasma 2 LC-MS/MS Human 23 o-hydroxyatorvastatin 0.4 to 102.5 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human p-hydroxyatorvastatin 0.04 to 10 ng / mL K EDTA - (Thermo) Plasma 2

Page 2 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Dog Atorvastatin 0.25 to 2500 ng / mL K EDTA 5 mg to 80 mg (Thermo) Plasma 2 LC-MS/MS Dog o-hydroxyatorvastatin 0.25 to 500 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Dog p-hydroxyatorvastatin 0.25 to 500 ng / mL K EDTA - (Thermo) Plasma 2 24 LC-MS/MS Dog Atorvastatin Lactone 0.5 to 2500 ng / mL K EDTA - (Thermo) Plasma 2 o-Hydroxy Atorvastatin LC-MS/MS Dog 0.5 to 250 ng / mL K EDTA - Lactone (Thermo) Plasma 2 p-Hydroxy Atorvastatin LC-MS/MS Dog 0.5 to 250 ng / mL K EDTA - Lactone (Thermo) Plasma 2 LC-MS/MS Dog Atorvastatin 10 to 2500 ng / mL K EDTA 5 mg to 80 mg (Thermo) Plasma 2 LC-MS/MS Dog o-hydroxyatorvastatin 1 to 250 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Dog p-hydroxyatorvastatin 1 to 250 ng / mL K EDTA - (Thermo) Plasma 2 25 LC-MS/MS Dog Atorvastatin Lactone 10 to 2500 ng / mL K EDTA - (Thermo) Plasma 2 o-Hydroxy Atorvastatin LC-MS/MS Dog 1 to 250 ng / mL K EDTA - Lactone (Thermo) Plasma 2 p-Hydroxy Atorvastatin LC-MS/MS Dog 1 to 250 ng / mL K EDTA - Lactone (Thermo) Plasma 2 C A N D LC-MS/MS Human Atorvastatin 10 to 15000 pg / mL K EDTA 10 mg (Thermo) Plasma 2 LC-MS/MS Human 26 o-Hydroxy Atorvastatin 10 to 10000 pg / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human p-Hydroxy Atorvastatin 10 to 5000 pg / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human Atorvastatin 0.1 to 40 ng / mL K EDTA 20 mg (Thermo) Plasma 2 LC-MS/MS Human o-Hydroxy Atorvastatin 0.1 to 40 ng / mL K EDTA - (Thermo) Plasma 2 27 LC-MS/MS Human p-Hydroxy Atorvastatin 0.05 to 20 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human Glimepiride 0.5 to 200 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human 28 Atazanavir 20 to 8000 ng/mL K EDTA 300 mg (Thermo) Plasma 2 LC-MS/MS Human 29 Axitinib 0.1 to 100 ng/mL K EDTA 5 mg (Thermo) Plasma 2 LC-MS Human Sodium 30 Azithromycin 5 to 1280 ng / mL 600 mg (API 150) Plasma heparin Location : India LC-MS/MS Human 31 Abacavir 10 to 6000 ng / mL K EDTA 300 mg (Waters QPXE) Plasma 2 LC-MS/MS Human Abacavir 25 to 12000 ng / mL K EDTA 600 mg (Waters QPXE) Plasma 2 32 LC-MS/MS Human Lamivudine 25 to 6000 ng / mL K2EDTA 300 mg

I N D I A D I N (Waters QPXE) Plasma LC-MS/MS Human Abacavir 25 to 10000 ng / mL K EDTA 300mg (Waters QPXE) Plasma 2 33 LC-MS/MS Human Lamivudine 20 to 5000 ng / mL K EDTA 150mg (Waters QPXE) Plasma 2

Page 3 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human Abacavir 25 to 6000 ng/mL K EDTA 300mg (Shimadzu 8045) Plasma 2 34 LC-MS/MS Human Lamivudine 20 to 5000 ng/mL K EDTA 150mg (Shimadzu 8045) Plasma 2 LC-MS/MS Human 35 Abiraterone 0.250 to 100 ng/mL K EDTA 250 mg (Thermo) Plasma 2 LC-MS/MS Human 2 X 333 mg i.e. 36 Acamprosate 0.5 to 400 ng / mL K EDTA (Thermo) Plasma 2 666mg dose LC-MS/MS Human 37 Acetazolamide 0.1 to 40 μg/mL K EDTA 500 mg (API 3200) Plasma 2 LC-MS/MS Human Sodium 38 Aceclofenac 75 to 22000 ng / mL 100 mg (API 2000) Plasma heparin Human K EDTA / Acetyl salicylic acid HPLC-UV 0.05 to 8 µg / mL 2 650 mg Plasma Heparin 39 Human K EDTA / Salicylic acid HPLC-UV 0.4 to 40 µg / mL 2 - Plasma Heparin LC-MS/MS Human Acetyl salicylic acid 2.5 to 500 ng/ mL K EDTA 25 mg (API 4000) Plasma 2 40 LC-MS/MS Human Salicylic acid 100 to 6000 ng / mL K EDTA - (API 4000) Plasma 2 LC-MS/MS Human 41 Acetyl salicylic acid 2.5 to 750 ng / mL K EDTA 25 mg (API 4000) Plasma 2 LC-MS/MS Human Acetyl salicylic acid 2.5 to 1500 ng / mL K EDTA 100 mg (API 4000) Plasma 2 42 LC-MS/MS Human Salicylic acid 150 to 10000 ng / mL K EDTA - (API 4000) Plasma 2 LC-MS/MS Human Acitretin (Shimadzu 1 to 400 ng / mL K EDTA 25 mg Plasma 2 8060) 43 LC-MS/MS Human 13-Cis - Acitretinin (Shimadzu 0.5 to 100 ng / mL K EDTA - Plasma 2 8060)

I N D I A D I N LC-MS/MS Human 44 1 to 300 ng / mL K EDTA 8mg (API 4000) Plasma 2

LC-MS/MS Human Albendazole 0.3 to 150 ng / mL K EDTA 400mg (Waters QPXE) Plasma 2 45 Albendazole LC-MS/MS Human 5 to 2500 ng / mL K EDTA NA Sulfoxide (Waters QPXE) Plasma 2

LC-MS/MS Human 46 Albuterol 0.1 to 30 ng/mL K EDTA 4 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 47 Alectinib 1 to 600 ng/mL K EDTA 150 mg (API 4000) Plasma 2

LC-MS/MS Human 48 *Alendronate 2 to 600 ng / mL NA 70 mg (API 4000) Urine

LC-MS/MS Human 49 *Alendronate 0.3 to 150 ng / mL K EDTA 70 mg (API 4000) Plasma 2

LC-MS/MS Human 50 *Alendronate 0.05 to 20 ng / mL K EDTA 10 mg (Thermo) Plasma 2

LC-MS/MS Human 51 Allopurinol 10 to 5000 ng / mL K EDTA 300 mg (API 3200) Plasma 2

LC-MS/MS Human Allopurinol 15 to 5000 ng / mL K EDTA 300 mg (Waters QPXE) Plasma 2 52 LC-MS/MS Human Oxypurinol 50 to 10000 ng / mL K EDTA - (Waters QPXE) Plasma 2

Page 4 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method

LC-MS/MS Human 53 Alogliptin 1 to 300 ng / mL K EDTA 25 mg (API 3200) Plasma 2

LC-MS/MS Human 54 Alogliptin 0.5 to 150 ng / mL K2EDTA 12.5 mg (API 4000) Plasma

LC-MS/MS Human 55 Alverine 20 to 7500 pg/mL K EDTA 120 mg (API 4000) Plasma 2

LC-MS/MS Human 56 Amantadine 2 to 600 ng / mL K2EDTA 100 mg (Thermo) Plasma LC-MS/MS Human 57 Ambrisentan 5 to 1500 ng/mL K2EDTA 10 mg (Thermo) Plasma LC-MS/MS Human Sodium 58 Amlodipine 0.2 to 10 ng / mL 5 mg / 10 mg (API 4000) Plasma heparin LC-MS/MS Human *Amlodipine (R ) 0.1 to 5 ng / mL K EDTA 5 mg / 10 mg (API 4000) Plasma 2 59 LC-MS/MS Human *Amlodipine (S) 0.1 to 7.5 ng / mL K EDTA 5 mg / 10 mg (API 4000) Plasma 2 LC-MS/MS Human Sodium *Amlodipine (R ) 0.1 to 5 ng / mL 5 mg / 10 mg (API 4000) Plasma heparin 60 LC-MS/MS Human Sodium *Amlodipine (S) 0.1 to 7.5 ng / mL 5 mg / 10 mg (API 4000) Plasma heparin LC-MS/MS Human *Amlodipine (R ) 0.05 to 5 ng/mL K EDTA 5 mg (API 4000) Plasma 2 61 LC-MS/MS Human *Amlodipine (S) 0.05 to 7 ng/mL K EDTA 5 mg (API 4000) Plasma 2 LC-MS/MS Human Amlodipine 0.2 to 10 ng / mL K EDTA 10 mg (API 4000) Plasma 2 62 LC-MS/MS Human Olmesartan 2.5 to 2200 ng / mL K EDTA 40 mg (API 4000) Plasma 2 LC-MS/MS Human Amlodipine 0.1 to 7 ng / mL K EDTA 10 mg (API 4000) Plasma 2

I N D I A D I N 63 LC-MS/MS Human Valsartan 50 to 8000 ng / mL K EDTA 160 mg (API 4000) Plasma 2 LC-MS/MS Human Amlodipine 0.1 to 15 ng / mL K EDTA 10 mg (API 4000) Plasma 2 64 LC-MS/MS Human Valsartan 50 to 20000 ng / mL K EDTA 320 mg (API 4000) Plasma 2 LC-MS/MS Human Amlodipine 0.15 to 10 ng / mL K EDTA 10 mg (Waters QPXE) Plasma 2 65 LC-MS/MS Human Telmisartan 2 to 1000 ng / mL K EDTA 80 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 66 Amiloride 0.15 to 20 ng / mL K EDTA 5 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 67 3 to 1500 ng / mL K EDTA 200 mg (Waters QPXE) Plasma 2 LC-MS/MS Human Amiodarone 1 to 300 ng / mL K EDTA 200 mg (Waters QPXE) Plasma 2 68 N-Desethyl LC-MS/MS Human 2 to 100ng / mL K EDTA - Amiodarone (Waters QPXE) Plasma 2 LC-MS/MS Human Amitriptyline 0.1 to 30 ng / mL K EDTA 25 mg (Waters QPXE) Plasma 2 69 LC-MS/MS Human Nortriptyline 0.2 to 15 ng / mL K EDTA - (Waters QPXE) Plasma 2 LC-MS/MS Human Amitriptyline 0.1 to 50 ng/mL K EDTA 25 mg (Waters QPXE) Plasma 2 70 LC-MS/MS Human Nortriptyline 0.2 to 18 ng/mL K EDTA - (Waters QPXE) Plasma 2 LC-MS/MS Human 71 Amitriptiline 0.3 to 90 ng/mL K EDTA 25mg (Waters QPXE) Plasma 2 LC-MS/MS Human 72 Amitriptiline 0.15 to 30 ng/mL K EDTA 10 mg (Waters QPXE) Plasma 2

Page 5 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human Amodiaquine 0.5 to 100 ng / mL K EDTA 150 mg (Waters QPXE) Plasma 2 73 N-desethyl LC-MS/MS Human 2 to 500 ng / mL K EDTA - Amodiaquine (Waters QPXE) Plasma 2 LC-MS/MS Human 74 Amoxicillin 0.1 to 35 µg / mL K EDTA 1 gm (Waters QPXE) Plasma 2 Human K EDTA / 75 Amoxicillin HPLC-UV 0.5 to 15 µg / mL 2 500 mg Plasma Heparin LC-MS/MS Human 76 Amoxicillin 0.05 to 12 µg / mL K EDTA 250 mg (Waters QPXE) Plasma 2 LC-MS/MS Human Sodium 77 Amoxicillin 75 to 35000 ng / mL 500 mg (Waters XEVO TQ-S) Plasma heparin LC-MS/MS Human 100 to Sodium Amoxicillin 400 mg (API 4000) Plasma 15000 ng / mL heparin 78 LC-MS/MS Human Sodium Clavulanic acid 5 to 2000 ng / mL 57 mg (API 4000) Plasma heparin LC-MS/MS Human Sodium Amoxyxillin 75 to 35000 ng / mL 600 mg (Waters QPXE) Plasma Heparin 79 LC-MS/MS Human Sodium Clavulanic acid 10 to 3450 ng / mL 42.9 mg (Waters QPXE) Plasma Heparin Human 80 Amphotericin B HPLC-UV 0.25 to 10 µg / mL K EDTA 2 mg Plasma 2 LC-MS/MS Human 0.6 mg/kg to 1.5 81 Amphotericin-B 5 to 5000 ng / mL K EDTA (API 4000) Plasma 2 mg/kg LC-MS/MS Human 82 Amphotericin B 100 to 2000 pg / mL K EDTA NA (Waters XEVO TQ-S) Plasma 2 LC-MS/MS Human 83 Amphotericin-B (Total) 0.5 to 100 µg / mL K EDTA 20 mg/kg (Thermo) Plasma 2 *Amphotericin B (free) LC-MS/MS Human 84 10 to 3000 ng / mL K EDTA 50mg/vial (Liposomal) (API 4000) Plasma 2 LC-MS/MS Human 85 *Amphotericin B (free) 10 to 3000 ng/mL K EDTA 3mg/KG (Shimadzu 8045) Plasma 2 *Amphotericin B Encapsulated LC-MS/MS Human 2mg/kg(50mg 86 0.25 to 75 µg/mL K EDTA & Total (Shimadzu 8045) Plasma 2 Injection)

I N D I A D I N LC-MS/MS Human 87 *Amphotericin-B (Free) 10 to 5000 ng/mL K EDTA 3mg/kg & 2mg/kg (Shimadzu 8045) Plasma 2 *Amphotericin B Encapsulated LC-MS/MS Human 88 0.25 to 75 µg/mL K EDTA 3mg/kg & 2mg/kg & Total (Shimadzu 8045) Plasma 2 LC-MS/MS Human Sodium 89 Anastrozole 0.25 to 25 ng / mL 1 mg (API 3200) Plasma heparin LC-MS/MS Human 90 *Anagrelide 0.05 to 10 ng / mL K EDTA 0.5 mg (Thermo) Plasma 3 LC-MS/MS Human 91 Apixaban 0.25 to 300 ng / mL K EDTA 50 mg (Thermo) Plasma 2 Apovincaminic LC-MS/MS Human 5 mg of 92 0.25 to 50 ng / mL K EDTA acid (Waters QPXE) Plasma 2 Vinpocetine LC-MS/MS Human 15 mg of 93 Apovincaminic acid 0.5 to 180 ng / mL K EDTA (Waters QPXE) Plasma 2 Vinpocetine LC-MS/MS Human 94 Apremilast 1 to 600 ng / mL K2EDTA 30 mg (API 4000) Plasma LC-MS/MS Human 0.1 to 50 ng / mL K EDTA 5 mg (Waters QPXE) Plasma 2 95 LC-MS/MS Human Dehydro aripiprazole 0.1 to 50 ng / mL K EDTA - (Waters QPXE) Plasma 2 LC-MS/MS Human 96 Aripiprazole 0.5 to 150 ng / mL K EDTA 10 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 97 Aripiprazole 0.5 to 50 ng / mL K EDTA 5 mg (Waters QPXE) Plasma 2 LC-MS/MS Human Artemether 2 to 200 ng / mL K EDTA 80 mg (API 4000) Plasma 2 98 LC-MS/MS Human Dihydroartemisinin 2 to 250ng / mL K EDTA 80 mg (API 4000) Plasma 2 LC-MS/MS Human 99 Atazanavir 10 to 5000 ng/mL K EDTA 300 mg (Thermo) Plasma 2 LC-MS/MS Human 100 Atazanavir 10 to 5000 ng / mL K EDTA 300 mg (Waters QPXE) Plasma 2

Page 6 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 101 Atazanavir 10 to 5000 ng/mL K EDTA 300 mg (API 4000) Plasma 2 Human K EDTA / 102 HPLC - Flurosence 10 to 800 ng / mL 2 100 mg Plasma Heparin LC-MS/MS Human Atenolol 5 to 1000 ng / mL K EDTA 50 mg (Waters QPXE) Plasma 2 103 LC-MS/MS Human Nifedipine 0.5 to 150 ng / mL K EDTA 20 mg (Waters QPXE) Plasma 2 LC-MS/MS Human Atorvastatin 0.1 to 40 ng / mL K EDTA 20 mg (Thermo) Plasma 2 LC-MS/MS Human 104 O-Hydroxy Atorvastatin 0.1 to 40 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human P-Hydroxy Atorvastatin 0.05 to 20 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human Atorvastatin 0.3 to 300 ng / mL K EDTA 80 mg (API 4000) Plasma 2 LC-MS/MS Human 105 O-Hydroxy Atorvastatin 0.25 to 150 ng / mL K EDTA - (API 4000) Plasma 2 LC-MS/MS Human P-Hydroxy Atorvastatin 0.05 to 15 ng / mL K EDTA - (API 4000) Plasma 2 LC-MS/MS Human Atorvastatin 0.3 to 125 ng / mL K EDTA 40 mg (API 4000) Plasma 2 LC-MS/MS Human 106 O-Hydroxy Atorvastatin 0.25 to 70 ng / mL K EDTA - (API 4000) Plasma 2 LC-MS/MS Human P-Hydroxy Atorvastatin 0.05 to 6 ng / mL K EDTA - (API 4000) Plasma 2 LC-MS/MS Human 107 Atorvastatin 0.1 to 40 ng / mL K EDTA 20 mg (API 3200) Plasma 2 LC-MS/MS Human 108 Atorvastatin 0.1 to 60 ng / mL K EDTA 40 mg (Thermo) Plasma 2 LC-MS/MS Human 109 Atorvastatin 0.1 to 150 ng / mL K EDTA 80 mg (API 3200) Plasma 2

I N D I A D I N LC-MS/MS Human 110 Atorvastatin 0.1 to 150 ng/mL K EDTA 80 Mg (API 4000) Plasma 2 LC-MS/MS Human 111 Atovaquone 10 to 5000 ng / mL K EDTA 250 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 112 Atovaquone 30 to 7500 ng/mL K EDTA 750 mg / 5 mL (API 3200) Plasma 2 LC-MS/MS Human 113 Atovaquone 100 to 20000 ng/mL K EDTA 750 mg / 5 mL fed (API 4000) Plasma 2 LC-MS/MS Human Sodium 114 *5-Azacytidine 5 to 3000 ng / mL 100 mg (Waters QPXE) Plasma heparin LC-MS/MS Human 115 Azathioprine 0.15 to 50 ng/mL K EDTA 50 mg (Thermo) Plasma 2 LC-MS/MS Human * 5 to 1000 pg / mL K EDTA 0.56 mg (Thermo) Plasma 2 116 *N-desmethyl LC-MS/MS Human 7 to 500 pg / mL K EDTA - Azelastine (Thermo) Plasma 2

LC-MS/MS Human 117 Azithromycin 5 to 1000 ng / mL K EDTA 600 mg (API 3200) Plasma 2

LC-MS/MS Human 118 Azithromycin 1 to 500 ng/mL K EDTA 200mg/5mL (Shimadzu 8045) Plasma 2 LC-MS/MS Human 119 Azithromycin (Shimadzu 5 to 1010 ng/mL K EDTA 200mg/5 mL Plasma 2 8045) LC-MS/MS Human 120 Azithromycin 1 to 250 ng / mL K EDTA 200 mg (API 3200) Plasma 2

Page 7 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method B Location : Canada

LC-MS/MS Human 121 Barnidipine 50 to 10000 ng/mL K EDTA 20 mg (Thermo) Plasma 2

LC-MS/MS Human 122 Barnidipine 15 to 7000 pg/mL K EDTA 20mg (Thermo) Plasma 2

LC-MS/MS Human 123 R-Baclofen 1 to 500 ng / mL K EDTA 10 mg (Thermo) Plasma 2

LC-MS/MS Human R-Baclofen 1 to 500 ng / mL K EDTA 20 mg (Thermo) Plasma 2 124 LC-MS/MS Human S-Baclofen 1 to 500 ng / mL K EDTA 20 mg (Thermo) Plasma 2

LC-MS/MS Human Not R-Baclofen 2 to 2000 ng / mL 20 mg (Thermo) Urine applicable 125 LC-MS/MS Human Not S-Baclofen 2 to 2000 ng / mL 20 mg (Thermo) Urine applicable

LC-MS/MS Human Betamethasone 0.5 to 128 ng / mL K EDTA - (Thermo) Plasma 2

Betamethasone LC-MS/MS Human 126 0.5 to 128 ng / mL K EDTA - Acetate (Thermo) Plasma 2

Betamethasone LC-MS/MS Human 2 to 512 ng / mL K EDTA - Phosphate (Thermo) Plasma 2 C A N D LC-MS/MS Human Sodium 127 Budesonide 20 to 10000 pg/mL 3 x 3 mg (API 6500) Plasma heparin

LC-MS/MS Human or Sodium 1 to 1023 ng / mL 348 mg (API 3000) Rat Plasma heparin

Bupropion Erythroamino LC-MS/MS Human or Sodium 1 to 1024 ng / mL - (API 3000) Rat Plasma heparin 128 Bupropion Threoamino LC-MS/MS Human or Sodium 1 to 1024 ng / mL - Alcohol (API 3000) Rat Plasma heparin

LC-MS/MS Human or Sodium 3 to 4000 ng / mL - (API 3000) Rat Plasma heparin

LC-MS/MS Human Sodium Bupropion 1 to 512 ng / mL 174 mg (API 3000) Plasma heparin

Bupropion Erythroamino LC-MS/MS Human Sodium 1 to 512 ng / mL - Alcohol (API 3000) Plasma heparin 129 Bupropion Threoamino LC-MS/MS Human Sodium 1 to 512 ng / mL - Alcohol (API 3000) Plasma heparin

LC-MS/MS Human Sodium Hydroxybupropion 4 to 2000 ng / mL - (API 3000) Plasma heparin

Page 8 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human Not Bupropion 16 to 1024 ng / mL 174 mg (API 3000) Urine applicable

Bupropion Erythroamino LC-MS/MS Human Not 16 to 1024 ng / mL - Alcohol (API 3000) Urine applicable 130 Bupropion Threoamino LC-MS/MS Human Not 16 to 1024 ng / mL - Alcohol (API 3000) Urine applicable

LC-MS/MS Human Not Hydroxybupropion 62.5 to 4000 ng / mL - (API 3000) Urine applicable

LC-MS/MS Rat Sodium Bupropion 5 to 5120 ng / mL - (Thermo) Plasma heparin

Bupropion Erythroamino LC-MS/MS Rat Sodium 1 to 1024 ng / mL - Alcohol (Thermo) Plasma heparin 131

Bupropion Threoamino LC-MS/MS Rat Sodium 1 to 1024 ng / mL - Alcohol (Thermo) Plasma heparin LC-MS/MS Rat Sodium Hydroxybupropion 2 to 2048 ng / mL - (Thermo) Plasma heparin Human LC-MS/MS Plasma Sodium Buprenorphine 0.1 to 25 ng / mL - (API 3000) or Dog heparin Plasma 132 Human LC-MS/MS Plasma Sodium Norbuprenorphine 0.1 to 25 ng / mL - (API 3000) or Dog heparin Plasma LC-MS/MS Human Sodium Buprenorphine 25 to 10000 pg / mL 8 mg (API 6500) Plasma heparin 133 LC-MS/MS Human Sodium Norbuprenorphine 50 to 10000 pg / mL -

C A N D (API 6500) Plasma heparin LC-MS/MS Human Sodium (API 300 0.02 to 10 ng / mL - Plasma heparin or 3000) 134 LC-MS/MS Human Sodium 1-(2-Pyrimidyl) (API 300 0.2 to 25 ng / mL - Plasma heparin or 3000) Human LC-MS/MS Plasma Buspirone 0.4 to 77 ng / mL K EDTA - (API 3000) or Mouse 3 135 Plasma Human LC-MS/MS Plasma 1-(2-Pyrimidyl)Piperazine 1.6 to 307.2 ng / mL K EDTA - (API 3000) or Mouse 3 Plasma Human Plasma or Mouse LC-MS/MS Plasma Sodium Buspirone 0.05 to 10 ng / mL - (API 3000) or Rat heparin Plasma or Dog Plasma 136 Human Plasma or Mouse LC-MS/MS Plasma Sodium 1-(2-Pyrimidyl)Piperazine 0.2 to 38 ng / mL - (API 3000) or Rat heparin Plasma or Dog Plasma

Page 9 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method Human Plasma LC-MS/MS or Rat Buspirone (API 300 0.4 to 50 ng / mL Heparin - Plasma or 3000) or Dog Plasma 137 Human Plasma LC-MS/MS or Rat 1-(2-Pyrimidyl) Piperazine (API 300 0.4 to 50 ng / mL Heparin - Plasma or 3000) or Dog Plasma C A N D LC-MS/MS Human Sodium Buspirone 0.04 to 10 ng / mL - (API 3000) Plasma heparin LC-MS/MS Human Sodium 138 1-(2-Pyrimidyl)Piperazine 0.15 to 40 ng / mL - (API 3000) Plasma heparin LC-MS/MS Human Sodium 6-Hydroxybuspirone 0.625 to 160 ng / mL - (API 3000) Plasma heparin Location : India LC-MS/MS Human 139 *Baclofen(R & S) (Shimadzu 1 to 500 ng/mL K EDTA 25 mg Plasma 2 8045) LC-MS/MS Human Benazepril 2 to 2500 ng / mL K EDTA 40 mg (Waters QPXE) Plasma 2 140 LC-MS/MS Human Benazeprilat 3 to 1500 ng / mL K EDTA - (Waters QPXE) Plasma 2

LC-MS/MS Human Benazepril 0.5 to 250 ng / mL K EDTA 10 mg (Waters QPXE) Plasma 2 141 LC-MS/MS Human Benazeprilat 0.5 to 500 ng / mL K EDTA - (Waters QPXE) Plasma 2

LC-MS/MS Human 142 Bendroflumethiazide 0.5 to 250 ng/mL K EDTA 5mg (Waters QPXE) Plasma 2

LC-MS/MS Human Bendroflumethiazide 0.1 to 70 ng/mL K EDTA 2.5 mg (Thermo) Plasma 2 143 LC-MS/MS Human Bendroflumethiazide impurity 0.1 to 15 ng/mL K EDTA 2.5 mg (Thermo) Plasma 2 I N D I A D I N LC-MS/MS Human Benzbromarone 10 to 5000 ng/mL K EDTA 50mg (Waters QPXE) Plasma 2 144 LC-MS/MS Human 6-Hydroxy benzbromarone 10 to 3000 ng/mL K EDTA 50mg (Waters QPXE) Plasma 2

LC-MS/MS Human 145 Benzhexol 0.02 to 20 ng/mL K EDTA 2mg (Shimadzu 8060) Plasma 2

LC-MS/MS Human 146 Bestatin 10 to 1500 ng/mL K EDTA 10mg (Waters QPXE) Plasma 2

LC-MS/MS Human 147 * 7.5 to 2000 pg/mL K EDTA 24 and 48 mg (API 6500) Plasma 2

LC-MS/MS Human 148 Bexarotene 1 to 500 ng / mL K EDTA 75 mg (API 3200) Plasma 2

LC-MS/MS Human 149 Bezafibrate 80 to 22000 ng/mL K EDTA 200mg/400mg (API 4000) Plasma 2

Page 10 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method

LC-MS/MS Human 150 Bezafibrate 20 to 22000 ng/mL K EDTA 400 mg (API 4000) Plasma 2

LC-MS/MS Human 10 to to 151 Bicalutamide Heparin 25 mg (API 2000) Plasma 1000 ng / mL

LC-MS/MS Human 152 Bicalutamide 25 to 4500 ng/mL K EDTA 150mg (API 3200) Plasma 2

LC-MS/MS Human 153 Bicalutamide 50 to 2000 ng / mL K EDTA / Heparin 50 mg (API 2000) Plasma 2

LC-MS/MS Human 100 to 154 Bicalutamide K EDTA 150 mg (API 2000) Plasma 5000 ng / mL 2

LC-MS/MS Human 155 *Bicalutamide (R & S) 5 to 1000 ng / mL K EDTA 50 mg (Waters QPXE) Plasma 2

LC-MS/MS Human *R- Bicalutamide 5 to 2500 ng/mL K EDTA 150 mg (API 3200) Plasma 2 156 LC-MS/MS Human *S- Bicalutamide 4 to 1000 ng/mL K EDTA NA (API 3200) Plasma 2

LC-MS/MS Human 157 Bictegravir 30 to 12000 ng/mL K EDTA 50mg Fast/Fed (Waters QPXE) Plasma 2

LC-MS/MS Human 158 2 to 600 ng/mL K EDTA 20mg (API 4000) Plasma 2

LC-MS/MS Human 159 0.5 to 80 ng / mL K EDTA 10 mg (API 3200) Plasma 2

LC-MS/MS Human 160 Bosentan 5 to 6000 ng / mL K EDTA 125 mg (API 3200) Plasma 2

I N D I A D I N 62.5 µg/kg to 250 LC-MS/MS Rat Sodium 161 *Bortezomib 0.5 to 500 ng / mL µg/kg (Thermo) Plasma heparin (Subcutaneous) LC-MS/MS Rat Sodium 62.5 µg/kg to 250 162 *Bortezomib 2 to 8000 ng / mL (Waters QPXE) Plasma heparin µg/kg (IV) LC-MS/MS Human 163 0.25 to 60 ng / mL K EDTA 2mg (Thermo) Plasma 2

LC-MS/MS Human 164 *Budesonide 5 to 4000 pg / mL K EDTA 3 mg (Waters XEVO TQ-S) Plasma 2

LC-MS/MS Human Sodium 165 *Budesonide 20 to 10000 pg / mL 3 X 3 mg (Thermo) Plasma heparin LC-MS/MS Human Sodium 166 *Budesonide (Waters 20 to 10000 pg / mL 3X3 mg Plasma heparin XEVO TQ-S) LC-MS/MS Human 167 *Budesonide (Shimadzu 10 to 5000 ng/mL K EDTA 3 mg Plasma 2 8060) LC-MS/MS Human 1mg/2mL 168 *Budesonide 5 to 5000 pg/mL K EDTA (Shimadzu 8060) Plasma 2 inhalation 1mg/2mL LC-MS/MS Human 169 *Budesonide 5 to 5000 pg/mL K EDTA inhalation single (Waters XEVO TQ-S) Plasma 2 dose LC-MS/MS Human 170 *Budesonide 10 to 5000 pg / mL K EDTA 800mcq (Waters XEVO TQ-S) Plasma 2

LC-MS/MS Human 20 to 171 Buspirone K EDTA 15 mg (Waters QPXE) Plasma 30000 pg / mL 2

Page 11 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method

LC-MS/MS Human 172 Bupropion 1 to 400 ng/mL K EDTA 150 mg (API 4000) Plasma 2

LC-MS/MS Human 173 Bupropion 1 to 400 ng/mL K EDTA 150 mg Yes (Shimadzu 8045) Plasma 2

LC-MS/MS Human 174 Bupropion 1 to 400 ng / mL K EDTA 300 mg/150mg (Waters QPXE) Plasma 2

LC-MS/MS Human Bupropion 0.5 to 250 ng / mL K EDTA 150 mg (Waters QPXE) Plasma 2 175 LC-MS/MS Human Hydroxybupropion 2 to 1000 ng / mL K EDTA - (Waters QPXE) Plasma 2

LC-MS/MS Human *Bupropion 1 to 300 ng / mL K EDTA 150 mg (Waters QPXE) Plasma 2

LC-MS/MS Human *Hydroxy Bupropion 2 to 800 ng / mL K EDTA - (Waters QPXE) Plasma 2 176 LC-MS/MS Human *Erythro hydro Bupropion 0.5 to 100 ng / mL K EDTA - (Waters QPXE) Plasma 2

LC-MS/MS Human * Threo hydro Bupropion 1.5 to 600 ng / mL K EDTA - (Waters QPXE) Plasma 2

LC-MS/MS Human Bupropion 1 to 500 ng/mL K EDTA 300 mg (API 6500) Plasma 2

LC-MS/MS Human Hydroxy Bupropion 2 to 1500 ng/mL, K EDTA - (API 6500) Plasma 2

I N D I A D I N 177 LC-MS/MS Human Erythro Hydro Bupropion 0.5 to 176 ng/mL K EDTA - (API 6500) Plasma 2

LC-MS/MS Human Threo Hydro Bupropion 1.5 to 1000 ng/mL K EDTA - (API 6500) Plasma 2

LC-MS/MS Human 1 to 500 ng/mL Bupropion K EDTA 2x90 mg (Shimadzu 8060) Plasma 2

LC-MS/MS Human Hydroxy Bupropion 2 to 1500 ng/mL K EDTA - (Shimadzu 8060) Plasma 2 178 Yes LC-MS/MS Human Erythro hydro Bupropion 0.5 to 175 ng/mL K EDTA - (Shimadzu 8060) Plasma 2

LC-MS/MS Human Threo hydro Bupropion 1.5 to 1000 ng/mL K EDTA - (Shimadzu 8060) Plasma 2

LC-MS/MS Human *Bupropion 1 to 500 ng / mL K EDTA 300 mg (Thermo) Plasma 2

LC-MS/MS Human *Hydroxy Bupropion 2 to 1500 ng / mL K EDTA - (Thermo) Plasma 2 179 LC-MS/MS Human *Erythro hydro Bupropion 0.5 to 175 ng / mL K EDTA - (Thermo) Plasma 2

LC-MS/MS Human * Threo hydro Bupropion 1.5 to 1000 ng / mL K EDTA - (Thermo) Plasma 2

Page 12 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method C

Human Sodium Carbamazepine HPLC-UV 48 to 25000 ng / mL 400 mg Plasma heparin 180 Human Sodium Carbamazepine-10,11-epoxide HPLC-UV 10 to 5000 ng / mL - Plasma heparin LC-MS/MS Human 1 to 128 ng / mL K EDTA 40 mg (Thermo) Plasma 2 LC-MS/MS Human O-Desmethylcarvedilol 0.2 to 25 ng / mL K EDTA - (Thermo) Plasma 2 181 LC-MS/MS Human 4'-Hydroxyphenyl carvedilol 0.2 to 25 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human 5'-Hydroxyphenyl carvedilol 0.2 to 25 ng / mL K EDTA - (Thermo) Plasma 2 Human Lithium 182 Cefaclor HPLC-UV 0.2 to 25 µg / mL 500 mg Plasma heparin Human Sodium 183 Cefixime HPLC-UV 0.1 to 13 µg / mL 400 mg Plasma heparin Human 184 Cefuroxime HPLC-UV 0.2 to 27 µg / mL K EDTA 500 mg Plasma 2 LC-MS/MS Human 185 Cefuroxime 100 to 20135 ng / mL K EDTA 500 mg (Thermo) Plasma 2 HPLC Human Sodium 186 Celecoxib 20 to 2560 ng / mL 200 mg - Flurosence Plasma heparin LC-MS/MS Human 187 Celecoxib 20 to 2560 ng / mL K EDTA 200 mg (API 3000) Plasma 2 Human 188 Cephalexin HPLC-UV 0.2 to 25 µg / mL K EDTA - Plasma 3 LC-MS/MS Human 189 2 to 512 ng / mL K EDTA 10 mg (API 3000) Plasma 2 LC-MS/MS Human Cetirizine 1 to 250 ng / mL K EDTA 5 mg (Waters QPXE) Plasma 2 190 LC-MS/MS Human 5 to 1500 ng / mL K EDTA 120 mg (Waters QPXE) Plasma 2

CANADA LC-MS/MS Human 191 Chlorpheniramine 0.1 to 51 ng / mL K EDTA 8 mg / 5 mL (API 3000) Plasma 2 LC-MS/MS Human 192 Chlorthalidone 2 to 1000 ng/mL K EDTA 50 mg (Thermo) Plasma 2 LC-MS/MS Human 193 Chlorzoxazone 0.1 to 50 µg/mL K EDTA 750mg (Thermo) Plasma 2 LC-MS/MS Human Cilazapril 1 to 256 ng / mL K EDTA 1 mg (API 3000) Plasma 3 194 LC-MS/MS Human Cilazaprilat 0.25 to 64 ng / mL K EDTA 1 mg (API 3000) Plasma 3 LC-MS/MS Human Cilazapril 4 to 1024 ng / mL K EDTA 2.5 mg (API 3000) Plasma 3 195 LC-MS/MS Human Cilazaprilat 1 to 256 ng / mL K EDTA 2.5 mg (API 3000) Plasma 3 HPLC Human 196 Ciprofloxacin 25 to 6400 ng / mL K EDTA - - Flurosence Plasma 3 HPLC Human 197 Ciprofloxacin 20 to 2561 ng / mL K EDTA - - Flurosence Plasma 3 Human Not Ciprofloxacin HPLC-UV 1.5 to 15 µg / mL - Urine applicable Human Not Desethyleneciprofloxacin HPLC-UV 0.5 to 5 µg / mL - Urine applicable Human Not 198 Sulfociprofloxacin HPLC-UV 0.5 to 5 µg / mL - Urine applicable Human Not Oxociprofloxacin HPLC-UV 0.5 to 5 µg / mL - Urine applicable Human Not Formylciprofloxacin HPLC-UV 0.5 to 5 µg / mL - Urine applicable

Page 13 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method HPLC Human 199 0.25 to 32 ng / mL Heparin - - Flurosence Plasma HPLC Human Sodium 200 Citalopram 0.25 to 64 ng / mL - - Flurosence Plasma heparin LC-MS/MS Human Sodium Citalopram 0.25 to 32 ng / mL 20 mg (API 3000) Plasma heparin LC-MS/MS Human Sodium 201 Demethylcitalopram 0.05 to 6 ng / mL - (API 3000) Plasma heparin LC-MS/MS Human Sodium Didemethylcitalopram 0.05 to 6 ng / mL - (API 3000) Plasma heparin LC-MS/MS Human Sodium Citalopram 0.25 to 64 ng / mL 40 mg (API 3000) Plasma heparin LC-MS/MS Human Sodium 202 Demethylcitalopram 0.05 to 12 ng / mL - (API 3000) Plasma heparin LC-MS/MS Human Sodium Didemethylcitalopram 0.05 to 13 ng / mL - (API 3000) Plasma heparin LC-MS/MS Human Sodium S-Citalopram 0.25 to 64 ng / mL 40 mg (API 3000) Plasma heparin 203 LC-MS/MS Human Sodium S-Demethylcitalopram 0.05 to 13 ng / mL - (API 3000) Plasma heparin LC-MS/MS Human Sodium Citalopram 0.251 to 128 ng / mL 40 mg (Thermo) Plasma heparin

LC-MS/MS Human Sodium 204 Demethylcitalopram 0.126 to 64 ng / mL - (Thermo) Plasma heparin

LC-MS/MS Human Sodium Didemethylcitalopram 0.025 to 13 ng / mL - (Thermo) Plasma heparin

LC-MS/MS Human Sodium Citalopram Chiral (R and S) 0.25 to 64 ng / mL 40 mg (API 3000) Plasma heparin

LC-MS/MS Human Sodium 205 Demethylcitalopram (R and S) 0.2 to 51 ng / mL - CANADA (API 3000) Plasma heparin

LC-MS/MS Human Sodium Didemethylcitalopram (S) 0.2 to 51 ng / mL - (API 3000) Plasma heparin

LC-MS/MS Human Sodium 206 Clarithromycin 20 to 5120 ng / mL - (API 300 or 3000) Plasma heparin

LC-MS/MS Human Sodium 207 Clavulanic Acid 25 to 1600 ng / mL 125 mg (API 300 or 3000) Plasma heparin

LC-MS/MS Human Clobazam 5 to 600 ng/mL K EDTA 20mg (Thermo) Plasma 2 208 LC-MS/MS Human N-Desmethyl Clobazam 5 to 500 ng/mL K EDTA 20mg (Thermo) Plasma 2

LC-MS/MS Human 209 Clobazam 1 to 400 ng / mL K EDTA 2 mg / mL (Waters QPXE) Plasma 2

LC-MS/MS Human Sodium 210 Clonazepam 0.1 to 51 ng / mL - (API 300 or 3000) Plasma heparin

LC-MS/MS Human 211 0.03 to 2 ng / mL K EDTA 0.3 mg (Thermo) Plasma 2

LC-MS/MS Human Sodium 212 Clopidogrel 0.05 to 51 ng / mL 300 mg (Thermo) Plasma heparin

LC-MS/MS Human 300 mg of 213 Clopidogrel Carboxylic Acid 0.049 to 25 µg / mL K EDTA (Thermo) Plasma 2 Clopidogrel

Page 14 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 300 mg of 214 Clopidgorel Thiol 0.1 to 100 ng / mL K EDTA (Thermo) Plasma 2 Clopidogrel

LC-MS/MS Human 215 Codeine 0.7 to 400 ng / mL K EDTA 30 mg (Thermo) Plasma 2

LC-MS/MS Human 2% Ointment(50 216 Crisaborole 0.05 to 100 ng/ mL K EDTA (Thermo) Plasma 2 mg & 100 mg)

CANADA LC-MS/MS Human Lithium Cyproterone Acetate 0.3 to 25 ng / mL - (API 3000) Plasma heparin 217 LC-MS/MS Human Lithium Ethinyl Estradiol 15 to 1280 pg / mL - (API 3000) Plasma heparin Location : India Human / Multiple dosage LC-MS/MS 218 Cabazitaxel (Total) Dog 0.5 to 250 ng / mL K EDTA (0.25 mg/kg to (Waters QPXE) 2 Plasma 0.75 mg/kg) LC-MS/MS Human 219 Cabazitaxel (Total) 0.75 to 500 ng / mL K EDTA 15 to 25 mg / m2 (Waters QPXE) Plasma 2

LC-MS/MS Human 220 Cabazitexel (Free) 0.05 to 40 ng / mL K EDTA Multiple dose (Thermo) Plasma 2

LC-MS/MS Human 221 * 0.5 to 80 pg / mL K EDTA 2 X 0.5 mg (API 6500) Plasma 3

LC-MS/MS Human 222 Cabozanitinib 2 to 800 ng/mL K EDTA 60mg (Waters QPXE) Plasma 2

LC-MS/MS Human 223 Candesartan 5 to 750 ng / mL K EDTA 32 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 224 Candesartan 1 to 350 ng / mL K EDTA 16 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 225 Candesartan 0.4 to 160 ng / mL K EDTA 8 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 226 Candesartan 5 to 750 ng/ml K EDTA 32 mg (API 3200) Plasma 2

I N D I A D I N LC-MS/MS Human 500 mg 227 Capecitabine 10 to 12000 ng / mL K EDTA (API 4000) Plasma 2 (multiple dosing)

LC-MS/MS Human 500 mg *Capecitabine 10 to 5000 ng / mL K EDTA (Thermo) Plasma 2 (multiple dosing) 228 LC-MS/MS Human *5-fluorouracil 5 to 760 ng / mL K EDTA - (Thermo) Plasma 2

LC-MS/MS Human 2 *Capecitabine 10 to 10000 ng / mL K2EDTA 2X 1250 mg / M (Thermo) Plasma 229 LC-MS/MS Human 2X 1250 mg / M2 of *5-Fluorouracil 5 to 1000 ng / mL K2EDTA (Thermo) Plasma Capecitabine

LC-MS/MS Human 500 mg Capecitabine 10 to 8000 ng / mL K EDTA (API 4000) Plasma 2 (multiple dosing) 230 LC-MS/MS Human 5-Deoxy-5-Fluorocytidine 10 to 8000 ng / mL K EDTA - (API 4000) Plasma 2 S-Methyl N,N-Diethyl LC-MS/MS Human 231 0.2 to 50 ng/mL K EDTA 200 mg dithiocarbamate (Thermo) Plasma 2 S-Methyl N,N-Diethyl LC-MS/MS Human 232 0.25 to 50 ng / mL K EDTA 200 mg dithiocarbamate (API 6500) Plasma 2

Page 15 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 300 / 233 Carbamazepine 50 to 7000 ng / mL K EDTA (API 3200) Plasma 2 400 mg LC-MS/MS Human 400 mg 234 Carbamazepine 0.5 to 20 µg / mL K EDTA (API 2000) Plasma 2 (steady state ) Carbamazepine 10, 11- LC-MS/MS Human 235 5 to 500 ng / mL K EDTA 400 mg Yes Epoxide (Waters QPXE) Plasma 2 LC-MS/MS Human 100 to 300 / Carbamazepine K EDTA (API 2000) Plasma 7000 ng / mL 2 400 mg 236 LC-MS/MS Human C 10, 11- Epoxide Metabolite 5 to 500 ng /mL K EDTA - (API 2000) Plasma 2 Beagle LC-MS/MS 237 *Carprofen Dog 0.5 to 100 µg / mL K EDTA 100 mg (API 3200) 2 Plasma LC-MS/MS Human 238 Captorpil 2 to 500 ng / mL K EDTA 25 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 239 Carbidopa 0.7 to 230 ng / mL K EDTA 25 mg (Thermo) Plasma 2 LC-MS/MS Human 240 Carvedilol 0.1 to 100 ng / mL K EDTA 12.5 mg (Waters QPXE) Plasma 2 LC-MS/MS Human *Carvedilol 0.1 to 50 ng / mL K EDTA 12.5 mg (Thermo) Plasma 2 241 LC-MS/MS Human *4-Hydroxy Phenyl Carvedilol 0.05 to 5 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human *Carvedilol 0.1 to 50 ng / mL K EDTA 40 mg (Waters QPXE) Plasma 2 242 LC-MS/MS Human *4-Hydroxy Phenyl Carvedilol 0.05 to 5 ng / mL K2EDTA -

I N D I A D I N (Waters QPXE) Plasma Human 243 Cefaclor HPLC-UV 0.2 to 25 µg / mL Heparin 500 mg Plasma Human 244 Cefadroxil HPLC-UV 0.5 to 50 µg / mL Heparin 500 mg Plasma Human 245 Cefdinir HPLC-UV 0.035 to 5 ng / mL Heparin 250 mg Plasma

Human K EDTA / 246 Cefixime HPLC-UV 0.05 to 8 µg / mL 2 400 mg Plasma Heparin

LC-MS/MS Human 247 Cefixime 5 to 3000 ng/mL K EDTA 50mg granules (Shimadzu 8045) Plasma 2

Human 248 Ceftazidime HPLC-UV 0.3 to 60 µg / mL Heparin 1 g injection Plasma

LC-MS/MS Human 249 Cefpodoxime 25 to 5000 ng/mL K EDTA 100 mg (Shimadzu 8045) Plasma 2

Human 250 Cefuroxime HPLC-UV 0.3 to 35 µg / mL Heparin 750 mg injection Plasma

Human 251 Cefuroxime HPLC-UV 0.075 to 13 µg / mL Heparin 500 mg Plasma

LC-MS/MS Human 252 Cefuroxime 0.025 to 7.5 μg / mL K EDTA 250 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 253 Celecoxib 10 to 4000 ng / mL Heparin 200 mg / 400 mg (Waters QPXE) Plasma

Page 16 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method Human 254 Cephalexin HPLC-UV 0.3 to 40 µg / mL Heparin 500 mg Plasma

LC-MS/MS Human 255 Cephalexin 0.1 to 50 µg/mL K EDTA 500 mg (Shimadzu 8045) Plasma 2

LC-MS/MS Human Sodium 256 Cetrizine (Shimadzu 5 to 600 ng / mL 10 mg Plasma heparin 8045)

LC-MS/MS Human 257 Cetrizine 5 to 500 ng / mL Heparin 10 mg (API 3200) Plasma

LC-MS/MS Human * 0.2 to 125 ng/mL K EDTA (API 4000) Plasma 2 258 100mg LC-MS/MS Human *7-Hydroxy Chlorpromazine 0.1 to 25 ng/mL K EDTA (API 4000) Plasma 2

Human 259 Chlorthalidone HPLC-UV 10 to 500 ng / mL CPD 25 mg Plasma

Human 260 Chlorthalidone HPLC-UV 50 to 3000 ng / mL CPD 200 mg Plasma

LC-MS/MS Human 261 Cilostazol 10 to 2000 ng / mL K EDTA 100 mg (API 2000) Plasma 2

LC-MS/MS Human 262 Cinacalcet 0.25 to 150 ng / mL K EDTA 90 mg (API 3200) Plasma 2

LC-MS/MS Human 263 Cinacalcet 0.25 to 100 ng / mL K EDTA 90 mg (API 3200) Plasma 2

HPLC Human 264 Ciprofloxacin 0.05 to 4 µg / mL K EDTA 750 mg - Flurosence Plasma 2

LC-MS/MS Human 265 5 to 1000 ng / mL Heparin 200 mg (Waters QPXE) Plasma I N D I A D I N LC-MS/MS Human 266 Cimetidine 15 to 6000 ng / mL Heparin 800 mg (Waters QPXE) Plasma

HPLC Human 267 Citalopram 2 to 80 ng / mL Heparin 40 mg - Flurosence Plasma

LC-MS/MS Human 268 Citalopram 0.25 to 100 ng / mL K EDTA 40 mg (Waters QPXE) Plasma 2

LC-MS/MS Human *Citalopram (R & S) 0.25 to 25 ng / mL Heparin 20 mg (Waters QPXE) Plasma 269 LC-MS/MS Human *S- desmethyl citalopram 0.25 to 15 ng / mL Heparin - (Waters QPXE) Plasma

LC-MS/MS Human 10 mg / S-citalopram 0.25 to 50 ng / mL K EDTA (API 3200) Plasma 2 20 mg 270 LC-MS/MS Human S- desmethyl citalopram 0.125 to 8 ng / mL K EDTA - (API 3200) Plasma 2

LC-MS/MS Human S-citalopram 0.25 to 50 ng / mL Heparin 20 mg (API 3200) Plasma 271 LC-MS/MS Human S- desmethyl citalopram 0.125 to 25 ng / mL Heparin - (API 3200) Plasma

LC-MS/MS Human 10 mg / 272 S-citalopram 0.25 to 50 ng / mL K EDTA (Waters QPXE) Plasma 2 20 mg

LC-MS/MS Human 273 S-citalopram 0.25 to 50 ng / mL K EDTA 10 mg / 20 mg (Shimadzu 8040) Plasma 2

Human Urine, LC-MS/MS 274 *Citric Acid Artificial 5 to 1500 µg / mL N/AP 15mEq (Waters QPXE) Matrix

Page 17 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 275 Clarithromycin 10 to 5000 ng / mL K EDTA 500 mg (API 3200) Plasma 2 LC-MS/MS Human 14- hydroxy Clarithromycin 10 to 2000 ng / mL K EDTA - (API 3200) Plasma 2 276 LC-MS/MS Human Sodium Clavulanic acid 15 to 5000 ng/mL 125 mg (Waters QPXE) Plasma heparin Human K EDTA / 277 Clavulanic acid HPLC-UV 0.05 to 4 µg / mL 2 125 mg Plasma Heparin LC-MS/MS Human 278 Clindamycin 50 to 8000 ng / mL K EDTA 300 mg (API 2000) Plasma 2 LC-MS/MS Human 279 Clobazam 1 to 400 ng / mL K EDTA 10 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 2.5 mg/mL (total Clobazam 5 to 600 ng / mL K EDTA (Thermo) Plasma 2 20 mg) 280 N-desmethyl LC-MS/MS Human 5 to 500 ng / mL K EDTA - clobazam (Thermo) Plasma 2 LC-MS/MS Human 281 *Clonidine 2 to 800 ng/ml K EDTA 0.025 mg/0.2 mg (API 6500) Plasma 2 LC-MS/MS Human 282 *Clonidine 2 to 250 pg/mL K EDTA 0.025mg (API 6500) Plasma 2 LC-MS/MS Human 283 *Clonidine 5 to 2000 pg / mL K EDTA 0.2mg (API 6500) Plasma 2

LC-MS/MS Human 284 Clopidogrel 20 to 4000 pg / mL Heparin 75 mg (API 4000) Plasma

LC-MS/MS Human Sodium 285 Clopidogrel 5 to 3000 pg/mL 75mg (API 6500) Plasma heparin

LC-MS/MS Human Sodium 300 mg (fasting 286 Clopidogrel 20 to 8000 pg / mL (API 4000) Plasma heparin study) LC-MS/MS Human Sodium I N D I A D I N 287 Clopidogrel 0.1 to 40 ng / mL 300 mg (Fed study) (API 4000) Plasma heparin LC-MS/MS Human Sodium 75 mg 288 *Clopidogrel (Shimadzu 5 to 4000 pg / mL Plasma heparin ( Fasting) 8060) LC-MS/MS Human Sodium 289 Clopidogrel 5 to 4000 pg/mL 75 mg (API 6500) Plasma heparin

LC-MS/MS Human 75 mg of 290 Clopidogrel Carboxy acid 30 to 5000 ng / mL Heparin (API 2000) Plasma clopidogrel

LC-MS/MS Human 200 mg multiple 291 2 to 1200 ng / mL K EDTA (Waters QPXE) Plasma 2 dose LC-MS/MS Human 292 Clozapine 0.2 to 80 ng / mL K EDTA 12.5 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 293 Colchicine 25 to 6000 pg / mL K EDTA 500 mcg (API 4000) Plasma 2 LC-MS/MS Human 294 *Copper Isochlorin-E4 20 to 2000 ng/mL K EDTA 750mg (Thermo) Plasma 2 LC-MS/MS Human 295 0.5 to 125 ng/mL K EDTA 50mg (Thermo) Plasma 2 LC-MS/MS Human 296 Cyclophosphamide 10 to 2500 ng / mL K EDTA Multiple dose (Waters QPXE) Plasma 2 LC-MS/MS Human 297 Cycloserine 0.1 to 20 µg / mL K EDTA 250mg (Thermo) Plasma 2 LC-MS/MS Human 298 Cyclosporine 10 to 1000 ng / mL K EDTA 50 mg (API 4000) Blood 2 LC-MS/MS Human 299 Cyproterone 0.2 to 40 ng / mL K EDTA 2mg (Shimadzu 8045) Plasma 2

Page 18 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method D Location : Canada LC-MS/MS Human 300 Darunavir 10 to 6400 ng / mL K EDTA 600 mg (API 3000) Plasma 2 LC-MS/MS Human 301 Dexamethasone 0.2 to 60 ng / mL K EDTA 0.5 mg (Thermo) Plasma 2 LC-MS/MS Human 302 0.2 to 40 ng/mL NaF & KOx 40 mg (Thermo) Plasma LC-MS/MS Human 303 Dextroamphetamine 0.2 to 51 ng / mL K EDTA 30 mg (API 3000) Plasma 2 LC-MS/MS Human Dextromethrophan 0.1 to 100 ng/mL K EDTA 60 mg (Thermo) Plasma 2 304 LC-MS/MS Human Detrorphan 0.1 to 50 ng/mL K EDTA NA (Thermo) Plasma 2 LC-MS/MS Human Sodium 0.1 to 51 ng / mL 30 mg (API 3000) Plasma heparin LC-MS/MS Human Sodium 305 1 to 512 ng / mL - (API 3000) Plasma heparin LC-MS/MS Human Sodium Pseudoephedrine 1 to 512 ng / mL - (API 3000) Plasma heparin LC-MS/MS Human Dextromethorphan 0.05 to 12 ng / mL K EDTA 10mg (Thermo) Plasma 2 LC-MS/MS Human 306 Pseudoephedrine 1 to 300 ng / mL K EDTA 30mg (Thermo) Plasma 2 LC-MS/MS Human 0.05 to 12 ng / mL K EDTA 2mg (Thermo) Plasma 2 LC-MS/MS Human 307 Diclofenac 0.05 to 25 ng / mL K EDTA 1 % gel (Thermo) Plasma 2

LC-MS/MS Human Sodium 308 Didanosine 10 to 1280 ng / mL -

C A N D (API 3000) Plasma heparin

LC-MS/MS Human 309 Dienogest 3 to 120 ng / mL K EDTA 2 mg (Thermo) Plasma 2

Human Diltiazem HPLC-UV 3 to 385 ng / mL K EDTA - Plasma 3

Human 310 Desacetyldiltiazem HPLC-UV 1 to 128 ng / mL K EDTA - Plasma 3

Human N-Desmethyldiltiazem HPLC-UV 3 to 385 ng / mL K EDTA - Plasma 3

Human Diltiazem HPLC-UV 3 to 770 ng / mL K EDTA - Plasma 3

Human 311 Desacetyldiltiazem HPLC-UV 1 to 255 ng / mL K EDTA - Plasma 3

Human N-Desmethyldiltiazem HPLC-UV 3 to 780 ng / mL K EDTA - Plasma 3

LC-MS/MS Human Diltiazem 1 to 256 ng / mL K EDTA - (API 3000) Plasma 3

LC-MS/MS Human 312 Desacetyldiltiazem 0.125 to 32 ng / mL K EDTA - (API 3000) Plasma 3

LC-MS/MS Human N-Desmethyldiltiazem 0.25 to 64 ng / mL K EDTA - (API 3000) Plasma 3

Page 19 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human Diltiazem 0.8 to 800 ng / mL K EDTA - (Thermo) Plasma 2

LC-MS/MS Human 313 Desacetyldiltiazem 0.2 to 200 ng / mL K EDTA - (Thermo) Plasma 2

LC-MS/MS Human N-Desmethyldiltiazem 0.4 to 400 ng / mL K EDTA - (Thermo) Plasma 2

LC-MS/MS Human Diltiazem 2.5 to 750 ng / mL K EDTA 420 mg (Thermo) Plasma 2

LC-MS/MS Human 314 Desacetyldiltiazem 0.2 to 75 ng / mL K EDTA - (Thermo) Plasma 2

LC-MS/MS Human N-Desmethyldiltiazem 2 to 150 ng / mL K EDTA - (Thermo) Plasma 2

LC-MS/MS Human Sodium 315 0.5 to 128 ng / mL 25 to 38 mg (API 3000) Plasma heparin

LC-MS/MS Human 316 Donepezil 0.25 to 64 ng / mL K EDTA 10 mg (Thermo) Plasma 2

HPLC Human 317 0.5 to 128 ng / mL Heparin - - Flurosence Plasma C A N D LC-MS/MS Human Doxepine 0.1 to 100 ng/mL K EDTA 100 mg (Thermo) Plasma 2 318 LC-MS/MS Human Nordoxepine 0.101 to 50.476 ng/mL K EDTA - (Thermo) Plasma 2

Human 319 Doxycycline HPLC-UV 80 to 5120 ng / mL Heparin - Plasma

LC-MS/MS Human 320 0.5 to 128 ng / mL K EDTA 60 mg (API 3000) Plasma 2

LC-MS/MS Human 321 Duloxetine 0.5 to 128 ng / mL K EDTA 60 mg (Thermo) Plasma 2

LC-MS/MS Human Sodium 322 Duloxetine 0.5 to 400 ng/mL 120 mg Yes (Thermo) Plasma heparin

LC-MS/MS Human 323 Dutasteride 60 to 5120 pg / mL K EDTA 0.5 mg (Thermo) Plasma 2 Location : India *Dabigatran LC-MS/MS Human 324 [Total- (Conjugated + 1 to 500 ng / mL Sodium Citrate 150 mg (API 3200) Plasma Unconjugated)] LC-MS/MS Human 325 *Dabigatran (Unconjugated) 1 to 300 ng / mL Sodium Citrate 150 mg (API 4000) Plasma LC-MS/MS Human 326 *Dabigatran (Unconjugated) 1 to 300 ng / mL Sodium Citrate 150 mg (API 3200) Plasma Sprague LC-MS/MS 327 *Dabigatran (Unconjugated) Dawley 5 to 10000 ng / mL Sodium Citrate Multiple dose (API 3200) Rat plasma LC-MS/MS Human 328 Daclatasvir 10 to 3000 ng/mL K2EDTA 60 mg

I N D I A D I N (Waters QPXE) Plasma LC-MS/MS Human 329 *11-dehydro Thromboxane B2 0.1 to 20 ng / mL NA NA (Shimadzu 8040) Urine LC-MS/MS Human 330 Dalfampridine/Fampridine 0.2 to 60 ng / mL K EDTA 10 mg (API 3200) Plasma 2 LC-MS/MS Human 331 Dapsone 0.05 to 50 ng/mL K EDTA 5 % gel (API 4000) Plasma 2 LC-MS/MS Human 332 Dapsone 0.02 to 10 ng/mL K EDTA 5% gel (API 4000) Plasma 2

Page 20 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 333 Darunavir 20 to 10000 ng / mL K EDTA 600 mg / 800 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 334 Dasatinib 1 to 300 ng / mL K2EDTA 100mg (API 3200) Plasma

3 De-Methylthiocholchicine 3- LC-MS/MS Human 335 0.25 to 100 ng / mL K EDTA 8 mg O- ß -D-Glucuronide (API 4000) Plasma 2

LC-MS/MS Human 0.05 to 30 ng/mL 3-Demethyl Thiocolchicine K EDTA 8 mg (Shimadzu 8060) Plasma 2 336 3-demethylthiocolchicine 3-O- LC-MS/MS Human 0.25 to 150 ng/mL K EDTA 8 mg β-D-Glucuronide (Shimadzu 8060) Plasma 2

LC-MS/MS Human 0.5 mg of 337 17-Desacetyl Norgestimate 0.05 to 7.5 ng / mL K EDTA (API 4000) Plasma 2 norgestimate LC-MS/MS Human 338 Dexibuprofen 0.2 to 50 µg / mL K EDTA 400 mg (API 3200) Plasma 2 LC-MS/MS Human 10 to 25 mg / 339 Dexketoprofen K EDTA (API 2000) Plasma 10000 ng / mL 2 50 mg LC-MS/MS Human 340 Dexamethasone 0.5 to 60 ng / mL K EDTA 2 mg (Waters QPXE) Plasma 3 LC-MS/MS Human 341 Deferasirox 0.2 to 50 µg / mL K EDTA 360 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 342 *Diazepam 2 to 1000 ng / mL K EDTA 10 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 343 Diazepam 2 to 750 ng/mL K EDTA 5 mg/mL (Waters QPXE) Plasma 2 LC-MS/MS Human 344 Diclofenac 5 to 2000 ng / mL Heparin 50 mg (API 2000) Plasma LC-MS/MS Human 75 mg /

I N D I A D I N 345 Diclofenac 10 to 5000 ng / mL Heparin (API 2000) Plasma 100 mg LC-MS/MS Human 75 mg / 346 Diclofenac 5 to 5000 ng / mL K EDTA (API 4000) Plasma 2 100 mg LC-MS/MS Human 347 Diclofenac 2 to 1200 ng / mL K EDTA 22 mg (API 3200) Plasma 2 LC-MS/MS Human 348 Diclofenac 0.075 to 25 ng / mL K EDTA 1 % gel (API 4000) Plasma 2 LC-MS/MS Human 349 Dienogest 1 to 120 ng/mL K EDTA 2mg (API 6500) Plasma 2 LC-MS/MS Human Diltiazem 1 to 250 ng / mL K EDTA 240 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 350 N-Des Methyl Diltiazem 0.25 to 64 ng / mL K EDTA - (Waters QPXE) Plasma 2 LC-MS/MS Human Des Acetyl Diltiazem 0.15 to 40 ng / mL K EDTA - (Waters QPXE) Plasma 2 LC-MS/MS Human Diltiazem 2.5 to 750 ng / mL K EDTA 360 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 351 N-Des Methyl Diltiazem 2 to 150 ng / mL K EDTA - (Waters QPXE) Plasma 2 LC-MS/MS Human Des Acetyl Diltiazem 0.2 to 35 ng / mL K EDTA - (Waters QPXE) Plasma 2 *2,3-Dinor-6-keto LC-MS/MS Human 352 0.5 to 25 ng / mL NA NA prostaglandin F1α (Shimadzu 8040) Urine LC-MS/MS Human 353 Dipyridamole 10 to 3000 ng / mL K EDTA 200 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 354 Dipyridamole 10 to 3000 ng / mL K EDTA 200 mg (Shimadzu 8040) Plasma 2

Page 21 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 200 mg multiple 355 Dipyridamole 10 to 4000 ng / mL K EDTA (Shimadzu 8040) Plasma 2 dose LC-MS/MS Human 20 mg / 0.5 mL 356 Docetaxel 10 to 5000 ng / mL K EDTA (Waters QPXE) Plasma 2 injection LC-MS/MS Human 357 Docetaxel (total) 10 to 15000 ng / mL K EDTA Multiple dose (Waters QPXE) Plasma 2 Beagle LC-MS/MS 358 *Docetaxel Dog 10 to 4000 ng / mL K EDTA 80mg / 2mL (Waters QPXE) 2 Plasma LC-MS/MS Human 359 *Docetaxel (free) 0.1 to 300 ng / mL K EDTA Multiple dose (Waters QPXE) Plasma 2 LC-MS/MS Human 360 Dofetilide 20 to 6000 pg / mL K EDTA 0.5 mg (Waters XEVO TQ-S) Plasma 2 LC-MS/MS Human 361 Dofetilide 20 to 6000 pg / mL K EDTA 0.5 mg (API 6500) Plasma 2 LC-MS/MS Human 362 Domperidone 0.1 to 50 ng / mL K EDTA 10 mg (API 4000) Plasma 2 LC-MS/MS Human 363 Donepezil 0.5 to 40 ng / mL K EDTA 10 mg (API 3200) Plasma 2 LC-MS/MS Human 400 mg (fed Dronadarone 0.5 to 200 ng / mL K EDTA (Waters QPXE) Plasma 2 study) 364 LC-MS/MS Human N-desbutyl dronadarone 0.5 to 200 ng / mL K EDTA - (Waters QPXE) Plasma 2 LC-MS/MS Human 400 mg (fed Dronadarone 0.5 to 200 ng / mL K EDTA (Thermo) Plasma 2 study) 365 LC-MS/MS Human N-desbutyl dronadarone 0.5 to 200 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human 400 mg (fasting Dronedarone 0.2 to 100 ng / mL K EDTA (Waters QPXE) Plasma 2 study) 366 LC-MS/MS Human N-desbutyl Dronedarone 0.2 to 100 ng / mL K EDTA - (Waters QPXE) Plasma 2

I N D I A D I N LC-MS/MS Human 367 Drospirenone 0.5 to 175 ng / mL K EDTA 6 mg (API 4000) Plasma 2

LC-MS/MS Human 368 Drotaverine 1 to 600 ng / mL K EDTA 80 mg (Thermo) Plasma 2

LC-MS/MS Human 369 Dolutegravir 10 to 6000 ng / mL K EDTA 50 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 370 Doxazosin 0.1 to 16 ng / mL K EDTA 1 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 0.1 to 65 ng/mL K EDTA 50 mg (Thermo) Plasma 2 371 LC-MS/MS Human 0.1 to 30 ng/mL K EDTA 50 mg (Thermo) Plasma 2

LC-MS/MS Human 0.1 to 26 ng/mL Doxepin K EDTA 25 mg (Thermo) Plasma 2 372 LC-MS/MS Human Nordoxepin 0.1 to 12 ng/mL K EDTA 25 mg (Thermo) Plasma 2

Doxorubicin (Encapsulated LC-MS/MS Human 373 150 to 60000 ng / mL K EDTA 50mg / m2 and total) (Waters QPXE) Plasma 3

LC-MS/MS Human 374 *Doxorubicin(Free) 4 to 750 ng/mL K EDTA 50 mg/m2 (Waters QPXE) Plasma 3

LC-MS/MS Human 375 *Doxorubicinol 0.1 to 20 ng / mL K EDTA 50mg / m2 (API 6500) Plasma 3

LC-MS/MS Human 376 1 to 200 ng / mL K EDTA 20 mg (API 3200) Plasma 2

Page 22 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 377 Duloxetine 0.5 to 200 ng/mL Heparin 60 mg (API 3200) Plasma

LC-MS/MS Human Sodium 378 Duloxetine 0.5 to 200 ng/mL 60 mg (Shimadzu 8045) Plasma heparin

LC-MS/MS Human Sodium 379 Duloxetine 0.5 to 300 ng/mL 90 mg (Shimadzu 8045) Plasma heparin I N D I A D I N LC-MS/MS Human 380 Dutasteride 0.05 to 7.5 ng / mL K EDTA 0.5 mg (API 4000) Plasma 2

LC-MS/MS Human 381 *Dydrogesterone 50 to 5000 pg/mL K EDTA 10mg (API 6500) Plasma 2 E Location : Canada

LC-MS Human Sodium 382 0.02 to 5 µg / mL - (API 150) Plasma heparin

LC-MS/MS Human 383 Eliglustat 0.1 to 50 ng/mL K EDTA 84mg (Thermo) Plasma 2

LC-MS/MS Human Enalapril 0.25 to 80 ng / mL Heparin - (API 3000) Plasma

LC-MS/MS Human 384 Enalaprilat 0.25 to 80 ng / mL Heparin - (API 3000) Plasma

LC-MS/MS Human Hydrochlorthiazide 2.5 to 800 ng / mL Heparin - (API 3000) Plasma

LC-MS/MS Human Enalapril 0.25 to 256 ng / mL K EDTA - (API 3000) Plasma 2 385 LC-MS/MS Human Enalaprilat 0.25 to 256 ng / mL K EDTA - (API 3000) Plasma 2

LC-MS/MS Mice plasma 386 Endoxifen 0.1 to 100 ng/mL K EDTA 0.2 mg/mL (Thermo) Extract 2

LC-MS/MS Beagle Dog 387 Enrofloxacin 10 to 5000 ng/mL K EDTA 150 mg (Thermo) plasma 2

LC-MS/MS Human 388 Eprosartan 5 to 3840 ng / mL K EDTA - (Thermo) Plasma 2

CANADA LC-MS/MS Human 389 Esomeprazole 1 to 2000 ng / mL K EDTA 20 mg (Thermo) Plasma 2

LC-MS/MS Human 390 17 β-Estradiol 1 to 100 pg/mL K EDTA 0.1 % Gel (API 6500) Plasma 2

Human 391 Etodolac HPLC-UV 0.25 to 32 µg / mL Heparin - Plasma

LC-MS/MS Human 392 Ethinyl Estradiol 3 to 128 pg / mL K EDTA 0.03 mg (Thermo) Plasma 2

LC-MS/MS Human 393 Ethinyl Estradiol 0.5 to 125 pg / mL K EDTA 20 mcg (API 6500) Plasma 2

LC-MS/MS Human 394 Exemestane 0.2 to 25 ng / mL K EDTA 25 mg (API 3000) Plasma 2

LC-MS/MS Human 395 Exemestane 0.05 to 25 ng / mL K EDTA 25 mg (Thermo) Plasma 2

LC-MS/MS Human Sodium Ezetimibe 0.05 to 15 ng/mL 10 mg (API 6500) Plasma heparin 396 Ezetimibe Phenoxy LC-MS/MS Human Sodium 0.5 to 300 ng/mL 10 mg Glucuronide (API 6500) Plasma heparin

Page 23 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method Location : India

LC-MS/MS Human 0.05 to 10 ng / mL K EDTA 20 mg (API 3200) Plasma 2 397 LC-MS/MS Human Carebastine 1 to 300 ng / mL K EDTA - (API 3200) Plasma 2

LC-MS/MS Human Ebastine 12 to 7500 pg / mL K EDTA 10 mg (API 4000) Plasma 2 398 LC-MS/MS Human Carebastine 1 to 250 ng / mL K EDTA - (API 4000) Plasma 2 20 mg Film Ebastine LC-MS/MS Human 25 to 12000 pg / mL K EDTA Coated/Orodispos (API 4000) Plasma 2 able tablet 399 20 mg Film LC-MS/MS Human Carebastine 1 to 500 ng / mL K EDTA Coated/Orodispos (API 4000) Plasma 2 able tablet LC-MS/MS Human Ebastine 25 to 12000 pg/mL K EDTA 20mg (Waters QPXE) Plasma 2 400 LC-MS/MS Human Carebastine 1 to 500 ng/mL K EDTA NA (Waters QPXE) Plasma 2

LC-MS/MS Human 401 Efavirenz 10 to 6000 ng / mL K EDTA 600 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 402 Efavirenz 10 to 6000 ng / mL K EDTA 600 mg (API 4000) Plasma 2

LC-MS/MS Human 403 Efavirenz 5 to 5000 ng / mL K EDTA 600 mg (API 4000) Plasma 2

LC-MS/MS Human 404 Eliglustat 0.2 to 100 ng/mL K EDTA 84 mg (Thermo) Plasma 2

I N D I A D I N LC-MS/MS Human 405 Eltrombopag 50 to 15000 ng/mL K EDTA 75 mg (API 4000) Plasma 2

LC-MS/MS Human 406 Empagliflozin 2 to 1000 ng/mL K EDTA 25 mg (API 4000) Plasma 2

LC-MS/MS Human 407 Emtricitabine 5 to 5000 ng / mL K EDTA 200mg Fast/Fed (API 4000) Plasma 2

LC-MS/MS Human 408 Emtricitabine 20 to 6000 ng / mL K EDTA 200 mg (API 4000) Plasma 2

LC-MS/MS Human 0.5mg to 4.0 mg 409 Endoxifen 25 to 10000 pg /mL K EDTA (Thermo) Plasma 2 (Multiple dosing)

LC-MS/MS Human 410 Endoxifen 0.5 to 200 ng / mL K EDTA 40 mg (API 3200) Plasma 2

LC-MS/MS Human Enalapril 0.5 to 400 ng /mL K EDTA 10 mg (Thermo) Plasma 2 411 LC-MS/MS Human Enalaprilat 0.5 to 200 ng /mL K EDTA - (Thermo) Plasma 2

LC-MS/MS Human Enalapril 0.2 to 100 ng / mL K EDTA 2.5 mg (Thermo) Plasma 2 412 LC-MS/MS Human Enalaprilat 0.2 to 50 ng / mL K EDTA - (Thermo) Plasma 2

LC-MS/MS Human Enalapril 0.5 to 400 ng/mL K EDTA 20mg (Shimadzu 8045) Plasma 2 413 LC-MS/MS Human Enalaprilat 0.5 to 200 ng/mL K EDTA 20mg (Shimadzu 8045) Plasma 2

Page 24 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human Sodium 414 Entacapone 5 to 4000 ng / mL 200 mg (API 3200) Plasma heparin

LC-MS/MS Human 415 Entecavir 0.05 to 10 ng/mL K EDTA 0.5mg (API 4000) Plasma 2

LC-MS/MS Human Sodium 416 Eplerenone 5 to 2500 ng / mL 50 mg (Waters QPXE) Plasma heparin

LC-MS/MS Human 417 Eprosartan 10 to 5000 ng / mL Heparin 300 mg (API 2000) Plasma

LC-MS/MS Human 418 Erlotinib 3 to 3000 ng / mL K EDTA 150 mg (API 3200) Plasma 2

LC-MS/MS Human 419 Erlotinib 3 to 3000 ng / mL K2EDTA 150 mg (API 4000) Plasma

LC-MS/MS Human 420 0.15 to 30 ng/mL K EDTA 10 mg Yes (Waters QPXE) Plasma 2

LC-MS/MS Human 421 Eslicarbazepine 50 to 20000 ng / mL K EDTA 800mg (Thermo) Plasma 2

LC-MS/MS Human 422 Esomeprazole 1 to 3000 ng / mL K EDTA 20 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 423 Esomeprazole 5 to 4000 ng / mL K EDTA 40 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 424 Esomeprazole 5 to 4000 ng / mL K EDTA 40 mg (API 3200) Plasma 2

Sprague Multiple dosage LC-MS/MS 425 *Esomeprazole Dawley Rat 2 to 15000 ng / mL K EDTA (30 mg/kg to 180 (Waters QPXE) 2 plasma mg/kg)

LC-MS/MS Human 10 mcg / 426 *17 β-Estradiol 2 to 100 pg / mL K EDTA (Thermo) Plasma 2 20 mcg

I N D I A D I N LC-MS/MS Human 427 *17 β-Estradiol 2 to 600 pg / mL K EDTA 1.5 mg (Waters XEVO TQ-S) Plasma 3

LC-MS/MS Human 0.01 % vaginal 428 *17 β-Estradiol 2 to 800 pg / mL K EDTA (Thermo) Plasma 2 cream

LC-MS/MS Human 429 *17 β-Estradiol 1 to 100 pg / mL K EDTA 1 mg (Waters XEVO TQ-S) Plasma 2

*17 β-Estradiol LC-MS/MS Human 1 to 250 pg / mL K EDTA 1 mg estradiol (Unconjugated) (Waters XEVO TQ-S) Plasma 2 430 LC-MS/MS Human *Estrone (Unconjugated) 3 to 1200 pg / mL K EDTA - (Waters XEVO TQ-S) Plasma 2

LC-MS/MS Human 431 *Estrone (Total) 0.3 to 60 ng / mL K EDTA 1 mg of Estradiol (Waters QPXE) Plasma 2

LC-MS/MS Human 432 Ethosuximide 40 to 10000 ng/mL K EDTA 250 mg (Waters XEVO TQ-S) Plasma 2

LC-MS/MS Human 433 *Ethynyl estradiol 2 to 300 pg / mL K EDTA 0.035mg / 0.07 mg (Thermo) Plasma 2

LC-MS/MS Human 434 *Ethinyl estradiol 0.5 to 200 pg / mL K EDTA 0.02 mg (Waters XEVO TQ-S) Plasma 2

LC-MS/MS Human 435 *Ethinyl Estradiol 0.5 to 125 pg / mL K EDTA 20 mcg (API 6500) Plasma 2

LC-MS/MS Human 436 Etoposide 0.1 to 30 µg/ mL K EDTA 200 mg Yes (Waters QPXE) Plasma 2

LC-MS/MS Human 437 Etoricoxib 10 to 5000 ng / mL K EDTA 120 mg (Waters QPXE) Plasma 2

Page 25 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 438 Etravirine 1 to 700 ng/mL K EDTA 200mg Fast/Fed (API 4000) Plasma 2

LC-MS/MS Human 439 Everolimus 0.5 to 200 ng/mL K EDTA 10mg (Shimadzu 8045) Blood 2

LC-MS/MS Human 440 Everolimus 0.25 to 75 ng / mL K EDTA 5mg (Shimadzu 8045) Blood 2

LC-MS/MS Human Sodium 441 Exemestane 0.25 to 50 ng / mL 25 mg (Thermo) Plasma heparin

LC-MS/MS Human 442 *Ezetimibe (Total) 0.5 to 250 ng / mL Sodium Heparin 10 mg

I N D I A D I N (Waters QPXE) Plasma Ezetimibe LC-MS/MS Human Sodium 443 0.05 to 15 ng / mL 10 mg (Unconjugated) (API 4000) Plasma heparin LC-MS/MS Human 444 Ezetimibe (Unconjugated) 0.075 to 30 ng / mL Sodium Heparin 10 mg (API 4000) Plasma LC-MS/MS Human Ezetimibe 0.05 to 15 ng / mL Sodium Heparin 10 mg (API 4000) Plasma 445 Ezetimibe Phenoxy LC-MS/MS Human 0.5 to 300 ng / mL Sodium Heparin - Glucuronide (API 4000) Plasma F Location : Canada

Human 446 HPLC-UV 5 to 640 ng / mL Heparin - Plasma

LC-MS/MS Human 447 Felodipine 0.05 to 13 ng / mL K EDTA 10 mg (Thermo) Plasma 2

LC-MS/MS Human 448 Fenofibric acid 50 to 19200 ng / mL K EDTA 135 mg (API 3000) Plasma 2

Human K EDTA/Sodium 449 Fenofibric acid HPLC-UV 50 to 12800 ng / mL 2 - Plasma heparin

Human Sodium 450 Fenofibric acid HPLC-UV 10 to 5120 ng / mL - Plasma heparin

LC-MS/MS Human 451 Fenofibric acid 0.05 to 25 µg / mL K EDTA 215 mg (Thermo) Plasma 2

LC-MS/MS Human Sodium 452 Fentanyl 0.02 to 20 ng / mL - (API 3000) Plasma heparin

Human plasma LC-MS/MS Fesoterodine (Bufferized) 0.45 to 100 pg/mL K EDTA 3.1 mg (API 6500) 2 453 Yes Human plasma C A N D LC-MS/MS 5-Hydroxy Tolterodine (Bufferized) 30 to 11000 pg/mL K EDTA 6.2 mg (API 6500) 2

HPLC Human Sodium 454 5 to 640 ng / mL - - Flurosence Plasma heparin

LC-MS/MS Human 455 Fexofenadine 1 to 1000 ng / mL K EDTA 180 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 456 Fexofenadine 3 to 3500 ng/mL K EDTA 180mg (Thermo) Plasma 2

LC-MS/MS Human 457 Fingolimod 25 to 500 pg / mL K EDTA 3 X 0.5 mg (Thermo) Blood 2

LC-MS/MS Human 3 X 0.5 mg of 458 Fingolimod Phosphate 75 to 4000 pg / mL K EDTA (Waters QPXE) Blood 2 fingolimod

Human Sodium 459 Fluconazole HPLC-UV 0.1 to 13 µg / mL 150 mg Plasma heparin

Page 26 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS Human 0.15 to 37.5 ng / mL Heparin 20 mg (API 150) Plasma 460 LC-MS Human Norfluoxetine 0.15 to 37.5 ng / mL Heparin - (API 150) Plasma

LC-MS Human Sodium Fluoxetine 0.5 to 64 ng / mL - (API 150) Plasma heparin 461 LC-MS Human Sodium Norfluoxetine 0.5 to 64 ng / mL - (API 150) Plasma heparin

LC-MS/MS Human 462 Flupenthixol 0.1 to 13 ng / mL K EDTA 10 mg (API 3000) Plasma 2

Fluticasone LC-MS/MS Human 463 1 to 32 pg / mL K EDTA - Propionate (Thermo) Plasma 2

C A N D Fluticasone LC-MS/MS Human 464 5 to 640 pg / mL K EDTA - Propionate (Thermo) Plasma 2

LC-MS/MS Human 465 Fluvastatin 2 to 512 ng / mL K EDTA - (Thermo) Plasma 2

LC-MS/MS Human Sodium 466 0.5 to 64 ng / mL - (API 3000) Plasma heparin

LC-MS/MS Dog Sodium 467 Fulvestrant 0.5 to 40 ng / mL 50 mg (Thermo) Plasma heparin

LC-MS/MS Human 468 Fulvestrant 0.05 to 40 ng / mL K EDTA 50 mg (Thermo) Plasma 2 Location : India 1 to 10 g% total Human food & fat(expressed as 469 Fat analysis in food FTIR NA NA cucumber pulp triglyceride) sample weigh: 0.5 g 1 to 6 g% total fat Human food & (expressed as 60 mg multiple 470 *Fat analysis in food FT-IR NA cucumber pulp triglyceride) Sample dose weigh:0.5 g

471 Fat analysis in fecal FTIR Human Fecal 0.5 to 15 g% total fat NA 60 mg

LC-MS/MS Human 472 Febuxostat 10 to 8000 ng / mL K EDTA 80 mg (API 3200) Plasma 2

LC-MS/MS Human 473 Febuxostat 10 to 12000 ng / mL K EDTA 120 mg (API 3200) Plasma 2

LC-MS/MS Human 474 Felodipine 0.03 to 10 ng/mL K EDTA 10 mg (Shimadzu 8045) Plasma 2

I N D I A D I N LC-MS/MS Human 475 Fenofibric acid 0.1 to 20 µg / mL K EDTA 135/160 mg (API 3200) Plasma 2

LC-MS/MS Human 476 Fenofibric acid 0.1 to 40 μg /mL K2EDTA 267 mg (API 3200) Plasma

LC-MS/MS Human 477 2 to 700 ng /mL K EDTA 80 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 80 mg (steady 478 Fenspiride 5 to 2000 ng /mL K EDTA (Waters QPXE) Plasma 2 state)

LC-MS/MS Human Fesoterodine 10 to 3000 pg / mL K EDTA 8 mg (Waters QPXE) Plasma 2 479 LC-MS/MS Human 5-Hydroxymethyl Tolterodine 20 to 10000 pg / mL K EDTA - (Waters QPXE) Plasma 2

Page 27 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human *Fesoterodine (Waters 1 to 200 pg / mL K EDTA 8 mg Plasma 2 XEVO TQ-S) 480 LC-MS/MS Human *5-Hydroxymethyl Tolterodine (Waters 10 to 10000 pg / mL K EDTA - Plasma 2 XEVO TQ-S) LC-MS/MS Human 481 Finasteride 0.2 to 80 ng / mL Heparin 5 mg (Waters QPXE) Plasma

LC-MS/MS Human 482 Finasteride 0.2 to 30 ng / mL Heparin 1 mg (Waters QPXE) Plasma

LC-MS/MS Human 483 Finasteride 10 to 3000 pg/mL K2EDTA 0.1% Lipid Solution (Waters XEVO TQ-S) Plasma

LC-MS/MS Human 484 *Fingolimod 25 to 3000 pg / mL K EDTA 3 X 0.5 mg (API 4000) Blood 2

LC-MS/MS Human 485 Finglolimod 10 to 1000 pg/mL K EDTA 0.5mg (Waters XEVO TQ-S) Blood 2 LC-MS/MS Human 3 X 0.5 mg of 486 *Fingolimod Phosphate (Waters 50 to 4000 pg / mL K EDTA Blood 2 fingolimod XEVO TQ-S) LC-MS/MS Human 3 X 0.5 mg of 487 *Fingolimod Phosphate 75 to 4000 pg / mL K EDTA (Thermo) Blood 2 fingolimod

LC-MS/MS Human 3 X 0.5 mg of 488 *Fingolimod Phosphate 50 to 4000 pg / mL K EDTA (API 6500) Blood 2 fingolimod

LC-MS/MS Human 489 *Fingolimod Phosphate 20 to 1500 pg/mL K EDTA 0.5mg (API 6500) Blood 2

Human 490 Flucloxacilin HPLC-UV 0.3 to 20 µg / mL NA 500 mg Plasma I N D I A D I N LC-MS/MS Human 491 Flucloxacillin 0.050 to 50 µg / mL K EDTA 500 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 492 Flucloxacillin 0.1 to 100 µg / mL K EDTA 1 gm (Waters QPXE) Plasma 2 LC-MS/MS Human 50 to 493 Fluconazole K EDTA 150 mg (API 2000) Plasma 10000 ng / mL 2 LC-MS/MS Human 494 Flucytosine 0.1 to 20 µg / mL K EDTA 500mg (Waters QPXE) Plasma 2

LC-MS/MS Human Fluoxetine 0.25 to 25 ng /mL K EDTA 20 mg (API 4000) Plasma 2 495 LC-MS/MS Human Norfluoxetine 0.25 to 25 ng / mL K EDTA - (API 4000) Plasma 2

LC-MS/MS Human 496 Fluoxetine 2.5 to 50 ng /mL K EDTA 40 mg (API 3200) Plasma 2

LC-MS/MS Human 497 Fluoxetine 2.5 to 100 ng /mL K EDTA 60 mg (API 3200) Plasma 2

LC-MS/MS Human 498 Fluoxetine 0.5 to 10 ng /mL K EDTA 10 mg (API 4000) Plasma 2 LC-MS/MS *Fluticasone Human 499 (Waters 2 to 200 pg / mL K EDTA 500 µg Propionate Plasma 2 XEVO TQ-S) LC-MS/MS Human 500 *Fluticasone 1 to 200 pg/mL K EDTA 500 µg (Shimadzu 8060) Plasma 2

Page 28 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method

LC-MS/MS Human 40 mg / 501 Fluvastatin 0.5 to 500 ng / mL Heparin (API 4000) Plasma 80 mg

LC-MS/MS Human 502 *Fluvastatin (R & S) 0.5 to 200 ng / mL Heparin 40 mg (API 4000) Plasma

LC-MS/MS Human 503 *Fluvastatin (R & S) 1 to 400 ng / mL Heparin 80 mg (API 4000) Plasma

LC-MS/MS Human 504 * 0.4 to 150 pg/mL K EDTA 24 µg (Shimadzu 8060) Plasma 2

LC-MS/MS Human

I N D I A D I N 505 Fosfomycin 0.6 to 80 ng/mL K EDTA 5.631mg (Thermo) Plasma 2

LC-MS/MS Human 506 Fulvestrant 0.2 to 20 ng /mL K EDTA 250 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 507 Furosemide 5 to 2000 ng / mL K EDTA 40 mg (API 3200) Plasma 2

LC-MS/MS Human 508 Furosemide 10 to 8000 ng / mL K EDTA 80 mg (API 3200) Plasma 2 G Location : Canada

LC-MS/MS Human 509 Gabapentin 75 to 9600 ng / mL K EDTA 600 mg (API 3000) Plasma 2

LC-MS/MS Human 510 Galantamine 0.5 to 63 ng / mL K EDTA 8 mg (API 3000) Plasma 2

HPLC Human 511 Ganciclovir 30 to 1920 ng / mL K EDTA - - Flurosence Plasma 3

HPLC Human 512 Gatifloxacin 25 to 6400 ng / mL K EDTA - - Flurosence Plasma 3

LC-MS/MS Human 513 Glimepiride 2 to 1024 ng / mL K EDTA 4 mg (API 300 or 3000) Plasma 3

Human 514 Glipizide HPLC-UV 10 to 640 ng / mL K EDTA - Plasma 2

LC-MS Human 515 Glipizide 10 to 640 ng / mL K EDTA - (API 150) Plasma 2 C A N D

LC-MS/MS Human 516 Glipizide 10 to 1280 ng / mL K EDTA - (API 300 or 3000) Plasma 2

LC-MS/MS Human 517 Glipizide 2.5 to 640 ng / mL K EDTA 10 mg (API 3000) Plasma 2 LC-MS Human 518 Glyburide 2 to 128 ng / mL K EDTA - (API 150) Plasma 3 LC-MS/MS Human 519 Glycopyrrolate 1 to 400 pg/mL K EDTA 44 µg (Thermo) Plasma 2

LC-MS/MS Human 520 Griseofulvin 15 to 3840 ng / mL K EDTA - (API 300 or 3000) Plasma 3

LC-MS/MS Human 521 0.02 to 10 ng / mL K EDTA - (Thermo) Plasma 2

Page 29 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 522 Guaifenesin 10 to 1280 ng / mL K EDTA - (Thermo) Plasma 2

LC-MS/MS Human 523 Guaifenesin 10 to 5000 ng/mL K EDTA 1200 mg (Thermo) Plasma 2 C A N D Location : India

LC-MS/MS Human 400 / 524 Gabapentin 50 to 7500 ng / mL K EDTA (API 3200) Plasma 2 800 mg

LC-MS/MS Human 1200 / 525 Gabapentin 150 to 10000 ng / mL K EDTA (API 2000) Plasma 2 800 mg

LC-MS/MS Human 526 Gabapentin 25 to 9000 ng/mL K EDTA 600mg (API 4000) Plasma 2

LC-MS/MS Human 527 Galantamine 0.5 to 75 ng / mL K EDTA 8 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 528 Gefitinib 0.75 to 350 ng / mL K EDTA 250 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 529 Gefitinib 0.7 to 350 ng/mL K EDTA 250 mg (Waters XEVO TQ-S) Plasma 2

LC-MS/MS Human K EDTA / 530 Gemcitabine 0.1 to 35 µg / mL 2 1000 mg / m2 (API 3200) Plasma Sodium heparin

LC-MS/MS Human 531 *Gestodene 30 to 6000 pg/mL K EDTA 0.06 & 0.075 (API 6500) Plasma 2

LC-MS/MS Human 532 Gliclazide 0.1 to 10 µg / mL K EDTA 80 mg (API 3200) Plasma 2

LC-MS/MS Human 533 Gliclazide 5 to 5000 ng / mL K EDTA 60 mg (API 3200) Plasma 2

LC-MS/MS Human 534 Gliclazide 5 to 2000 ng / mL K EDTA 30 mg (API 3200) Plasma 2 I N D I A D I N LC-MS/MS Human 535 Gliclazide 5 to 5000 ng/mL K EDTA 60mg (API 3200) Plasma 2

LC-MS/MS Human 536 Glimepiride 3 to 600 ng / mL Heparin 4 mg (API 2000) Plasma

LC-MS/MS Human 537 Glimepiride 3 to 1200 ng/mL K2EDTA 6 mg (API 3200) Plasma

LC-MS/MS Human 538 Glipizide 2.5 to 1000 ng / mL K EDTA 10 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 539 Glipizide 2.5 to 1000 ng / mL K EDTA 10 mg (API 4000) Plasma 2 LC-MS/MS Human 540 *Glucagon (Waters 0.2 to 10 ng / mL K EDTA 1 mg/vial Plasma 2 XEVO TQ-S) LC-MS/MS Human 15 to 2000 ng / mL 541 Glucosamin K EDTA 750mg (Thermo) Plasma 2 LC-MS/MS Human 542 *Glycopyrronium (Waters 5 to 400 pg / mL K EDTA 50 mcg Plasma 2 XEVO TQ-S) LC-MS/MS Human 543 *Goserelin 50 to 10000 pg/mL K EDTA 3.6mg (API 6500) Plasma 2

LC-MS/MS Human 544 Guaifenesin 5 to 5000 ng / mL K EDTA 1200 mg (API 4000) Plasma 2

Page 30 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method H Location : Canada

LC-MS/MS Human 7.5 mg / 545 Hydrocodone 0.4 to 51 ng / mL K EDTA (Thermo) Plasma 2 5 mL

LC-MS/MS Human Sodium Hydrocodone 1 to 128 ng / mL - (API 3000) Plasma heparin

LC-MS/MS Human Sodium 546 Hydromorphone 1 to 128 ng / mL - (API 3000) Plasma heparin

LC-MS/MS Human 100 to Sodium Ibuprofen - (API 3000) Plasma 12800 ng / mL heparin

LC-MS/MS Human Hydralazine 0.25 to 128 ng/mL K EDTA 50 mg (Thermo) Plasma 2 547

C A N D hydralazine pyruvic acid LC-MS/MS Human 1.2 to 1250 ng/mL K EDTA - hydrazone (HPH) (Thermo) Plasma 2

LC-MS Human 548 Hydrochlorthiazide 5 to 1280 ng / mL K EDTA 12.5 mg to 25 mg (API 150) Plasma 2

LC-MS/MS Human 549 Hydromorphone 50 to 15000 pg / mL K EDTA 32 mg (Thermo) Plasma 2

LC-MS/MS Human 550 Hydromorphone 0.05 to 6 ng / mL K EDTA 16 mg (Thermo) Plasma 2 Location : India

LC-MS/MS Human 551 5 to 2500 pg/mL K EDTA - (API 6500) Plasma 2

LC-MS/MS Human 552 Haloperidol 20 to 7500 pg/mL K EDTA 5 mg (API 6500) Plasma 2

LC-MS/MS Human 553 HRF-4467 2 to 1000 ng/mL K EDTA 160 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 554 HRF-4467 20 to 10000 ng / mL K EDTA 80 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 555 Hydralazine 0.25 to 125 ng / mL K EDTA 50 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 556 Hydrochlorothiazide 1 to 300 ng / mL K EDTA 25 mg / 12.5 mg (API 4000) Plasma 2

LC-MS/MS Human 557 Hydrochlorothiazide 2 to 400 ng / mL K EDTA 50 mg (API 4000) Plasma 2

LC-MS/MS Human 50 mg / K EDTA

I N D I A D I N 558 Hydrochlorothiazide 2 to 600 ng / mL (API 3200) Plasma 2 25 mg

LC-MS/MS Human Hydrochlorthiazide 1 to 400 ng / mL K EDTA 12.5 mg / 25 mg (Waters QPXE) Plasma 2 559 LC-MS/MS Human Telmisartan 2 to 1000 ng / mL K EDTA 80 mg (Waters QPXE) Plasma 2

LC-MS/MS Human Hydrochlorthiazide 1 to 400 ng / mL K EDTA 12.5 mg / 25 mg (Thermo) Plasma 2 560 LC-MS/MS Human Telmisartan 2 to 1000 ng / mL K EDTA 80 mg (Thermo) Plasma 2

LC-MS/MS Human Hydrochlorthiazide 1 to 400 ng/mL K2EDTA 25 mg (API 6500) Plasma 561 LC-MS/MS Human 2 to 1000 ng/mL Telmisartan K2EDTA 80 mg (API 6500) Plasma

Page 31 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human Hydrochlorothiazide 1 to 400 ng / mL K EDTA 25 mg (API 4000) Plasma 2 562 LC-MS/MS Human Olmesartan 2.5 to 4000 ng / mL K EDTA 40 mg (API 4000) Plasma 2

LC-MS/MS Human 563 Hydrocortisone 0.25 to 100 ng / mL Not applicable - (API 3200) Urine

LC-MS/MS Human K EDTA

I N D I A D I N 564 *Hydrocortisone 2 to 500 ng / mL 20 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 565 Hydroxychloroquine 5 to 500 ng / mL K EDTA 200 mg (API 3200) Blood 2

LC-MS/MS Human 566 5-Hydroxytryptophan 10 to 1000 ng / mL K EDTA 100 mg (API 4000) Plasma 2 I Location : Canada

Human Sodium 567 Ibuprofen HPLC-UV 0.4 to 512 µg / mL 200 mg Plasma heparin

LC-MS/MS Human 568 Ibuprofen 0.1 to 40 µg/mL Sodium Heparin 200mg (API 6500) Plasma

LC-MS/MS Human 569 Ibuprofen 0.2 to 50 µg / mL K EDTA 600 mg (Waters QPXE) Plasma 2

LC-MS/MS Human Ibuprofen 0.2 to 51 µg/mL K EDTA 200 mg (Thermo) Plasma 2 570 LC-MS/MS Human Methocarbamol 0.06 to 15 µg/mL K EDTA 500 mg (Thermo) Plasma 2

LC-MS/MS Human 571 Imatinib 5 to 3500 ng / mL K EDTA 400 mg (Thermo) Plasma 2

Human 572 Indapamide HPLC-UV Whole 10 to 1280 ng / mL Heparin - Blood LC-MS/MS Human C A N D Itraconazole 1 to 320 ng / mL Heparin - (API 300 or 3000) Plasma 573 LC-MS/MS Human Hydroxy Itraconazole 1 to 320 ng / mL Heparin - (API 300or 3000) Plasma LC-MS/MS Human Itraconazole 2 to 512 ng / mL K EDTA 100 mg (API 3000) Plasma 2 574 LC-MS/MS Human Hydroxy Itraconazole 2 to 512 ng / mL K EDTA - (API 3000) Plasma 2 LC-MS/MS Human Ivabradine 20 to 20000 ng / mL K EDTA 15mg (Waters QPXE) Plasma 2 575 N-desmethyl LC-MS/MS Human 15 mg of 20 to 2480 ng / mL K EDTA Ivabradine (Waters QPXE) Plasma 2 Ivabradine LC-MS/MS Human 576 Ivermectin 0.25 to 50 ng/mL K EDTA 3 mg (API 6500) Plasma 2

Page 32 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method Location : India LC-MS/MS Human 577 *Ibandronate 0.1 to 100 ng / mL Heparin 50 mg (Thermo) Plasma LC-MS/MS Human 578 *Ibandronate 0.75 to 300 ng / mL Heparin 150 mg (API 4000) Plasma LC-MS/MS Human 579 *Ibuprofen (R & S) 0.1 to 50 µg/ mL Heparin 600 mg (Waters QPXE) Plasma LC-MS/MS Human Sodium 580 *Ibuprofen (R & S) 0.1 to 25 μg/mL 200mg (Waters QPXE) Plasma heparin Human 581 Ibuprofen HPLC-UV 1 to 100 µg / mL Heparin 800 mg Plasma LC-MS/MS Human Sodium 582 Ibuprofen 0.1 to 40 µg / mL 100mg & 200mg (API 3200) Plasma heparin LC-MS/MS Human 583 Ibuprofen 0.1 to 90 µg/mL K EDTA 400mg (API 3200) Plasma 2 LC-MS/MS Human 584 Ibuprofen 0.25 to 90 µg/mL Sodium Heparin 600mg (API 3200) Plasma LC-MS/MS Human 585 Imatinib 5 to 3500 ng / mL K EDTA 400 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 400 mg 586 Imatinib 5 to 7500 ng / mL K EDTA (Waters QPXE) Plasma 2 (multiple dosing)

LC-MS/MS Human 587 Imatinib 2 to 800 ng / mL K EDTA 100 mg (API 4000) Plasma 2 LC-MS/MS Human 588 Imanib 4 to 1500 ng/mL K EDTA 10 mg (Waters QPXE) Plasma 2 400 mg single and LC-MS/MS Human 589 Imatinib 10 to 7000 ng/mL K2EDTA 400mg multiple I N D I A D I N (Waters QPXE) Plasma dose LC-MS/MS Human Imatinib 5 to 3500 ng / mL K EDTA 400 mg (Waters QPXE) Plasma 2 590 LC-MS/MS Human N-Desmethyl Imatinib 2 to 500 ng / mL K EDTA - (Waters QPXE) Plasma 2 LC-MS/MS Human Imatinib 5 to 3000 ng / mL Lithium Heparin 400 mg (Waters QPXE) Plasma 591 LC-MS/MS Human N-Desmethyl Imatinib 2 to 400 ng / mL Lithium Heparin - (Waters QPXE) Plasma LC-MS/MS Human Imatinib 2 to 800 ng / mL K EDTA 100 mg (Waters QPXE) Plasma 2 592 LC-MS/MS Human N-Desmethyl Imatinib 0.5 to 125 ng / mL K EDTA - (Waters QPXE) Plasma 2 LC-MS/MS Human 10 to Sodium 593 Irbesartan 300 mg (API 3200) Plasma 10000 ng / mL heparin Iron Sucrose Human 100.050 to 4504.500 Vitros 5.1,FS (Total Iron) Serum µg/mL 594 NA 20mg/mL Iron Sucrose Human 20.007 to Vitros 5.1,FS (Transferrin Bound Iron) Serum 560.560µg/mL

LC-MS/MS Human Itraconazole 1 to 250 ng / mL Heparin 100 mg (Waters QPXE) Serum 595 LC-MS/MS Human OH-Itraconazole 1 to 250 ng / mL Heparin - (Waters QPXE) Plasma

Page 33 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method

LC-MS/MS Human Sodium Itraconazole 1 to 250 ng / mL 100 mg (API 4000) Plasma heparin 596 LC-MS/MS Human Sodium Hydroxy Itraconazole 1 to 250 ng / mL - (API 4000) Plasma heparin

LC-MS/MS Human Sodium Itraconazole 1 to 500 ng/mL 50mg (API 4000) Plasma heparin 597 LC-MS/MS Human Sodium Hydroxy Itraconazole 1 to 500 ng/mL 50mg (API 4000) Plasma heparin LC-MS/MS Human 598 Isosorbide (Shimadzu 10 to 2000 ng / mL K EDTA 120 mg Plasma 2 8060) LC-MS/MS Human 599 *Isotretinoin 10 to 1500 ng / mL K EDTA 40 mg (API 4000) Plasma 2 LC-MS/MS Human 600 Isotretinoin (Shimadzu 0.5 to 1500 ng / mL K EDTA 40 mg (fed study) Plasma 2 8060) LC-MS/MS Human 40 mg ( fasting

I N D I A D I N 601 *Isotretinoin (Shimadzu 0.5 to 600 ng / mL K EDTA Plasma 2 study) 8060) LC-MS/MS Human 300mg/200 602 Isoniazid 50 to 10000 ng / mL K EDTA (Waters QPXE) Plasma 2 mg/100 mg

LC-MS/MS Human 603 Isoniazid 25 to 15000 ng/mL K EDTA 300 mg (Waters QPXE) Plasma 2 Sprague LC-MS/MS 604 *Isotretinoin Dawley Rat 0.75 to 500 ng / mL NA NA (Waters QPXE) Skin LC-MS/MS Rabbit 605 *Isotretinoin 0.75 to 500 ng / mL NA NA (Waters QPXE) Skin

LC-MS/MS Human 606 Ivabradine 0.1 to 100 ng / mL K EDTA 7.5 mg (API 3200) Plasma 2

LC-MS/MS Human 607 Ivermectin 0.25 to 50 ng/mL K EDTA 3mg (Thermo) Plasma 2 K Location : India LC-MS/MS Human 0.3 mg of 608 3-Ketodesogestrel 20 to 5000 pg / mL K EDTA (Thermo) Plasma 2 desogestrel LC-MS/MS Human 609 *6-Keto prostaglandin F1α (Shimadzu 0.125 to 10 ng / mL NA NA Urine 8040)

INDIA HPLC Human 610 Ketoconazole 0.05 to 5 µg / mL CPD 200 mg - Flurosence Plasma

LC-MS/MS Human 611 S-Ketrolac 5 to 1500 ng/mL K EDTA 32 mg (Thermo) Plasma 2

Page 34 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method L Location : Canada LC-MS/MS Human 612 5 to 1500 ng/mL K EDTA 200 mg (Thermo) Plasma 2 LC-MS/MS Human Sodium 613 Lamotrigine 10 to 1280 ng / mL 50 mg (Thermo) Plasma heparin

LC-MS/MS Human Sodium 614 Lansoprazole 2 to 4096 ng / mL 30 mg (API 300 or 3000) Plasma heparin

LC-MS/MS Human 615 Leuprolide 0.025 to 13 ng / mL K EDTA - (Thermo) Plasma 2

LC-MS/MS Human 616 Letrozole 0.5 to 128 ng / mL K EDTA 2.5 mg (API 3000) Plasma 2

LC-MS Human 617 Levetiracetam 0.5 to 24 µg / mL K EDTA - (API 150) Plasma 3

LC-MS/MS Human 618 Levetiracetam 0.375 to 48 µg / mL K EDTA 1 gm (API 3000) Plasma 2

LC-MS/MS Human 619 20 to 10000 pg/mL K EDTA 2 mg (Thermo) Plasma 2

LC-MS/MS Human Lithium 620 Lisinopril 0.25 to 64 ng / mL - (API 300 or 3000) Plasma heparin

LC-MS/MS Human 621 Lisinopril 0.25 to 128 ng / mL Heparin - (API 300 or 3000) Plasma

LC-MS/MS Human Lithium 622 Lisinopril 1 to 256 ng / mL - (API 300 or 3000) Plasma heparin

LC-MS/MS Human 623 Loperamide 0.05 to 6 ng / mL K EDTA 2 mg (Thermo) Plasma 2

C A N D LC-MS/MS Human 0.1 to 51 ng / mL Heparin - (API 3000) Plasma

LC-MS/MS Human 624 Descarboethoxyloratadine 0.1 to 51 ng / mL Heparin - (API 3000) Plasma

LC-MS/MS Human Pseudoephedrine 2.5 to 1280 ng / mL Heparin - (API 3000) Plasma

LC-MS/MS Human Loratadine 0.1 to 51 ng / mL Heparin - (API 300 or 3000) Plasma 625 LC-MS/MS Human Descarboethoxyloratadine 0.1 to 25 ng / mL Heparin - (API 300 or 3000) Plasma

Human Loratadine LC-MS/MS (API 6500) 5 to 5000 pg / mL K EDTA 5mg Plasma 2

LC-MS/MS Human 626 Descarboethoxyloratadine 10 to 10000 pg / mL K EDTA - (API 6500) Plasma 2

LC-MS/MS Human Pseudoephedrine 2.5 to 1250 ng / mL K EDTA 120 mg (API 6500) Plasma 2

LC-MS/MS Human Loratadine 40 to 12000 pg/mL K EDTA 10 mg (API 6500) Plasma 2

LC-MS/MS Human 627 40 to 12000 pg/mL K EDTA N/AP (API 6500) Plasma 2

LC-MS/MS Human Pseudoephedrine 5 to 1600 ng/mL K EDTA 240 mg (API 6500) Plasma 2

Page 35 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 628 Lormetazepam 0.06 to 8 ng / mL K EDTA - (Thermo) Plasma 2

LC-MS/MS Human Losartan 4 to 1027 ng / mL K EDTA 100 mg (API 3000) Plasma 2 629 LC-MS/MS Human Losartan Hydroxy Acid 4 to 1024 ng / mL K EDTA - (API 3000) Plasma 2

C A N D LC-MS/MS Human Lovastatin 0.1 to 25 ng / mL Heparin - (API 300 or 3000) Plasma 630 LC-MS/MS Human Lovastatin Hydroxy Acid 0.2 to 51 ng / mL Heparin - (API 300 or 3000) Plasma Location : India

LC-MS/MS Human 631 Lacidipine 0.025 to 20 ng / mL K EDTA 4 mg / 6 mg (API 4000) Plasma 2

LC-MS/MS Human 632 Lacosamide 25 to 10000 ng / mL K EDTA 200 mg (API 3200) Plasma 2

LC-MS/MS Human 633 Lamivudine 25 to 3000 ng / mL Heparin 150 mg (API 2000) Plasma

LC-MS/MS Human 634 Lamivudine 25 to 6000 ng / mL K EDTA 300 mg (Thermo) Plasma 2

LC-MS/MS Human Lamivudine 10 to 3000 ng / mL K EDTA 150 mg (Shimadzu 8040) Plasma 2 635 LC-MS/MS Human Zidovudine 20 to 4000 ng / mL K EDTA 300 mg (Shimadzu 8040) Plasma 2

LC-MS/MS Human 636 Lamotrigine 25 to 6000 ng / mL K EDTA 200 mg (API 3200) Plasma 2

LC-MS/MS Human 637 Lamotrigine 5 to 1500 ng/mL K EDTA 50mg (Thermo) Plasma 2

LC-MS/MS Human 638 Lamotrigine 1 to 150 ng/mL K EDTA 5mg (Thermo) Plasma 2

LC-MS/MS Human 639 Lamotrigine 7.5 to 3000 ng/mL K EDTA 100mg (Waters QPXE) Plasma 2

I N D I A D I N LC-MS/MS Human Sodium 640 Lansoprazole 10 to 3000 ng/mL 30 mg (API 3200) Plasma heparin

LC-MS/MS Human 641 Lapatinib 15 to 6000 ng / mL K EDTA 1250 mg (API 2000) Plasma 2

LC-MS/MS Human Ledipasvir 5 to 800 ng / mL K2EDTA 90 mg (API 4000) Plasma 642 LC-MS/MS Human Sofosbuvir 10 to 2000 ng / mL K2EDTA 400 mg (API 4000) Plasma

LC-MS/MS Human 643 Lenalidomide 1 to 600 ng / mL K EDTA 10 mg (API 3200) Plasma 2

LC-MS/MS Human 644 Lenalidomide 1 to 1000 ng / mL K2EDTA 25 mg (API 3200) Plasma

LC-MS/MS Human 645 Lercanidipine 0.025 to 12 ng / mL Heparin 20 mg (API 3200) Plasma

LC-MS/MS Human Sodium 646 *Lercanidipine ( R& S) 10 to 4000 pg / mL 10 mg (Shimadzu 8040) Plasma heparin

LC-MS/MS Human 647 *Lercanidipine (R & S) 0.05 to 12 ng / mL Heparin 20 mg (Waters QPXE) Plasma

Page 36 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method

LC-MS/MS Human Sodium 648 *Lercanidipine (R & S) 10 to 16000 pg / mL 20 mg (Shimadzu 8060) Plasma heparin

LC-MS/MS Human 649 Letrozole 1 to 80 ng / mL Heparin 2.5 mg (API 3200) Plasma LC-MS/MS Human Sodium 650 Levetiracetam 0.25 to 40 µg / mL 1000 mg / 750 mg (API 3200) Plasma heparin

LC-MS/MS Human Sodium 651 Levetiracetam 0.25 to 25 µg /mL 750 mg (Thermo) Plasma heparin

LC-MS/MS Human 652 0.5 to 500 ng / mL K EDTA 5 mg (Waters QPXE) Plasma 2

LC-MS/MS Human Levodopa 10 to 3500 ng / mL K EDTA 200 mg (Thermo) Plasma 2 653 LC-MS/MS Human Carbidopa 0.75 to 250 ng / mL K EDTA 50 mg (Thermo) Plasma 2

LC-MS/MS Human Levodopa 15 to 2000 ng / mL K EDTA 200 mg (API 4000) Plasma 2 654 LC-MS/MS Human Carbidopa 1.5 to 250 ng / mL K EDTA 50 mg (API 4000) Plasma 2

LC-MS/MS Human Levodopa 10 to 1500 ng / mL K EDTA 50 mg (Thermo) Plasma 2 655 LC-MS/MS Human Carbidopa 0.5 to 100 ng / mL K EDTA 12.5 mg (Thermo) Plasma 2

Human 656 Levofloxacin HPLC-UV 0.1 to 12 µg / mL Heparin 500 mg Plasma

LC-MS/MS Human 657 Levofloxacin 50 to 16000 ng/mL K EDTA 750 mg (Waters QPXE) Plasma 2

I N D I A D I N LC-MS/MS Human 658 Levonorgestrel 0.2 to 75 ng / mL K EDTA 1.5 mg (API 4000) Plasma 2

LC-MS/MS Human 659 Levonorgestrel 0.2 to 50 ng / mL K EDTA 1.5 mg (API 3200) Plasma 2

LC-MS/MS Human 660 Levonorgestrel 0.05 to 15 ng / mL K EDTA 0.15 mg (API 4000) Plasma 2

LC-MS/MS Human 661 Levonorgestrel 20 to 15000 pg/mL K EDTA - (Waters QPXE) Plasma 2

* LC-MS/MS Human 662 2 to 750 pg/mL K EDTA 45X2 µg (Levabuterol) (Shimadzu 8060) Plasma 2

LC-MS/MS Human 663 *Levothyroxin (T4) 5 to 300 ng / mL NA 600 mcg (API 3200) Serum

LC-MS/MS Human 664 Levothyroxine 5 to 300 ng/mL NA 600 mcg (Shimadzu 8045) Serum

LC-MS/MS Human 665 Linagliptin 0.1 to 10 ng / mL K EDTA 2.5 mg / 5 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 666 Linagliptin 0.1 to 15 ng/mL K EDTA 5 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 50 to 667 Linezolid K EDTA 600 mg (API 3200) Plasma 25000 ng / mL 2

Charcoal stripped LC-MS/MS 668 *Liothyronine Human 0.2 to 20 ng / mL K EDTA 20 mcqx5 Yes (Thermo) 2 Plasma, Human Plasma

Page 37 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 669 Lisinopril 2 to 400 ng /mL K EDTA 40 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 670 Lisinopril 0.5 to 100 ng / mL K EDTA 10 mg (Thermo) Plasma 2

LC-MS/MS Human 671 Lisinopril 0.5 to 100 ng / mL K EDTA 10 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 672 Lisinopril 0.7 to 250 ng/mL K EDTA 20mg (Waters QPXE) Plasma 2

LC-MS/MS Human 673 Lisinopril 0.5 to 100 ng/mL K EDTA 10 mg (Waters XEVO TQ-S) Plasma 2

Human 674 Lithium Carbonate Vitros 5.1,FS 0.274 to 3.754 mol/L NA 450mg Serum

LC-MS/MS Human 0.1 to 40 ng / mL Heparin 75 mg (API 4000) Plasma 675 LC-MS/MS Human 0.2 to 80 ng / mL Heparin - (API 4000) Plasma

LC-MS/MS Human 676 Loperamide 15 to 2500 pg / mL K EDTA 2X2mg (Thermo) Plasma 2

LC-MS/MS Human Lopinavir 10 to 5000 ng / mL K EDTA 100 mg (Waters QPXE) Plasma 2 677 LC-MS/MS Human Ritonavir 0.5 to 300 ng / mL K EDTA 25 mg (Waters QPXE) Plasma 2

LC-MS/MS Human Lopinavir 30 to 20000 ng / mL K EDTA 400 mg (Waters QPXE) Plasma 2 678 LC-MS/MS Human Ritonavir 2.5 to 1600 ng / mL K EDTA 100 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 30 to 20000 ng/mL Lopinavir K EDTA 400 mg (Waters XEVO TQS) Plasma 2

I N D I A D I N 679 LC-MS/MS Human Ritonavir 2.5 to 1600 ng/mL K EDTA 100 mg (Waters XEVO TQS) Plasma 2

LC-MS/MS Human Lopinavir 30 to 20000 ng/mL K EDTA 400 mg (Shimadzu 8045) Plasma 2 680 LC-MS/MS Human Ritonavir 2.5 to 1600 ng/mL K EDTA 100 mg (Shimadzu 8045) Plasma 2

LC-MS/MS Human 681 Lornoxicam 10 to 2500 ng / mL K EDTA 8 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 682 Loratadine 0.1 to 15 ng / mL K EDTA 10 mg (Waters QPXE) Plasma 2

LC-MS/MS Human Loratadine 5 to 5100 pg / mL K EDTA 5 mg (API 6500) Plasma 2 683 LC-MS/MS Human Desloratadine 25 to 10500 pg / mL K EDTA - (API 6500) Plasma 2

LC-MS/MS Human 25 to 15000 pg/mL Loratadine K EDTA (API 6500) Plasma 2 684 10 mg Yes LC-MS/MS Human Desloratadine 25 to 10000 pg/mL K EDTA (API 6500) Plasma 2

LC-MS/MS Human K EDTA / Losartan 5 to 1200 ng / mL 2 - (API 2000) Plasma Heparin 685 LC-MS/MS Human K EDTA / Losartan carboxylic acid 5 to 1200 ng / mL 2 - (API 2000) Plasma Heparin

LC-MS/MS Human Losartan 10 to 1500 ng / mL K EDTA 100 mg (API 2000) Plasma 2 686 LC-MS/MS Human Losartan carboxylic acid 25 to 2000 ng / mL K EDTA - (API 2000) Plasma 2

Page 38 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human Losartan 2 to 2200 ng/mL K EDTA 100mg (API 4000) Plasma 2 687 LC-MS/MS Human Losartan carboxylic acid 3 to 2200 ng/mL K EDTA - (API 4000) Plasma 2

LC-MS/MS Human Losartan 0.25 to 500 ng/mL K EDTA (Waters XEVO TQ-S) Plasma 2 688 12.5 mg LC-MS/MS Human Losartan carboxylic acid 1 to 400 ng/mL K EDTA (Waters XEVO TQ-S) Plasma 2

LC-MS/MS Human Losartan 2 to 2500 ng/mL K EDTA 100mg (Waters XEVO TQ-S) Plasma 2 689 LC-MS/MS Human Losartan carboxylic acid 3 to 2200 ng/mL K EDTA (Waters XEVO TQ-S) Plasma 2

LC-MS/MS Human 690 Losartan 2 to 800 ng / mL K EDTA 50 mg (API 3200) Plasma 2

LC-MS/MS Human 691 Losartan 2 to 1500 ng / mL K EDTA 100 mg (API 3200) Plasma 2

LC-MS/MS Human Losartan 5 to 1500 ng / mL K EDTA 100 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 692 Losartan Carboxylic Acid 5 to 2000 ng / mL K EDTA - (Waters QPXE) Plasma 2

LC-MS/MS Human Hydrochlorthiazide 1 to 400 ng / mL K EDTA 25 mg (Waters QPXE) Plasma 2

LC-MS/MS Human Losartan 2 to 800 ng / mL K EDTA 50 mg (API 4000) Plasma 2 I N D I A D I N LC-MS/MS Human 693 Losartan carboxylic acid 3 to 1200 ng / mL K EDTA - (API 4000) Plasma 2

LC-MS/MS Human S-amlodipine 0.2 to 10 ng / mL K EDTA 5 mg (API 4000) Plasma 2

LC-MS/MS Human 48 mcg of 694 *15-hydroxy lubiprostone 1 to 100 pg / mL K EDTA (Waters XEVO TQ-S) Plasma 2 lubiprostone

LC-MS/MS Human 695 Lumefantrine 50 to 20250 ng / mL K EDTA 480 mg (API 4000) Plasma 2 LC-MS/MS Human 696 0.1 to 100 ng / mL K EDTA 40 mg (API 4000) Plasma 2 LC-MS/MS Human 697 Lurasidone 0.1 to 100 ng / mL K EDTA 40 mg (API 3200) Plasma 2 LC-MS/MS Human 698 Lurasidone 0.2 to 200 ng / mL K EDTA 40 mg (API 6500) Plasma 2 LC-MS/MS Human 699 Lurasidone 0.2 to 200 ng / mL K EDTA 40 mg (Waters QPXE) Plasma 2 LC-MS/MS Human *Lurasidone 0.2 to 100 ng / mL K EDTA 40 mg (API 4000) Plasma 2 LC-MS/MS Human 700 *Lurasidone 14283 0.1 to 30 ng / mL K EDTA - (API 4000) Plasma 2 LC-MS/MS Human *Lurasidone 14326 25 to 5000 pg / mL K EDTA - (API 4000) Plasma 2 M Location : Canada LC-MS/MS Human 701 1.01 to 256 ng / mL K EDTA 25 mg (API 3000) Plasma 2 Human 702 Mefanamic Acid HPLC-UV 50 to 6400 ng / mL K EDTA - Plasma 2

CANADA LC-MS/MS Human 703 Mefanamic Acid 50 to 12800 ng / mL K EDTA 250 mg (API 3000) Plasma 2

Page 39 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human Sodium 704 Medroxyprogesterone Acetate 0.02 to 10 ng / mL - (API 3000) Plasma heparin LC-MS/MS Human Sodium 705 Medroxyprogesterone Acetate 50 to 10000 pg/mL 150 mg (Thermo) Plasma heparin LC-MS/MS Human 706 Megestrol Acetate 0.3 to 153.6 ng/mL K EDTA 40 mg / mL (Thermo) Plasma 2 Human Plasma or 707 Meloxicam HPLC-UV 0.03 to 1.92 µg / mL K EDTA - Dog 2 Plasma LC-MS/MS Human Not 708 Meloxicam 1 to 128 ng / mL - (API 3000) Urine applicable LC-MS/MS Human 709 Meloxicam 10 to 2560 ng / mL K EDTA 15 mg (API 3000) Plasma 2 LC-MS/MS Human 710 Mesalamine 5 to 3000 ng/mL K EDTA 500 mg (API 6500) Plasma 2 Human 711 Metaxalone HPLC-UV 1 to 256 µg / mL Heparin - Plasma Human 712 Metaxalone HPLC-UV 1 to 256 µg / mL K EDTA - Plasma 3 Human 713 Metaxalone LC-MS (API 150) 5 to 2560 ng / mL K EDTA - Plasma 3 LC-MS/MS Human 714 Metaxalone 20 to 6000 ng / mL K EDTA 400 mg (API 6500) Plasma 2 LC-MS/MS Human 715 0.1 to 50 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human Sodium Fluoride & 716 Methylphenidate 0.1 to 50 ng/mL 54mg (Thermo) Plasma Potassium Oxalate CANADA LC-MS/MS Human 717 Methylphenidate 0.026 to 15 ng/mL K EDTA 20 mg (Thermo) Plasma 2 L-Threo- Human LC-MS/MS (API 6500) 1 to 195 pg/mL K EDTA 18 mg Methylphenidate Plasma 2 718 D-Threo- Human LC-MS/MS (API 6500) 25 to 9800 pg/mL K EDTA NA Methylphenidate Plasma 2 LC-MS/MS Human 719 Methylphenidate Achiral 0.1 to 50 ng/mL K EDTA 54 mg (Thermo) Plasma 2 Methylphenidate LC-MS/MS Human 100 to 30000 pg/mL(D) K EDTA 54 mg Chiral(L&D) (API 6500) Plasma 2 720 Methylphenidate LC-MS/MS Human 50 to 4000 pg/mL(L) K EDTA 54 mg Chiral(L&D) (API 6500) Plasma 2

Methylphenidate LC-MS/MS Human Sodium fluoride & 15 to 3000 pg/mL (L) 60 mg Chiral(L&D) (Thermo) Plasma Potassium oxalate 721 Methylphenidate LC-MS/MS Human 200 to 40000 pg/mL Sodium fluoride & 60 mg Chiral(L&D) (Thermo) Plasma (D) Potassium oxalate

LC-MS/MS Human Sodium fluoride 722 Methylprednisolone 0.4 to 51 ng / mL - (API 3000) Plasma potassium oxalate

80mg/mL LC-MS/MS Human Sodium Fluoride & 723 Methylprednisolone 0.4 to 75 ng/mL Injectable (API 6500) Plasma Potassium Oxalate suspension LC-MS/MS Human Sodium 724 1 to 512 ng / mL 200 mg (API 3000) Plasma heparin

Page 40 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 10.01 to 725 Metformin K EDTA 1000 mg (API 3000) Plasma 2002 ng / mL 2

LC-MS Human Not 726 Metformin 2 to 256 µg / mL 1000 mg (API 150) Urine applicable

LC-MS/MS Human 727 Methazolamide 5 to 10000 ng / mL K EDTA 150 mg (Waters QPXE) Plasma 2 Human LC-MS/MS 728 Methazolamide Whole 100 to 50000 ng / mL K EDTA 150 mg (Waters QPXE) 2 Blood LC-MS/MS Human 729 Methazolamide 5 to 9800 ng/mL K EDTA 150 mg (Thermo) Plasma 2

LC-MS/MS Human 5mg/0.1 mL Nasal Midazolam 1 to 200 ng/mL K EDTA (Thermo) Plasma 2 Spray 730 Yes LC-MS/MS Human α-Hydroxy Midazolam 0.1 to 20 ng/mL K EDTA - (Thermo) Plasma 2

LC-MS/MS Human 731 Minocycline 4 to 3500 ng / mL K EDTA 45 mg to 135 mg (Thermo) Plasma 2

LC-MS/MS Human Sodium 732 0.5 to 128 ng / mL - (API 300 or 3000) Plasma heparin

LC-MS/MS Human Lithium Misoprostol Acid 10 to 1280 pg / mL - (Thermo) Plasma heparin

CANADA 733 LC-MS/MS Human Lithium Diclofenac 20 to 2560 ng / mL - (Thermo) Plasma heparin

LC-MS/MS Human 734 Mometasone furoate 0.5 to 100 pg/mL K EDTA 50 µg Nasal spray Yes (Thermo) Plasma 2

LC-MS/MS Human 735 Monomethyl fumarate 10 to 6000 ng/mL K EDTA 120 mg (API 6500) Plasma 2

LC-MS/MS Human Monomethyl fumarate 20 to 5000 ng / mL K EDTA 240 mg DMF (Thermo) Plasma 2 736 LC-MS/MS Human Monoethyl fumarate 20 to 5000 ng / mL K EDTA (Thermo) Plasma 2

Human 737 Mycophenolic Acid HPLC-UV 0.1 to 51 µg / mL K EDTA - Plasma 2

LC-MS/MS Human Mycophenolate Mofetil 0.04 to 20 ng / mL K EDTA 250 mg (Thermo) Plasma 2 738 LC-MS/MS Human Mycophenolic Acid 0.1 to 51 µg / mL K EDTA - (Thermo) Plasma 2

6-Methoxy-2- HPLC Human 739 0.5 to 32 µg / mL Heparin - Naphthaleneacetic Acid - Flurosence Plasma Location : India

LC-MS/MS Human 740 Macitentan 2 to 400 ng/mL K EDTA 10 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 741 Mebendazole 0.2 to 125 ng / mL K EDTA 500mg (API 4000) Plasma 2 LC-MS/MS Human 135 mg of Mebeverine acid 1 to 1000 ng / mL K EDTA (Shimadzu 8060) Plasma 2 Mebeverine 742 LC-MS/MS Human 135 mg of Desmethyl Mebeverine acid 2 to 1200 ng / mL K EDTA (Shimadzu 8060) Plasma 2 Mebeverine I N D I A D I N LC-MS/MS Human 135 mg of Mebeverine acid 1 to 1000 ng / mL K EDTA (API 4000) Plasma 2 Mebeverine LC-MS/MS Human 135 mg of 743 Desmethyl mebeverine acid 2 to 1200 ng / mL K EDTA (API 4000) Plasma 2 Mebeverine LC-MS/MS Human 135 mg of Veratric acid 25 to 10000 ng / mL K EDTA (API 4000) Plasma 2 Mebeverine

Page 41 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method *Medroxy Progesterone LC-MS/MS Human 744 50 to 8000 pg / mL Sodium Heparin 150 mg Acetate (Thermo) Plasma

LC-MS/MS Human Sodium 745 Medroxy Progesterone 50 to 8000 pg/mL 150 mg (Shimadzu 8060) Plasma heparin

LC-MS/MS Human 746 Mefenamic Acid 25 to 10000 ng/mL K EDTA 250mg (Waters QPXE) Plasma 2

LC-MS/MS Human 747 Megestrol Accetate 1 to 300 ng / mL K EDTA 160 mg (API 3200) Plasma 2

LC-MS/MS Human 748 Melatonin 25 to 10000 pg / mL K EDTA 5 mg (API 4000) Plasma 2

LC-MS/MS Human 749 Melatonin 25 to 15000 pg/mL K EDTA 3mg (API 6500) Plasma 2

LC-MS/MS Human 750 Meloxicam 20 to 3000 ng / mL K EDTA 15 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 751 Meloxicam 20 to 3000 ng/mL K EDTA 15 mg (API 4000) Plasma 2

LC-MS/MS Human 752 0.2 to 25 ng / mL K EDTA 10 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 753 Memantine 0.5 to 50 ng / mL K EDTA 20 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 754 Memantine 0.5 to 50 ng / mL K EDTA 20 mg (API 3200) Plasma 2

LC-MS/MS Human 755 Memantine 0.5 to 100 ng / mL K EDTA 28 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 756 Memantine 0.5 to 100 ng/mL K EDTA 28mg (Shimadzu 8060) Plasma 2

LC-MS/MS Human

I N D I A D I N 757 6-Mercaptopurine 1 to 300 ng/mL K EDTA 50mg (Waters QPXE) Plasma 2

LC-MS/MS Human 758 Mesalamine 5 to 700 ng / mL K EDTA 1000 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 759 Mesalamine 5 to 3000 ng / mL K EDTA 1.2 gm (Waters QPXE) Plasma 2

LC-MS/MS Human 1000 mg rectal 760 Mesalamine 2 to 700 ng / mL K EDTA (API 4000) Plasma 2 suppository

LC-MS/MS Human Mesalamine 5 to 3000 ng/mL K EDTA 1000 mg (Thermo) Plasma 2 761 LC-MS/MS Human N-Acetyl Mesalamine 10 to 5000 ng/mL K EDTA 1000 mg (Thermo) Plasma 2

LC-MS/MS Human Sodium 762 Metformin 5 to 1600 ng / mL 500 mg (Waters QPXE) Plasma heparin

LC-MS/MS Human Sodium 763 Metformin 5 to 3500 ng / mL 1000 mg (Waters QPXE) Plasma heparin

LC-MS/MS Human Sodium 764 Metformin 5 to 1600 ng / mL 500mg (API 3200) Plasma heparin

LC-MS/MS Human Sodium 765 Metformin 5 to 3500 ng/mL 1000mg (Thermo) Plasma heparin

LC-MS/MS Human 766 Methazolamide 25 to 15000 ng/mL K EDTA 50 mg (Thermo) Blood 2

LC-MS/MS Human 767 Methimazole 2 to 500 ng/mL K EDTA 20 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 768 Methocarbamol 0.05 to 20 µg/mL K EDTA 750mg (Thermo) Plasma 2

Page 42 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 769 Methocarbamol 0.05 to 20 µg/mL K EDTA 750mg/500mg (API 4000) Plasma 2

LC-MS/MS Human 770 Methotrexate 0.5 to 150 ng / mL K EDTA 2.5 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 771 4-Methyl aminoantipyrine 20 to 10000 ng / mL K EDTA 250mg (Waters QPXE) Plasma 2 LC-MS/MS Human *L-Methylphenidate 50 o 4000 pg / mL K EDTA 54 mg (Waters QPXE) Plasma 2 772 LC-MS/MS Human 100 to *D-Methylphenidate K EDTA 54 mg (Waters QPXE) Plasma 20000 pg / mL 2

LC-MS/MS Human Sodium fluoride and 80 mg/mL (Multi 773 Methylprednisolone 0.4 to 50 ng/mL (API 4000) Plasma Potassium oxalate Dose Vials)

LC-MS/MS Human Sodium fluoride and 774 Methylprednisolone 0.4 to 75 ng/mL 4 mg (API 4000) Plasma Potassium oxalate

LC-MS/MS Human 5 mg/5 mL oral 775 0.25 to 50 ng/mL K EDTA (API 4000) Plasma 2 solution

LC-MS/MS Human 776 Metoprolol 0.3 to 50 ng /mL Heparin 23.75 mg (API 4000) Plasma

LC-MS/MS Human 47.5 / 777 Metoprolol 0.2 to 100 ng /mL Heparin (API 3200) Plasma 50 mg

LC-MS/MS Human Sodium 778 Metoprolol 0.7 to 150 ng/mL 100mg (API 3200) Plasma heparin

LC-MS/MS Human 100 / 779 Metoprolol 0.75 to 300 ng /mL Sodium Heparin (API 3200) Plasma 200 mg

LC-MS/MS Human I N D I A D I N 25 to 5000 ng / mL Heparin 200 mg (Thermo) Plasma

N-desmethyl LC-MS/MS Human 50 to 5000 ng / mL Heparin - Mifepristone (Thermo) Plasma 780 N, N-didesmethyl LC-MS/MS Human 10 to 2000 ng / mL Heparin - mifepristone (Thermo) Plasma

LC-MS/MS Human Hydroxy mifepristone 10 to 1000 ng / mL Heparin - (Thermo) Plasma

LC-MS/MS Human 781 1 to 300 ng / mL K EDTA 50 mg (Thermo) Plasma 2

LC-MS/MS Human 782 Miltefosine 10 to 2500 ng / mL K EDTA 100/150 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 783 Minocycline 10 to 3000 ng / mL Heparin 90 mg (Waters QPXE) Plasma

LC-MS/MS Human 784 Minocycline 25 to 3500 ng /mL K EDTA 135 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 785 Minoxidil 50 to 4000 pg / mL NA 5% lipid solution (API 4000) Serum

LC-MS/MS Human 786 Mirabegrone 0.2 to 100 ng / mL K EDTA 50 mg (API 3200) Plasma 2

LC-MS/MS Human 787 Mirabegrone 0.1 to 75 ng / mL K EDTA 50mg (API 4000) Plasma 2

LC-MS/MS Bufferised 788 Mirabegrone 0.1 to 75 ng / mL K EDTA 50mg PR (API 3200) Human Plasma 2

Page 43 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 789 Misoprostol Acid 5 to 750 pg / mL K EDTA 0.2 mg (fed study) (API 6500) Plasma 2

LC-MS/MS Human 0.2 mg ( fasting 790 *Misoprostol Acid 10 to 1700 pg / mL K EDTA (API 4000) Plasma 2 study)

LC-MS/MS Human 791 Moexipril 0.5 to 150 ng / mL K EDTA 15 mg (API 4000) Plasma 2

LC-MS/MS Human 792 Monomethyl Fumarate 10 to 6000 ng / mL K EDTA 240 mg DMF (Waters QPXE) Plasma 2

LC-MS/MS Human 793 Monomethyl Fumarate 10 to 6000 ng / mL K EDTA 120 mg (API 6500) Plasma 2

LC-MS/MS Human 794 Monomethyl Fumarate 10 to 6000 ng / mL K EDTA 240 mg (Shimadzu 8045) Plasma 2

LC-MS/MS Human 795 Monoxidine 30 to 7500 pg/mL K EDTA 400 µg (Thermo) Plasma 2

LC-MS/MS Human 796 Montelukast 5 to 1000 ng / mL Heparin 10 mg (API 3200) Plasma

LC-MS/MS Human 797 Montelukast 5 to 500 ng / mL Heparin 5 mg (API 3200) Plasma

LC-MS/MS Human 798 Moxifloxacin 15 to 6000 ng / mL Heparin 400 mg (Waters QPXE) Plasma

LC-MS/MS Human Sodium 799 Moxifloxacin 15 to 6000 ng / mL 400 mg (API 4000) Plasma heparin

LC-MS/MS Human Mycophenolate Mofetil 0.05 to 10 ng/mL K EDTA 250 mg (Waters QPXE) Plasma 2 800

I N D I A D I N LC-MS/MS Human Mycophenolic Acid 50 to 25000 ng/mL K EDTA NA (Waters QPXE) Plasma 2

LC-MS/MS Human Mycophenolate mofetil 0.1 to 10 ng / mL K EDTA 500 mg (Waters QPXE) Plasma 2 801 LC-MS/MS Human 75 to Mycophenolic acid K EDTA - (Waters QPXE) Plasma 25000 ng / mL 2 250 mg LC-MS/MS Human 0.05 to 10 ng/mL Mycophenolate Mofetil K EDTA (Bufferisesd (Waters QPXE) Plasma 2 plasma) 802 250 mg LC-MS/MS Human Mycophenolic Acid 80 to 40000 ng/mL K EDTA (Bufferisesd (Waters QPXE) Plasma 2 plasma) LC-MS/MS Human 803 Mycophenolic acid 0.1 to 50 µg / mL K EDTA 360 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 25 to 804 Mycophenolic acid K EDTA 180 mg (Waters QPXE) Plasma 15000 ng / mL 2

LC-MS/MS Human 805 Mycophenolic acid 60 to 60000 ng/mL K EDTA 1000 mg Yes (Waters QPXE) Plasma 2

LC-MS/MS Human 806 Mycophenolic acid 50 to 16000 ng/mL K EDTA 180 mg (API 3200) Plasma 2

LC-MS/MS Human Mycophenolate mofetil 0.05 to 20 ng / mL K EDTA 1 gm (Waters QPXE) Plasma 2 807 LC-MS/MS Human 100 to Mycophenolic acid K EDTA - (Waters QPXE) Plasma 50000 ng / mL 2

Page 44 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method N Location : Canada LC-MS/MS Human 2 to 256 ng / mL K EDTA - (API 3000) Plasma 2 808 LC-MS/MS Human Bendroflumethiazide 1 to 128 ng / mL K EDTA - (API 3000) Plasma 2 LC-MS/MS Human 809 Naloxone 1 to 500 pg/mL K EDTA 20 mg (API 6500) Plasma 2 LC-MS/MS Human 810 Naloxone 0.02 to 20 ng/mL K EDTA 0.4 mg/mL (Thermo) Plasma 2 LC-MS/MS Human Naloxone-3-β-D-Glucuronide 1 to 300 ng/mL K EDTA 20 mg (API 6500) Plasma 2 811 LC-MS/MS Human Oxycodone 0.5 to 150 ng/mL K EDTA 40 mg (API 6500) Plasma 2 Sodium heparin for Human or LC-MS/MS human plasma; Naltrexone Dog 0.1 to 205 ng / mL 50 mg (API 3000) K EDTA for dog Plasma 3 plasma 812 Sodium heparin for Human or LC-MS/MS human plasma; 6-ß-Naltrexol Dog 0.1 to 205 ng / mL - (API 3000) K3EDTA for dog Plasma plasma

LC-MS/MS Human Not Naltrexone 1 to 512 ng / mL - (API 3000) Urine applicable 813 LC-MS/MS Human 9.947 to Not 6-ß-Naltrexol - (API 3000) Urine 5092 ng / mL applicable Human 814 Naproxen HPLC - Flurosence 0.5 to 128 µg / mL Heparin - Plasma LC-MS/MS Human 815 15 to 5000 pg/mL K2EDTA 5 mg

C A N D (API 6500) Plasma Human LC-MS (API 150) 6.25 to 800 ng / mL Heparin - Plasma Human 816 2-Hydroxynefazodone LC-MS (API 150) 1.88 to 240 ng / mL Heparin - Plasma m- Human LC-MS (API 150) 1.25 to 160 ng / mL Heparin - Chlorophenylpiperazine Plasma LC-MS/MS Human Niacin 20 to 2000 ng / mL K EDTA 1000 mg (Thermo) Plasma 2 817 LC-MS/MS Human Nicotinuric acid 20 to 2000 ng / mL K EDTA - (Thermo) Plasma 2 Human 818 Nifedipine LC-MS (API 150) 0.5 to 200 ng / mL K EDTA 60 mg Plasma 3 LC-MS/MS Human 819 Nifedipine 0.5 to 200 ng / mL K EDTA 60 mg (API 3000) Plasma 2 LC-MS/MS Human 820 Nintedanib 0.050- 20 ng/mL K EDTA 150mg (Thermo) Plasma 2 LC-MS/MS Human 821 Nitisinone 10 to 2500 ng/mL K EDTA 10 mg (Thermo) Plasma 2 Human Sodium 822 Nitrofurantoin HPLC-UV 20 to 2560 ng / mL - Plasma heparin LC-MS/MS Human 25mg/5mL 823 Nitrofurantoin 5 to 1000 ng/mL K EDTA (Thermo) Plasma 2 suspension

Page 45 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human Nitroglycerin 20 to 4000 pg/mL K EDTA (API 6500) Plasma 2 LC-MS/MS Human 824 1,3-Dinitroglycerin 40 to 4000 pg/mL K EDTA 1.5mg (API 6500) Plasma 2 LC-MS/MS Human 1,2-Dinitroglycerin 40 to 8000 pg/mL K EDTA (API 6500) Plasma 2 Human HPLC-UV 10 to 5120 ng / mL Heparin 300 mg Plasma 825 Human Desmethylnizatidine HPLC-UV 5 to 2560 ng / mL Heparin - Plasma Human 826 Norfloxacin HPLC - Flurosence 20 to 2560 ng / mL K EDTA - Plasma 3 Human C A N D 827 Nortriptyline HPLC-UV 1 to 64 ng / mL K EDTA - Plasma 3 LC-MS/MS Human 828 Norethindrone 50 to 15000 pg / mL K EDTA 0.35 mg / 1 mg (Thermo) Plasma 2 LC-MS/MS Human 829 RS-Norketotifen 0.2 to 70 ng/mL K EDTA 8 mg (Thermo) Plasma 2 LC-MS/MS Human S-Norketotifen 1 - 1000 ng/mL K EDTA 4 mg/8mg/16mg (Thermo) Plasma 2 830 LC-MS/MS Human R- Norketotifen 1 - 1000 ng/mL K EDTA NA (Thermo) Plasma 2 Location : India LC-MS/MS Human 831 *Nabilone 40 to 5000 pg / mL K EDTA 0.3 mg (Thermo) Plasma 2 LC-MS/MS Human 832 Nadolol 0.25 to 45 ng / mL K EDTA 20 mg (API 4000) Plasma 2 LC-MS/MS Human 833 Nadolol 1 to 500 ng / mL K EDTA 80 mg (API 3200) Plasma 2 LC-MS/MS Human 834 Oxalate 1 to 600 ng/mL K EDTA 100 mg Yes (Thermo) Plasma 2 LC-MS/MS Human 835 Naloxegol 0.1 to 125 ng/mL K EDTA 25 mg (Shimadzu 8060) Plasma 2 LC-MS/MS Human 836 Naltrexone 50 to 35500 pg / mL Heparin 50 mg (Waters QPXE) Plasma LC-MS/MS Human Naltrexone 0.1 to 20 ng /mL Heparin 50 mg (Waters QPXE) Plasma 837 LC-MS/MS Human 6 beta Naltrexol 0.5 to 200 ng / mL Heparin - I N D I A D I N (Waters QPXE) Plasma LC-MS/MS Human Naltrexone 0.5 to 50 ng /mL Heparin 100 mg (Waters QPXE) Plasma 838 LC-MS/MS Human 6 beta Naltrexol 5 to 500 ng / mL Heparin - (Waters QPXE) Plasma LC-MS/MS Human 40 to 12000 pg/mL Naltrexone K EDTA 2x8 mg (API 4000) Plasma 2 839 Yes LC-MS/MS Human 6 beta Naltrexol 0.25 to 70 ng/mL K EDTA 2x8 mg (API 4000) Plasma 2 LC-MS/MS Human 840 0.1 to 20 ng / mL Heparin 2.5 mg (API 3200) Plasma LC-MS/MS Human 500 to 841 Naproxen K EDTA 200 mg (API 2000) Plasma 50000 ng /mL 2

Page 46 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 842 Naproxen 0.5 to 120 µg / mL K EDTA 500 mg (Waters QPXE) Plasma 2 LC-MS/MS Human Naproxen 0.5 to 120 µg / mL K EDTA 500 mg (Waters QPXE) Plasma 2 843 LC-MS/MS Human Esomeprazole 1 to 1500 ng / mL K EDTA 20 mg (Waters QPXE) Plasma 2 LC-MS/MS Human Naproxen 0.5 to 120 µg / mL K EDTA 500 mg (Waters QPXE) Plasma 2 844 LC-MS/MS Human Esomeprazole 1 to 350 ng / mL K EDTA 20 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 845 Nateglinide 0.1 to 10 µg / mL K EDTA 120 mg (API 3200) Plasma 2 LC-MS/MS Human 846 Nebivolol 0.075 to 20 ng / mL Heparin 20 mg (API 4000) Plasma LC-MS/MS Human Sodium *D-Nebivolol 15 to 2000 pg/mL (Shimadzu 8045) Plasma heparin 847 5mg LC-MS/MS Human Sodium *L-Nebivolol 20 to 3000 pg/mL (Shimadzu 8045) Plasma heparin Human 100 to 848 Nevirapine HPLC-UV CPD 200 mg Plasma 4000 ng / mL LC-MS/MS Human 849 *Niacin 2 to 2000 ng / mL K EDTA 1000 mg / 750 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 850 *Niacin 1 to 250 ng / mL K EDTA 500 mg (Waters QPXE) Plasma 2 LC-MS/MS Human *Niacin 4 to 2000 ng / mL K EDTA 1000 mg (Waters QPXE) Plasma 2 851 LC-MS/MS Human *Nicotinuric acid 3 to 1500 ng / mL K EDTA - (Waters QPXE) Plasma 2 I N D I A D I N LC-MS/MS Human 852 Nicorandil 0.5 to 500 ng / mL K EDTA 20 mg (API 3200) Plasma 2 LC-MS/MS Human 60 mg / 853 Nifedipine 2.5 to 250 ng / mL K EDTA (API 2000) Plasma 2 90 mg LC-MS/MS Human 854 Nimodipine 0.1 to 50 ng / mL K2EDTA 30 mg (Thermo) Plasma LC-MS/MS Human 855 Nintedanib 0.2 to 75 ng/mL K EDTA 150 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 856 *Nitrazepam 0.2 to 100 ng / mL K EDTA 5 mg (API 3200) Plasma 2 LC-MS/MS Human 857 Nitrofurantoin 2.5 to 500 ng/mL K EDTA 25mg/5mL (Thermo) Plasma 2 LC-MS/MS Human 858 Nitrofurantoin 5 to 1000 ng / mL K EDTA 100 mg (Thermo) Plasma 2 LC-MS/MS Human 859 Nitrofurantoin 5 to 1000 ng/mL K EDTA 100 mg (API 6500) Plasma 2 LC-MS/MS 0.6mg sublingual Human *Nitroglycerin (Shimadzu 20 to 4000 pg/mL K EDTA tablet fasting Plasma 2 8060) condition

LC-MS/MS 0.6mg sublingual Human 860 1,3-di Nitroglycerin (Shimadzu 40 to 8000 pg/mL K EDTA tablet fasting Plasma 2 8060) condition

LC-MS/MS 0.6mg sublingual Human 1,2-di Nitroglycerin (Shimadzu 40 to 8000 pg/mL K EDTA tablet fasting Plasma 2 8060) condition Human K EDTA / 861 Nizatidine HPLC-UV 20 to 4000 ng / mL 2 300 mg Plasma Heparin LC-MS/MS Human 862 Nomegestrol Acetate 0.1 to 20 ng / mL K EDTA 2.5 mg (Shimadzu 8040) Plasma 3

Page 47 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 863 19-Norethindrone 0.25 to 50 ng / mL K EDTA 5 mg (API 4000) Plasma 2 LC-MS/MS Human 864 19-Norethindrone 0.075 to 15 ng / mL K EDTA 1 mg (Thermo) Plasma 2 LC-MS/MS Human 865 19-Norethindrone 50 to 15000 pg / mL K EDTA 0.35 mg (Thermo) Plasma 2

I N D I A D I N LC-MS/MS Human 866 Nortriptyline 0.1 to 75 ng / mL K2EDTA 50 mg (Thermo) Plasma LC-MS/MS Human 867 Nortriptyline 0.1 to 20 ng / mL K EDTA 25 mg (Waters QPXE) Plasma 2 O Location : Canada LC-MS/MS Human 868 0.2 to 25 ng / mL K EDTA 10 mg (API 3000) Plasma 2 LC-MS/MS Human Olmesartan 6 to 1536 ng / mL K EDTA 40 mg (API 3000) Plasma 2 869 LC-MS/MS Human 2.01 to Hydrochlorthiazide K EDTA 25 mg (API 3000) Plasma 512.46 ng / mL 2 LC-MS/MS Human Sodium 870 Omeprazole 1 to 1024 ng / mL - (API 3000) Plasma heparin LC-MS/MS Human 871 Omeprazole 5 to 3450 ng / mL K EDTA 40 mg (Thermo) Plasma 2 LC-MS/MS Human 872 Omeprazole 5 to 3400 ng/mL K EDTA 20 mg (Thermo) Plasma 2 LC-MS/MS Human Lithium 873 0.5 to 128 ng / mL 8 mg (API 3000) Plasma heparin LC-MS/MS Human 300 mg/ 874 Oxcarbazepine 0.01 to 10 µg / mL K EDTA (API 3000) Plasma 2 5 mL 10,11-dihydro-10- LC-MS/MS Human 875 0.05 to 51.2 µg / mL K EDTA - Hydroxycarbamazepine (API 3000) Plasma 2 LC-MS/MS Human 300 mg/ Oxcarbazepine 0.01 to 5.12 µg / mL K EDTA (Thermo) Plasma 2 5 mL 876 10,11-dihydro-10- LC-MS/MS Human 0.05 to 25.6 µg / mL K EDTA - Hydroxycarbamazepine (Thermo) Plasma 2 LC-MS/MS Human 877 Oxycodone 0.1 to 60 ng / mL K EDTA 5 mg (Thermo) Plasma 2 CANADA LC-MS/MS Human 878 Oxycodone 0.5 to 150 ng / mL K EDTA 80 mg (Thermo) Plasma 2 LC-MS/MS Human Oxycodone 0.1 to 101 ng / mL Heparin - (API 3000) Plasma 879 LC-MS/MS Human Oxymorphone 0.1 to 100 ng / mL Heparin - (API 3000) Plasma LC-MS/MS Human Oxycodone 0.234 to 60 ng / mL K EDTA 20 mg (Thermo) Plasma 2 880 LC-MS/MS Human Oxymorphone 0.234 to 60 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human Oxycodone 0.5 to 255 ng / mL K EDTA - (API 3000) Plasma 3 LC-MS/MS Human 881 Noroxycodone 0.5 to 256 ng / mL K3EDTA - (API 3000) Plasma LC-MS/MS Human Oxymorphone 0.1 to 51.2 ng / mL K EDTA - (API 3000) Plasma 3 LC-MS/MS Human Oxybutynin 0.16 to 20 ng / mL Heparin - (API 300 or 3000) Plasma 882 LC-MS/MS Human Desethyloxybutynin 0.3 to 40 ng / mL Heparin - (API 300 or 3000) Plasma

Page 48 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human Oxymorphone 40 to 1280 pg / mL K EDTA - (Thermo) Plasma 2 883 LC-MS/MS Human Hydroxy Oxymorphone 25 to 800 pg / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human Oxymorphone 40 to 3200 pg / mL K EDTA 10 mg (Thermo) Plasma 2 884 LC-MS/MS Human Hydroxy Oxymorphone 25 to 2000 pg / mL K2EDTA 10 mg CANADA (Thermo) Plasma LC-MS/MS Human 0.025 to Oxymorphone K EDTA 20 mg (Thermo) Plasma 8.000 ng/mL 2 885 LC-MS/MS Human 0.025 to Hydroxy Oxymorphone K EDTA 20 mg (Thermo) Plasma 8.000 ng/mL 2 Location : India Human Fecal/ 60 mg / 886 *Orlistate (Fat analysis) FT-IR 0.25 to 10 g % NA Human 120 mg Food LC-MS/MS Human Oglimilast (GRC 3886) 0.5 to 100 ng / mL K EDTA 200 mg (API 4000) Plasma 2 887 Oglimilat N-Oxide LC-MS/MS Human 0.5 to 100 ng / mL K EDTA - (GRC 3886 N-Oxide) (API 4000) Plasma 2 LC-MS/MS Human Sodium 888 Olanzapine 0.1 to 25 ng / mL 5 mg (Waters QPXE) Plasma heparin LC-MS/MS Human 889 Olanzapine 0.1 to 45 ng / mL Sodium Heparin 10 mg (Waters QPXE) Plasma LC-MS/MS Human 2.5 to 890 Olmesartan K EDTA 20 mg (API 3200) Plasma 1500 ng / mL 2 LC-MS/MS Human 891 Olmesartan 0.25 to 500 ng / mL K EDTA 5 mg (API 3200) Plasma 2 LC-MS/MS Human 892 Olmesartan 5 to 4500 ng/mL K EDTA 40 mg (API 3200) Plasma 2 LC-MS/MS Human 893 Omeprazole 1 to 1000 ng / mL K EDTA 10 mg (Waters QPXE) Plasma 2 I N D I A D I N LC-MS/MS Human 894 Omeprazole 5 to 1500 ng / mL K EDTA 20 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 895 Omeprazole 5 to 3500 ng / mL K EDTA 40 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 896 Omeprazole 2 to 2200 ng/ml K EDTA 20 mg (API 3200) Plasma 2 LC-MS/MS Human 20 mg (without 897 Omeprazole 2 to 2200 ng/mL K EDTA (API 3200) Plasma 2 buffer) LC-MS/MS Human 898 Ondansetron 0.5 to 50 ng / mL Heparin 8 mg (Waters QPXE) Plasma LC-MS/MS Human 899 Ondansetron 0.25 to 100 ng / mL K EDTA 8 mg (Waters QPXE) Plasma 2 O-Desmethyl LC-MS/MS Human 900 1 to 350 ng / mL K EDTA 50 mg (Waters QPXE) Plasma 2 O-Desmethy LC-MS/MS Human 901 1 to 600 ng / mL K EDTA 100 mg l Venlafaxine (Waters QPXE) Plasma 2

Page 49 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method

Human Plasma LC-MS/MS containing 1M Oseltamivir 0.5 to 300 ng/mL K EDTA (Waters QPXE) Sodium 2 Fluoride 902 150mg Human Plasma LC-MS/MS containing 1M Oseltamivir Carboxylic acid 2 to 1000 ng/mL K EDTA (Waters QPXE) Sodium 2 Fluoride

LC-MS/MS Human 903 Ospemifene 3 to 2400 ng / mL NA 60 mg (Waters QPXE) Serum LC-MS/MS Human 904 *Oxazepam 2 to 1200 ng / mL K EDTA 50 mg (Waters QPXE) Plasma 2 LC-MS/MS Human Oxcarbazepine 20 to 4000 ng /mL K EDTA 600 mg (API 3200) Plasma 2 905 10,11-dihydro-10- LC-MS/MS Human 50 to K EDTA - hydroxycarbamazepine (API 3200) Plasma 16000 ng / mL 2 LC-MS/MS Human 906 *Oxybutynin (S & R) 25 to 7500 pg / mL K EDTA 5 mg (API 4000) Plasma 2 LC-MS/MS Human *S-Oxybutynin 10 to 2000 pg/mL K EDTA (Shimadzu 8060) Plasma 2 907 5mg PR LC-MS/MS Human *R-Oxybutynin 7.5 to 2000 pg/mL K EDTA (Shimadzu 8060) Plasma 2 I N D I A D I N LC-MS/MS Human *S-Oxybutynin 20 to 5000 pg/mL K2EDTA (Shimadzu 8045) Plasma 10 mg prolong 908 LC-MS/MS Human release *R-Oxybutynin 10 to 2500 pg/mL K EDTA (Shimadzu 8045) Plasma 2 LC-MS/MS Human 30 to 11000 pg/mL *S-Oxybutynin K2EDTA (Shimadzu 8045) Plasma 10 mg Prolong 909 Yes LC-MS/MS Human release *R-Oxybutynin 20 to 7000 pg/mL K EDTA (Shimadzu 8045) Plasma 2 LC-MS/MS Human Oxybutynin 0.07 to 15 ng / mL K EDTA 5 mg (Waters QPXE) Plasma 2 910 LC-MS/MS Human N-Desethyl Oxybutynin 0.38 to 75 ng / mL K EDTA - (Waters QPXE) Plasma 2 Oxybutynin LC-MS/MS Human 0.2 to 70 ng/mL K EDTA 2x5mg (Waters QPXE) Plasma 2 911 LC-MS/MS Human N-Desethyl Oxybutynin K EDTA 2x5mg (Waters QPXE) Plasma 0.6 to 225 ng/mL 2 LC-MS/MS Human Oxybutynin 0.08 to 15 ng / mL K EDTA 15 mg (Waters QPXE) Plasma 2 912 LC-MS/MS Human N-Desethyl Oxybutynin 0.2 to 75 ng / mL K EDTA - (Waters QPXE) Plasma 2 P Location : Canada LC-MS/MS Human 913 Pantoprazole 20 to 5120 ng / mL K EDTA 40 mg (API 3000) Plasma 2 Human Sodium 914 HPLC - Flurosence 0.2 to 50 ng / mL - Plasma heparin Human Sodium

C A N D 915 Paroxetine HPLC - Flurosence 1.6 to 200 ng / mL - Plasma heparin Human 916 Pentoxifylline HPLC-UV 5 to 240 ng / mL K EDTA - Plasma 3

Page 50 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 917 0.2 to 1.28 ng / mL Heparin - (API 3000) Plasma LC-MS/MS Human 50 mg/mL Oral 918 Phenobarbital 20 to 2000 ng/mL K EDTA Yes (Thermo) Plasma 2 solution LC-MS/MS Human 919 (Total) 4 to 512 ng / mL K EDTA 10 mg (Thermo) Plasma 2 Human 920 Phenytoin HPLC-UV 0.04 to 2.56 µg / mL K EDTA - Plasma 3 LC-MS/MS Human Phytonadione- Trans 0.3 to 100 ng/mL K EDTA 5 mg (API 6500) Plasma 2 921 LC-MS/MS Human Phytonadione- Cis 0.3 to 100 ng/mL K EDTA 5 mg (API 6500) Plasma 2 LC-MS/MS Human Phytonadione- Trans 1 to 500 ng/mL K EDTA 5 mg (API 6500) Plasma 2 922 LC-MS/MS Human Phytonadione- Cis 1 to 500 ng/mL K EDTA 5 mg (API 6500) Plasma 2

LC-MS/MS Human Sodium fluoride and 923 Pomalidomide 0.2 to 125 ng/mL 4 mg (API 6500) Plasma Potassium oxalate

LC-MS/MS Human 924 Pramipexole 50 to 3200 pg / mL K EDTA - (Thermo) Plasma 2 *Prasugrel active metabolite LC-MS/MS Human 925 0.2 to 150 ng / mL K EDTA 10 mg of Prasugrel (R-138727) (Thermo) Plasma 2 *Prasugrel inactive metabolite LC-MS/MS Human 926 0.25 to 127 ng / mL K EDTA 10 mg of Prasugrel (R-95913) (Thermo) Plasma 2

C A N D LC-MS/MS Human Sodium Pravastatin 0.25 to 128 ng / mL - (API 3000) Plasma heparin 927 LC-MS/MS Human Sodium 3-α-Hydroxy Pravastatin 0.25 to 128 ng / mL - (API 3000) Plasma heparin LC-MS/MS Human Sodium Pravastatin 1 to 512 ng / mL 80 mg (API 3000) Plasma heparin 928 LC-MS/MS Human Sodium 3-α-Hydroxy Pravastatin 1 to 512 ng / mL - (API 3000) Plasma heparin LC-MS/MS Human Sodium Pravastatin 1 to 512 ng / mL 80 mg (Thermo) Plasma heparin 929 LC-MS/MS Human Sodium 3-α-Hydroxy Pravastatin 1 to 512 ng / mL - (Thermo) Plasma heparin LC-MS/MS Human Primidone 0.2 to 25 µg / mL K EDTA - (API 3000) Plasma 2 LC-MS/MS Human 930 Phenobarbital 0.2 to 25 µg / mL K EDTA - (API 3000) Plasma 2 LC-MS/MS Human Phenylethylmalonamide 0.2 to 25 µg / mL K EDTA - (API 3000) Plasma 2 LC-MS/MS Human 931 Progesterone 0.04 to 40 ng/mL K EDTA 200 mg (API 6500) Plasma 2 LC-MS/MS Human 932 Pseudoephedrine 1 to 400 ng/mL Sodium Heparin 30mg / 120 mg (API 6500) Plasma

Page 51 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method Location : India LC-MS/MS Human 933 Paclitaxel (Total) 10 to 4500 ng / mL Heparin 175 mg (Waters QPXE) Plasma

Human LC-MS/MS 934 Paclitaxel (Total) Whole 50 to 30000 ng / mL Heparin 220 mg / m2 (IV) (Waters QPXE) Blood

LC-MS/MS Human 935 *Paclitaxel (Free) 5 to 2000 ng / mL Heparin 220 mg / m2 (IV) (Waters QPXE) Plasma Cynomolgus LC-MS/MS 936 Paclitaxel (Total) Monkey 25 to 25000ng / mL K2EDTA 100 mg (API 6500) Plasma Cynomolgus LC-MS/MS 937 Paclitaxel (Free) Monkey 10 to 5000 ng / mL K2EDTA 21.7 (mg/kg) (API 6500) Plasma

LC-MS/MS Cynomolgus 938 Paclitaxel (Total) 25 to 25000 ng / mL K2EDTA - (API 6500) Monkey Blood

LC-MS/MS Wistar Sodium 939 *Paricalcitol 50 to 30500 pg / mL Multiple dose (Waters XEVO TQ-S) Rat Plasma heparin

LC-MS/MS Human 940 Palbociclib 0.2 to 150 ng/mL K EDTA 125 mg (Shimadzu 8045) Plasma 2

LC-MS/MS Human 941 0.5 to 40 ng / mL K EDTA 6 mg (API 3200) Plasma 2

LC-MS/MS Human 942 Paliperidone 0.5 to 60 ng / mL K EDTA 156 mg/mL (Waters QPXE) Plasma 2

LC-MS/MS Human 50 to 943 Paracetamol K EDTA 300 mg / 500 mg (API 3200) Plasma 10000 ng / mL 2 I N D I A D I N LC-MS/MS Human 944 Paracetamol 50 to 10000 ng/mL K EDTA 665 mg (Shimadzu 8045) Plasma 2 LC-MS/MS Human 945 Paracetamol 50 to 24000 ng/mL K EDTA 665x2 mg (Shimadzu 8045) Plasma 2 LC-MS/MS Human 946 Paroxetine 0.03 to 35 ng/mL K EDTA 37.5 mg (API 6500) Plasma 2 LC-MS/MS Human 947 Paroxetine 0.25 to 125 ng/mL K EDTA 37.5 mg (API 4000) Plasma 2 LC-MS/MS Human 948 Pantoprazole 2 to 5000 ng / mL Heparin 40 mg (API 3200) Plasma LC-MS/MS Human 949 Pazopanib 0.1 to 50 µg / mL K EDTA 200/400 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 950 Penciclovir 20 to 8000 ng / mL K EDTA 500 mg (API 4000) Plasma 2 Human 951 Penicillin V HPLC-UV 0.1 to 4 µg / mL Heparin 250 mg Plasma LC-MS/MS Human 952 Perampanel 2 to 700 ng / mL K EDTA 12 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 953 15 to 2500 pg / mL K EDTA 16 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 954 Phenytoin 10 to 10000 ng / mL K2EDTA 300mg (3X100mg) (API 3200) Plasma LC-MS/MS Human 955 Phenyl butyrate 0.1 to 50 µg / mL K EDTA 500 mg (API 3200) Plasma 2

Page 52 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method *Phytonadione (Vitamin K1) LC-MS/MS Human 5 mg (fasting 0.4 to 100 ng / mL K EDTA (Trans) (Waters XEVO TQ-S) Plasma 2 study) 956 *Phytonadione (Vitamin K1) LC-MS/MS Human 5 mg (fasting 0.3 to 25 ng / mL K EDTA (Cis) (Waters XEVO TQ-S) Plasma 2 study)

UV light exposed *Phytonadione (Vitamin K1) LC-MS/MS human plasma, 0.4 to 100 ng / mL K EDTA 5 mg fasting (Trans) (API 6500) 2 Human Plasma 957

UV light *Phytonadione (Vitamin K1) LC-MS/MS exposed 0.3 to 25 ng / mL K EDTA 5 mg fasting (Cis) (API 6500) human plasma, 2 Human Plasma

*Phytonadione (Vitamin K1) LC-MS/MS Human 1 to 500 ng / mL K EDTA 5 mg (fed study) (Trans) (API 6500) Plasma 2 958 *Phytonadione (Vitamin K1) LC-MS/MS Human 1 to 100 ng / mL K EDTA 5 mg (fed study) (Cis) (API 6500) Plasma 2 LC-MS/MS Human Pilocarpine 0.4 to 50 ng/mL K EDTA (Waters QPXE) Plasma 2 959 5mg LC-MS/MS Human Pilocarpic Acid 0.3 to 20 ng/mL K EDTA (Waters QPXE) Plasma 2 LC-MS/MS Human 960 Pioglitazone 10 to 2500 ng / mL Heparin 45 mg (API 2000) Plasma LC-MS/MS Human 961 Pioglitazone 10 to 2500 ng / mL Heparin 45 mg (Waters QPXE) Plasma LC-MS/MS Human Pioglitazone 5 to 2800 ng / mL Sodium Heparin 45 mg (Waters QPXE) Plasma 962 LC-MS/MS Human Hydroxy Pioglitazone 2 to 1500 ng / mL Sodium Heparin - (Waters QPXE) Plasma I N D I A D I N LC-MS/MS Human Pioglitazone 5 to 1000 ng / mL Heparin 20 mg (Waters QPXE) Plasma LC-MS/MS Human Keto Pioglitazone 1 to 200 ng / mL Heparin - (Waters QPXE) Plasma 963 LC-MS/MS Human Hydroxy Pioglitazone 1 to 200 ng / mL Heparin - (Waters QPXE) Plasma LC-MS/MS Human Metformin 25 to 3000 ng / mL Heparin 850 mg (Waters QPXE) Plasma LC-MS/MS Human 964 Pirfenidone 50 to 20000 ng / mL K EDTA 3 X 267 mg (Thermo) Plasma 2 LC-MS/MS Human 965 Pirfenidone 50 to 30000 ng / mL K EDTA 3 X 267 mg (Thermo) Plasma 2 LC-MS/MS Human 966 Pirfenidone (Shimadzu 50 to 30000 ng / mL K EDTA 801 mg Plasma 2 8060)

LC-MS/MS Human 967 Pirfenidone 10 to 7500 ng / mL K EDTA 267 mg (Shimadzu 8060) Plasma 2

LC-MS/MS Human 968 Piroxicam 20 to 4000 ng / mL K EDTA 20 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 969 Pomalidomide 0.2 to 125 ng / mL K EDTA 4 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 970 Posaconazole 4 to 800 ng/mL K EDTA 100mg (Waters QPXE) Plasma 2 Human 2.041 to 150.358 971 Potassium Chloride Vitros 5.1,FS NA 80mEq Urine mEq/L Potassium Citrate (Analyte - Human 60 mEq (4 X 15 972 Vitros 5.1,FS 2 to 150 mmol/L NA Potassium ) Urine mEq)

Page 53 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 973 Pramipexole 10 to 1000 pg / mL K EDTA 0.25 mg (Waters XEVO TQ-S) Plasma 2 *Prasugrel active LC-MS/MS Human 974 0.2 to 150 ng / mL K EDTA 10 mg of Prasugrel metabolite (R-138727) (Waters QPXE) Plasma 2 *Prasugrel active LC-MS/MS Human 975 0.2 to 150 ng / mL K EDTA 10 mg of Prasugrel metabolite (R-138727) (API 4000) Plasma 2 *Prasugrel active metabolite LC-MS/MS Human 976 0.2 to 150 ng/mL K EDTA 10 mg of Prasugrel (R-138727) (Thermo) Plasma 2 *Prasugrel inactive LC-MS/MS Human 977 0.25 to 100 ng / mL K EDTA 10 mg of Prasugrel metabolite (R-95913) (Waters QPXE) Plasma 2 *Prasugrel inactive LC-MS/MS Human 978 0.25 to 150 ng / mL K EDTA 10 mg of Prasugrel metabolite (R-95913) (API 4000) Plasma 2 LC-MS/MS Human Pravastatin 2 to 600 ng / mL K EDTA 40 mg/ 80 mg (Waters QPXE) Plasma 2 979 LC-MS/MS Human 3-α-Hydroxy Pravastatin 2 to 400 ng / mL K EDTA - (Waters QPXE) Plasma 2 LC-MS/MS Human Pravastatin 2 to 600 ng / mL K EDTA 40 mg/ 80 mg (Waters QPXE) Plasma 3 980 LC-MS/MS Human 3-α-Hydroxy Pravastatin 2 to 400 ng / mL K EDTA - (Waters QPXE) Plasma 3 LC-MS/MS Human 981 Pravastatin 2 to 600 ng / mL K EDTA 40 mg/ 80 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 982 Praziquantel 3 to 1500 ng / mL K EDTA 600 mg (Shimadzu 8045) Plasma 2 LC-MS/MS Human 983 Prednisolone 2 to 1000 ng / mL K EDTA 25 mg (API 3200) Plasma 2 LC-MS/MS Human 984 Prednisolone 1.5 to 1300 ng/mL K EDTA 20mg/40mg (API 3200) Plasma 2

I N D I A LC-MS/MS Human 985 Prednisolone 1 to 400 ng / mL K EDTA 5 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 986 Pregabalin 50 to 15000 ng / mL K EDTA 300 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 987 Pregabalin 20 to 2500 ng / mL K EDTA 50 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 988 Pregabalin 20 to 5000 ng /mL K EDTA 75 mg (Shimadzu 8040) Plasma 2 LC-MS/MS Human 989 Pregabalin 25 to 7000 ng/mL K EDTA 165 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 990 5 to 300 pg / mL Heparin 5 mg (API 4000) Plasma LC-MS/MS Human Sodium 991 Prochlorperazine 2 to 300 pg / mL 3 mg (Shimadzu 8060) Plasma heparin LC-MS/MS Human Sodium 3 mg (buccal 992 prochlorperazine 2 to 700 pg / mL (Shimadzu 8060) Plasma heparin tablet) LC-MS/MS Human 993 *Progesterone 0.04 to 40 ng / mL K EDTA 200 mg (fasting) (Thermo) Plasma 2 LC-MS/MS Human 994 *Progesterone 0.15 to 150 ng / mL K EDTA 200 mg (fed) (Waters QPXE) Plasma 2 LC-MS/MS Human 995 *Progesterone 25 to 15000 pg / mL K EDTA 100 mg (Thermo) Plasma 2 LC-MS/MS Human 996 Proguanil 0.5 to 200 ng / mL K EDTA 100 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 997 0.1 to 50 ng/mL K EDTA 50mg/5mL (API 4000) Plasma 2

Page 54 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 998 0.05 to 15 ng/mL K EDTA 25 mg (API 4000) Plasma 2 LC-MS/MS Human 0.5 to 500 ng / mL K EDTA 300 mg (Waters QPXE) Plasma 2 999 LC-MS/MS Human 5-Hydroxy Propafenone 0.5 to 400 ng / mL K EDTA - (Waters QPXE) Plasma 2 LC-MS/MS Human 1000 Propafenone 1 to 1000 ng / mL K EDTA 300 mg / 500 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 1001 S-Propanolol (Total) 1 to 500 ng /mL K EDTA 40 mg (API 3200) Plasma 2 LC-MS/MS Human 1002 Propylthiouracil 7.5 to 4000 ng / mL K EDTA 50 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 1003 Pseudoephedrine 2 to 400 ng /mL Heparin 30 mg (API 3200) Plasma LC-MS/MS Human Sodium 1004 Pseudoephedrine 1 to 400 ng/mL 30mg (Shimadzu 8060) Plasma heparin I N D I A LC-MS/MS Human 1005 Pyrazinamide 75 to 30000 ng/mL K EDTA 600 mg (Waters QPXE) Plasma 2

Human Plasma LC-MS/MS containing 1M 1006 Pyridostigmine 0.4 to 100 ng/mL K EDTA 60mg (Waters QPXE) Sodium 2 Fluoride (10%)

LC-MS/MS Human 16 mg of 1007 2-Pyridylacetic acid 5 to 800 ng / mL K EDTA (Waters QPXE) Plasma 2 Betahistine

5% Selegiline LC-MS/MS 1008 2-Pyridyl acetic acid buffered 10 to 1500 ng/mL K EDTA 24 mg (Thermo) 2 Human Plasma

Q Location : Canada LC-MS/MS Human 1009 1 to 1024 ng / mL K EDTA 200 mg (Thermo) Plasma 2 LC-MS/MS Human

C A N D 1010 Quetiapine 1 to 1000 ng / mL K EDTA 20 mg (Waters QPXE) Plasma 2 Location : India LC-MS/MS Human Quetiapine 0.5 to 200 ng / mL Heparin 25 mg (Waters QPXE) Plasma 1011 LC-MS/MS Human N-desalkyl Quetiapine 0.08 to 20 ng / mL Heparin - (Waters QPXE) Plasma LC-MS/MS Human Quetiapine 2 to 400 ng / mL K EDTA 50 mg (API 2000) Plasma 2 1012 LC-MS/MS Human N-desalkyl Quetiapine 0.25 to 50 ng / mL K EDTA - (API 2000) Plasma 2 LC-MS/MS Human 1013 Quetiapine 0.5 to 350 ng / mL Heparin 25 mg / 50 mg I N D I A D I N (Waters QPXE) Plasma LC-MS/MS Human 1014 Quetiapine 2 to 400 ng / mL K EDTA 50 mg (API 2000) Plasma 2 LC-MS/MS Human Quetiapine 2 to 1500 ng / mL Heparin 200 mg (API 2000) Plasma 1015 LC-MS/MS Human N-Des Alkylated Quetiapine 0.5 to 150 ng / mL Heparin - (API 2000) Plasma

Page 55 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human Sodium 1016 Quetiapine 1 to 1000 ng / mL 150 mg / 200 mg (Waters QPXE) Plasma heparin LC-MS/MS Human 1017 Quetiapine 1 to 1000 ng / mL K EDTA 150 mg / 200 mg (Waters QPXE) Plasma 2 LC-MS/MS Human Quetiapine 20 to 2000 ng / mL K EDTA 300 /400 mg (API 2000) Plasma 2 1018 LC-MS/MS Human N-Des Alkylated Quetiapine 2 to 500 ng / mL K EDTA - (API 2000) Plasma 2 LC-MS/MS Human Sodium 1019 Quetiapine 20 to 2500 ng / mL 300 /400 mg (API 3200) Plasma heparin

I N D I A D I N LC-MS/MS Human Sodium 1020 Quetiapine 0.5 to 350 ng / mL 25 mg (Waters XEVO TQ-S) Plasma heparin LC-MS/MS Human Sodium 1021 Quetiapine 1 to 1000 ng/mL 100 mg (API 4000) Plasma heparin LC-MS/MS Human 1022 Quinapril 1 to 500 ng / mL K EDTA 10 mg (Waters QPXE) Plasma 3 LC-MS/MS Human 1023 Quinine 25 to 5000 ng /mL K EDTA 300 mg (Waters QPXE) Plasma 2 R Location : Canada LC-MS/MS Human 1024 Rabeprazole 2 to 1024 ng / mL K EDTA 20 mg (API 3000) Plasma 2 LC-MS/MS Human Ramipril 0.05 to 6 ng / mL K EDTA 2.5 mg (API 3000) Plasma 3 1025 LC-MS/MS Human Ramiprilat 0.05 to 6 ng / mL K EDTA - (API 3000) Plasma 3 LC-MS/MS Human Ramipril 0.05 to 6 ng / mL K EDTA 2.5 mg (Thermo) Plasma 2 1026 LC-MS/MS Human Ramiprilat 0.05 to 6 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human Ramipril 0.05 to 51 ng / mL K EDTA 10 mg (API 3000) Plasma 3 1027 LC-MS/MS Human Ramiprilat 0.05 to 51 ng / mL K EDTA - (API 3000) Plasma 3 LC-MS/MS Human Ramipril 0.05 to 51 ng / mL K EDTA 10 mg (Thermo) Plasma 2 1028 LC-MS/MS Human Ramiprilat 0.05 to 51 ng / mL K EDTA - (Thermo) Plasma 2 C A N D LC-MS/MS Human 1029 15 to 1920 ng / mL K EDTA 300 mg (Thermo) Plasma 2 Human Rifabutin LC-MS (API 150) 10 to 1280 ng / mL K EDTA - Plasma 2 Human 1030 25-O-Desacetylrifabutin LC-MS (API 150) 2.5 to 320 ng / mL K EDTA - Plasma 2 Human Clofazimine LC-MS (API 150) 5 to 640 ng / mL K EDTA - Plasma 2 LC-MS/MS Human 1031 Risedronate 0.2 to 25 ng / mL K EDTA 35 mg (Thermo) Plasma 2 LC-MS/MS Human 1032 Risedronate 0.2 to 128 ng / mL K EDTA 75 mg (Thermo) Plasma 2 LC-MS/MS Human Transdermal Patch 1033 Rivastigmine 0.3 to 63 ng / mL K EDTA (Thermo) Plasma 2 9.5 mg

Page 56 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 1034 Rivastigmine 0.3 to 63 ng / mL K EDTA 9.5 mg (API 6500) Plasma 2 LC-MS/MS Human Sodium 1035 Rosiglitazone 2 to 1024 ng / mL 8 mg (API 3000) Plasma heparin LC-MS/MS Human 1036 Rosuvastatin 0.1 to 25 ng / mL K EDTA 20 mg (Thermo) Plasma 2 C A N D LC-MS/MS Human 1037 Rosuvastatin 0.5 to 100 ng / mL K EDTA 40 mg (Thermo) Plasma 2 Location : India LC-MS/MS Human 1038 Rabeprazole 5 to 1000 ng / mL K EDTA/ Heparin 20 mg (API 3200) Plasma 3 LC-MS/MS Human 1039 Rabeprazole 2 to 1200 ng / mL K EDTA 10 / 20 mg (API 4000) Plasma 2 LC-MS/MS Human 1040 Rabeprazole 2 to 1200 ng / mL K EDTA 10 / 20 mg (API 3200) Plasma 2 LC-MS/MS Human *Raloxifene 20 to 1000 pg / mL K EDTA 60 mg (Thermo) Plasma 2 LC-MS/MS Human 1041 *Raloxifene 4-glucuronide 0.6 to 400 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human *Raloxifene 6-glucuronide 0.35 to 100 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human *Raloxifene 20 to 1000 pg / mL Heparin 60 mg (Thermo) Plasma LC-MS/MS Human 1042 *Raloxifene 4-glucuronide 0.6 to 400 ng / mL Heparin - (Thermo) Plasma LC-MS/MS Human *Raloxifene 6-glucuronide 0.35 to 100 ng / mL Heparin - (Thermo) Plasma LC-MS/MS Human Sodium Ramipril 0.2 to 100 ng / mL 10 mg (API 4000) Plasma heparin 1043 LC-MS/MS Human Sodium Ramiprilat 0.5 to 50 ng / mL - (API 4000) Plasma heparin LC-MS/MS Human 1044 *Ramipril 0.2 to 150 ng / mL Heparin 15 mg

I N D I A D I N (API 3200) Plasma LC-MS/MS Human 2.5 mg / 1045 *Ramipril 0.05 to 40 ng / mL Heparin (API 3200) Plasma 5 mg LC-MS/MS Human Sodium 1046 Ramipril 0.2 to 100 ng/mL 10mg (API 3200) Plasma heparin LC-MS/MS Human 1047 Ranolazine 5 to 2500 ng / mL K EDTA 1000 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 1048 Ranolazine 10 to 5000 ng/mL K EDTA 1000 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 1049 Ranolazine 5 to 2000 ng/mL K EDTA 500 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 150 / 1050 Ranitidine 10 to 2000 ng / mL Heparin (API 2000) Plasma 300 mg

Human K EDTA / 1051 Ranitidine HPLC-UV 25 to 1500 ng / mL 2 300 mg Plasma Heparin

LC-MS/MS Human K EDTA / 1052 Ranitidine 5 to 600 ng / mL 2 75 mg (API 2000) Plasma Heparin

LC-MS/MS Human 1 mg (Fasting 1053 Rasagiline 40 to 14000 pg / mL K EDTA (Waters QPXE) Plasma 2 study)

LC-MS/MS Human 1054 Rasagiline 40 to 6000 pg/mL K2EDTA 1 mg ( Fed study) (Waters QPXE) Plasma

Page 57 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 1055 Repaglinide 0.25 to 30 ng / mL K EDTA 2 mg (API 3200) Plasma 2

LC-MS/MS Human 1056 Ribociclib 2 to 500 ng/mL K EDTA 200 mg Yes (Waters QPXE) Plasma 2

LC-MS/MS Human Rifampicin 200 to 15000ng / mL K EDTA 150mg (API 4000) Plasma 2 1057 LC-MS/MS Human Desacetyl Rifampicin 10 to 2000ng / mL K EDTA 150mg (API 4000) Plasma 2

LC-MS/MS Human Rifampicin 75 to 15000 ng /mL K EDTA 150mg/300mg (API 4000) Plasma 2 1058 LC-MS/MS Human 25 Desacetyl Rifampicin 10 to 4000 ng /mL K EDTA NA (API 4000) Plasma 2

LC-MS/MS Human 25 to 1059 Rifaximin K EDTA 550 mg (Thermo) Plasma 15000 pg / mL 2

LC-MS/MS Human 1060 Rifaximin 0.05 to 100 ng / mL K EDTA 550 mg (Thermo) Plasma 2

LC-MS/MS Human 1061 Rifaximin 5 to 1500 pg/mL K EDTA 200 mg (API 6500) Plasma 2

LC-MS/MS Human 1062 Rifaximin 25 to 6000 pg/mL K EDTA 550 mg (Thermo) Plasma 2

LC-MS/MS Human 1063 Rifaximin 100 to 36000 pg/mL K EDTA 550 mg (Thermo) Plasma 2

LC-MS/MS Human 1064 Rilpivirine 0.5 to 300 ng/mL K EDTA 25mg (Shimadzu 8060) Plasma 2

LC-MS/MS Human 1065 Rilpivirine 0.5 to 300 ng/mL K2EDTA 25mg (Shimadzu 8045) Plasma I N D I A D I N LC-MS/MS Human 1066 Rivaroxaban 0.2 to 125 ng / mL K EDTA 2.5 mg (Waters XEVO TQ-S) Plasma 2

LC-MS/MS Human 1067 Rivaroxaban 1 to 600 ng / mL K EDTA 10 mg / 20 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 1068 Rivaroxaban 1 to 600 ng/mL K EDTA 10 mg / 20 mg (Shimadzu 8045) Plasma 2

LC-MS/MS Human 1069 Rivaroxaban 1 to 600 ng/mL K EDTA 10 mg/20 mg Yes (API 3200) Plasma 2

LC-MS/MS Human 1070 *Risedronate 0.1 to 80 ng / mL Heparin 35 mg (Thermo) Plasma

LC-MS/MS Human Sodium 1071 *Risedronate 30 to 80000 pg / mL 35 mg (Waters XEVO TQ-S) Plasma heparin

LC-MS/MS Human 1072 *Risedronate 0.5 to 160 ng / mL Heparin 75 mg (Thermo) Plasma

LC-MS/MS Human 1073 *Risedronate 0.5 to 250 ng / mL Heparin 150 mg (Thermo) Plasma

LC-MS/MS Human 0.1 to 15 ng / mL Heparin 1 mg (API 4000) Plasma 1074 LC-MS/MS Human 9- hydroxy Risperidone 0.1 to 15 ng / mL Heparin - (API 4000) Plasma

LC-MS/MS Human 1075 Rivastigmine 0.1 to 15 ng / mL K EDTA 9.5 mg/24 hour (API 4000) Plasma 2

LC-MS/MS Human 1076 0.25 to 60 ng / mL K EDTA 10 mg (Waters QPXE) Plasma 2

Page 58 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 1077 0.05 to 10 ng / mL K EDTA 10 mg (API 3200) Plasma 2

LC-MS/MS Human 1078 Ropinirole 0.05 to 10 ng / mL K EDTA 2 mg (API 3200) Plasma 2

LC-MS/MS Human 1079 Ropinirole 10 to 3000 pg / mL K EDTA 0.25 mg (API 4000) Plasma 2

LC-MS/MS Human 1080 Rosiglitazone 15 to 900 ng / mL K EDTA 8 mg (API 2000) Plasma 2

LC-MS/MS Human 1081 Rosiglitazone 5 to 500 ng / mL K EDTA 4 mg (API 2000) Plasma 2

I N D I A D I N LC-MS/MS Human 1082 Rosuvastatin 0.05 to 25 ng / mL K EDTA 5 mg / 10 mg (Thermo) Plasma 2

LC-MS/MS Human 1083 Rosuvastatin 0.15 to 60 ng / mL K EDTA 20 mg (Thermo) Plasma 2

LC-MS/MS Human 1084 Rosuvastatin 0.5 to 150 ng / mL K EDTA 40 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 1085 Roxithromycin (Shimadzu 0.05 to 25 μg/mL K EDTA 150 mg Plasma 2 8045) S Location : Canada LC-MS/MS Human 1086 Scopolamine 1 to 400 pg/mL K EDTA 1 mg Patch (API 6500) Plasma 2 LC-MS/MS Human Sodium 0.25 to 250 ng / mL 100 mg (API 3000) Plasma heparin 1087 LC-MS/MS Human Sodium N- 0.25 to 250 ng / mL - (API 3000) Plasma heparin LC-MS/MS Human Sildenafil 1 to 500 ng/mL K EDTA 10 mg/mL (API 6500) Plasma 2 1088 LC-MS/MS Human N-Desmethyl Sildenafil 0.5 to 75 ng/mL K EDTA - (API 6500) Plasma 2 LC-MS/MS Human Sodium Simvastatin 0.1 to 25 ng / mL - (API 300 or 3000) Plasma heparin 1089 Simvastatin LC-MS/MS Human Sodium 0.1 to 25 ng / mL - Hydroxy Acid (API 300 or 3000) Plasma heparin LC-MS/MS Human Simvastatin 0.1 to 51.2 ng / mL K EDTA 80 mg (Thermo) Plasma 2

C A N D 1090 Simvastatin LC-MS/MS Human 0.1 to 25.6 ng / mL K EDTA - Hydroxy Acid (Thermo) Plasma 2 Human LC-MS/MS 1091 Sirolimus Whole 0.4 to 51 ng / mL K EDTA 2 mg (API 3000) 2 Blood LC-MS/MS Human 1092 Sitagliptin 1 to 512 ng / mL K EDTA 100 mg (Thermo) Plasma 2 HPLC Human 1093 10 to 2560 ng / mL heparin - - Flurosence Plasma Human Sulfamethoxazole HPLC-UV 0.2 to 102 µg / mL K EDTA - Plasma 3 1094 Human Trimethoprim HPLC-UV 0.02 to 2.56 µg / mL K EDTA 50 mg Plasma 3

Page 59 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human Sufentanil 0.01 to 1.28 ng / mL K EDTA - (Thermo) Plasma 2 1095 LC-MS/MS Human Triazolam 0.1 to 12.8 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human Sufentanil 2 to 256 pg / mL K EDTA 10 mcg (Thermo) Plasma 2 1096 LC-MS/MS Human Triazolam 0.05 to 6.4 ng / mL K EDTA 200 mcg (Thermo) Plasma 2 LC-MS Human Sulfasalazine 20 to 2560 ng / mL K EDTA - (API 150) Plasma 3 LC-MS Human Sulfapyridine 200 to 25600 ng / mL K EDTA - (API 150) Plasma 3 1097 LC-MS Human C A N D 5-Aminosalicylic Acid 20 to 2560 ng / mL K EDTA - (API 150) Plasma 3 LC-MS Human Acetyl-5-Aminosalicylic Acid 10 to 1280 ng / mL K EDTA - (API 150) Plasma 3 LC-MS/MS Human 1098 0.1 to 40 ng/mL K EDTA 20 mg (Thermo) Plasma 2 Human LC-MS/MS Plasma 1099 Sumatriptan 0.5 to 128 ng / mL K EDTA - (API 300 or 3000) or Pig 3 Plasma Location : India LC-MS/MS Human 1100 * 2 to 200 pg / mL K EDTA 50 mcg (Waters XEVO TQ-S) Plasma 2 LC-MS/MS Human 1101 Secnidazole 0.2 to 40 µg / mL K EDTA 1 gm (API 3200) Plasma 2 LC-MS/MS Human 1102 Sertraline 1 to 100 ng / mL Sodium Heparin 100 mg (API 3200) Plasma LC-MS/MS Human 1103 Sertraline 0.5 to 40 ng / mL Heparin 50 mg (Waters QPXE) Plasma LC-MS/MS Human 100 to Heparin / 15 mg (Waters QPXE) Plasma 20000 pg / mL K2EDTA LC-MS/MS Human 50 to Heparin / 1104 Desmethyl Sibutramine - (Waters QPXE) Plasma 10800 pg / mL K2EDTA LC-MS/MS Human 75 to Heparin / Didesmethyl Sibutramine - (Waters QPXE) Plasma 15000 pg / mL K2EDTA LC-MS/MS Human Sildenafil 4 to 2000 ng / mL K EDTA 100 mg (API 3200) Plasma 2 1105 I N D I A D I N LC-MS/MS Human Desmethyl Sildenafil 2 to 700 ng / mL K EDTA - (API 3200) Plasma 2 LC-MS/MS Human Sildenafil 1 to 500 ng / mL K EDTA 20 mg (API 3200) Plasma 2 1106 LC-MS/MS Human Desmethyl Sildenafil 0.5 to 75 ng / mL K EDTA - (API 3200) Plasma 2 LC-MS/MS Human Simvastatin 0.2 to 100 ng / mL Heparin 80 mg (API 4000) Plasma 1107 LC-MS/MS Human Simvastatin acid 0.2 to 50 ng / mL Heparin - (API 4000) Plasma LC-MS/MS Human Simvastatin 0.1 to 75 ng / mL Heparin 40 mg (API 4000) Plasma 1108 LC-MS/MS Human Simvastatin acid 0.1 to 50 ng / mL Heparin - (API 4000) Plasma

Page 60 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human Sodium 1109 Simvastatin 30 to 15000 pg / mL 10 mg (Thermo) Plasma heparin LC-MS/MS Human 1110 Sirolimus 0.15 to 25 ng / mL K EDTA 2 mg (Waters QPXE) Blood 2 LC-MS/MS Human 1111 Sirolimus 40 to 12000 pg / mL K EDTA 0.5 mg (Waters XEVO TQ-S) Blood 2 LC-MS/MS Human Sodium 1112 Sitagliptin 1 to 600 ng/mL 100mg/50mg (API 4000) Plasma heparin LC-MS/MS Human Sodium 1113 Sitagliptin 2 to 1200 ng / mL 100mg (API 3200) Plasma heparin LC-MS/MS Human Sodium 1114 Sitagliptin 2 to 1200 ng / mL 100mg (API 4000) Plasma Heparin LC-MS/MS Human Sodium 1115 Sitagliptin 1 to 500 ng/mL 50 mg (API 3200) Plasma Heparin LC-MS/MS Human 1116 Sofosbuvir 5 to 5000 ng / mL K EDTA 400 mg (API 4000) Plasma 2 LC-MS/MS Human 1117 Solifenacin 0.2 to 50 ng/mL K EDTA 10 mg (Thermo) Plasma 2 LC-MS/MS Human 1118 Solifenacin 0.2 to 50 ng/mL K EDTA 10mg (API 4000) Plasma 2 LC-MS/MS Human 1119 Sorafenib 20 to 6000 ng/mL K EDTA 200 mg (Waters QPXE) Plasma 2 LC-MS/MS Human Spironolactone 0.5 to 300 ng / mL K EDTA 100 mg (API 3200) Plasma 2 1120 I N D I A D I N LC-MS/MS Human Canrenone 1 to 200 ng / mL K EDTA - (API 3200) Plasma 2 LC-MS/MS Human 1121 Spironolactone 0.1 to 75 ng / mL K EDTA 25 mg (API 4000) Plasma 2 LC-MS/MS Human 1122 Spironolactone 0.7 to 300 ng / mL K EDTA 100 mg (Waters XEVO TQ-S) Plasma 2 LC-MS/MS Human 1123 Spironolactone 0.1 to 75 ng/mL K EDTA 25mg (Shimadzu 8045) Plasma 2 LC-MS/MS Human 100 to Sulfamethoxazole K EDTA 800 mg (Waters QPXE) Plasma 90000 ng / mL 2 1124 LC-MS/MS Human Trimethoprim 10 to 5000 ng / mL K EDTA 160 mg (Waters QPXE) Plasma 2 LC-MS/MS Human Sulfasalazine 50 to 15000 ng/mL K2EDTA (Waters QPXE) Plasma 1125 500mg LC-MS/MS Human Sulfapyridine 20 to 2500 ng/mL K2EDTA (Waters QPXE) Plasma LC-MS/MS Human 1126 Sumatriptan 1 to 100 ng / mL Heparin 100 mg (API 2000) Plasma LC-MS/MS Human Sodium 1127 Sunitinib 0.1 to 12 ng/mL 12.5 mg (API 4000) Plasma heparin LC-MS/MS Human Sodium 1128 Sunitinib 0.5 to 50 ng/mL 50mg (API 3200) Plasma heparin T Location : Canada Human LC-MS/MS 1129 Tacrolimus Whole 0.2 to 25 ng / mL K EDTA 0.5 to 4 mg (Thermo) 2 Blood LC-MS/MS Human 1130 Tamoxifen 0.25 to 64 ng / mL K2EDTA 20 mg

C A N D (API 3000) Plasma

Page 61 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS Human Tamoxifen 0.25 to 64 ng / mL Heparin - (API 150) Plasma 1131 LC-MS Human N-Desmethyltamoxifen 0.25 to 64 ng / mL Heparin - (API 150) Plasma LC-MS/MS Human 1132 0.05 to 25 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human 1133 Temazepam 4 to 1024 ng / mL K EDTA 30 mg (API 3000) Plasma 2 HPLC Human 1134 0.5 to 64 ng / mL Heparin - - Flurosence Plasma Human 1135 Terbinafine HPLC-UV 0.01 to 2.5 µg / mL K EDTA 250 mg Plasma 3 LC-MS/MS Human 1136 Testosterone 0.1 to 25 ng / mL K EDTA 1% gel (Waters QPXE) Plasma 2 LC-MS/MS Human 1137 Testosterone 0.1 to 25 ng/mL N/AP 1.62 % Gel Yes (Thermo) Serum LC-MS/MS Human 0.015 to 3.84 ng / mL K EDTA 50 mg (Thermo) Plasma 2 LC-MS/MS Human 1138 α- 0.625 to 160 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human β-Dihydrotetrabenazine 0.469 to 120 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human 1139 Tetracycline 200 to 20000 ng / mL K EDTA 500 mg (Thermo) Plasma 2 Human 1140 Theophylline HPLC-UV 0.15 to 19 µg / mL K3EDTA -

C A N D Plasma LC-MS/MS Human Ticagrelor 2.5 to 1500 ng/mL K EDTA 90mg (Thermo) Plasma 2 1141 LC-MS/MS Human Deshydroxyethoxy Ticagrelor 1 to 300 ng/mL K EDTA 90mg (Thermo) Plasma 2 Human 1142 Ticlopidine HPLC-UV 10 to 1280 ng / mL K EDTA - Plasma 3 LC-MS/MS Human 1143 Tofacitinib 0.2 to 100 ng/mL K EDTA 11 mg and 5 mg (Thermo) Plasma 2 Human LC-MS/MS Plasma Sodium 1144 Topiramate 5 to 2560 ng / mL 50 mg (API 3000) or Dog heparin Plasma LC-MS/MS Human Sodium 1145 Topiramate 50 to 12800 ng / mL 200 mg (API 3000) Plasma heparin LC-MS/MS Human 25 mg/mL oral 1146 Topiramate 2 to 1000 ng/mL K EDTA Yes (Thermo) Plasma 2 solution LC-MS/MS Human 1147 Torsemide 10 to 10240 ng / mL K EDTA - (API 300 or 3000) Plasma 3 HPLC Human 2.5 to 320 ng / mL K EDTA - - Flurosence Plasma 3 1148 HPLC Human O-Desmethyltramadol 2.5 to 320 ng / mL K EDTA - - Flurosence Plasma 3

Page 62 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method Human Plasma LC-MS/MS 1149 Tramadol or 2 to 1024 ng / mL K EDTA 89 mg (API 3000) 2 Mouse Plasma Human Plasma LC-MS/MS O-Desmethyltramadol or 1 to 512 ng / mL K EDTA - (API 3000) 2 Mouse Plasma 1150 Human Plasma LC-MS/MS O,N-di-Desmethyltramadol or 1 to 512 ng / mL K EDTA - (API 3000) 2 Mouse Plasma LC-MS/MS Human Not Tramadol 0.2 to 50 µg / mL - (API 3000) Urine applicable LC-MS/MS Human Not 1151 O-Desmethyltramadol 0.05 to 12.5 µg / mL - (API 3000) Urine applicable O,N-di- LC-MS/MS Human Not 0.05 to 12.5 µg / mL - Desmethyltramadol (API 3000) Urine applicable LC-MS/MS Dog Tramadol 2 to 1024 ng / mL K EDTA 89 mg (API 3000) Plasma 2 1152 LC-MS/MS Dog O-Desmethyltramadol 1 to 512 ng / mL K EDTA - (API 3000) Plasma 2

C A N A D A D A N A C LC-MS/MS Human Tramadol 2 to 1024 ng / mL K EDTA 89 mg (Thermo) Plasma 2 LC-MS/MS Human O-Desmethyltramadol 1 to 512 ng / mL K EDTA - (Thermo) Plasma 2 1153 O,N-di- LC-MS/MS Human 1 to 512 ng / mL K EDTA - Desmethyltramadol (Thermo) Plasma 2 LC-MS/MS Human Meloxicam 3.75 to 1920 ng / mL K EDTA - (Thermo) Plasma 2 LC-MS/MS Human 1154 Tramadol 2 to 500 ng/mL K EDTA 100 mg (Thermo) Plasma 2 LC-MS/MS Human 1155 Tramadol 2 to 800 ng/mL K EDTA 200 mg (Thermo) Plasma 2 HPLC Human 1156 10 to 2560 ng / mL Heparin - - Flurosence Plasma Triamcinolone LC-MS/MS Human 1157 0.025 to 6.4 ng/mL K EDTA 10 mg/mL acetonide (Thermo) Plasma 2 LC-MS/MS Human Trimebutine 1 to 256 ng / mL K EDTA 96 mg (Thermo) Plasma 2 1158 LC-MS/MS Human N-Desmethyltrimbutine 10 to 2560 ng / mL K EDTA - (Thermo) Plasma 2 Location : India Human LC-MS/MS 40 to 1159 Tacrolimus Whole K EDTA 0.5 mg (Thermo) 12000 pg / mL 2 Blood LC-MS/MS Human 1160 Tacrolimus 40 to 12000 pg / mL K EDTA 0.5 mg / 1 mg (Waters QPXE) Blood 2 LC-MS/MS Human 1161 Tacrolimus 0.25 to 100 ng / mL K EDTA 5 mg (Waters QPXE) Blood 2 I N D I A D I N LC-MS/MS Human 1162 *Tacrolimus 5 to 500 pg / mL K EDTA 0.1 % gel (Shimadzu 8060) Blood 2 LC-MS/MS Human 1163 Tacrolimus 40 to 12000 pg/mL K EDTA 1 mg (Thermo) Blood 2

Page 63 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 1164 Tadalafil 4 to 1000 ng / mL K EDTA 20 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 1165 Tadalafil 2 to 500 ng / mL K EDTA 10 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 1166 Tadalafil 4 to 1000 ng / mL K EDTA 20mg (Shimadzu 8045) Plasma 2 LC-MS/MS Human 1167 Tadalafil 1 to 200 ng / mL K EDTA 5 mg (Shimadzu 8040) Plasma 2 LC-MS/MS Human 1168 Tamsulosin 0.1 to 50 ng / mL K EDTA 0.4 mg (Waters QPXE) Plasma 2 LC-MS/MS Human Tamoxifen 0.5 to 100 ng / mL K EDTA 20 mg (API 3200) Plasma 2 1169 LC-MS/MS Human Endoxifen 0.5 to 100 ng / mL K EDTA 20 mg (API 3200) Plasma 2 LC-MS/MS Human 1170 0.4 to 225 ng/mL K EDTA 250 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 1171 Tapentadol 0.4 to 225 ng/mL K EDTA 250 mg (Waters XEVO TQ-S) Plasma 2

*Teicoplanin components (A2- LC-MS/MS Human 1172 2 to 250 µg/ mL K EDTA 400 mg injection 1, A2-2, A2-3, A2-4, and A2-5) (Waters QPXE) Plasma 2

*Teicoplanin LC-MS/MS Human 1173 2 to 250 µg/ mL K EDTA 400 mg injection component (A 3) (Waters QPXE) Plasma 2 LC-MS/MS Human 1174 Telmisartan 2 to 1200 ng / mL K EDTA 80 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 100 to 1175 *Temozolomide Heparin 250 mg (Waters QPXE) Plasma 20000 ng / mL *Temozolomide LC-MS/MS Human 250 mg of

I N D I A D I N 1176 3 to 600 ng /mL Heparin Metabolite (MTIC) (Waters QPXE) Plasma Temozolamide LC-MS/MS Human 1177 Teneligliptin 10 to 800 ng/mL K EDTA 2X20 mg (Shimadzu 8045) Plasma 2 LC-MS/MS Human 1178 Tenofovir 2 to 800 ng / mL K EDTA 245 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 1179 Tenofovir 3 to 800 ng / mL NA 245 mg (Waters QPXE) Serum LC-MS/MS Human 1180 Tenofovir 2 to 800 ng / mL K EDTA 245 mg (API 4000) Plasma 2 LC-MS/MS Human 1181 Tenofovir 0.5 to 25 ng/mL K EDTA 25 mg (Thermo) Plasma 2 LC-MS/MS Human 1182 Tenofovir Alafenamide 2 to 1000 ng/mL K EDTA 25 mg (Waters QPXE) Plasma 2 Human K EDTA / 1183 Tenoxicam HPLC-UV 0.05 to 5 µg / mL 2 20 mg Plasma Heparin Human K EDTA / 1184 Tenoxicam HPLC-UV 0.05 to 5 µg / mL 2 20 mg Plasma Heparin LC-MS/MS Human 1185 *Tetranor-PGEM 1 to 50 ng / mL NA NA (API 4000) Urine LC-MS/MS Human 1186 Terbinafine 5 to 3000 ng / mL K EDTA 250 mg (API 2000) Plasma 2 LC-MS/MS Human 1187 Teriflunomide 10 to 4000 ng / mL K EDTA 14 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 1188 Testosterone 0.2 to 25 ng / mL K EDTA 1 % gel (Waters QPXE) Plasma 2

Page 64 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human Tetrabenazine 5 to 2500 pg / mL K EDTA 25 mg (API 6500) Plasma 2 1189 LC-MS/MS Human dihydro Tetrabenazine 0.2 to 100 ng / mL K EDTA - (API 6500) Plasma 2 LC-MS/MS Human Tetrabenazine 5 to 2500 pg/mL K EDTA 25 mg (API 6500) Plasma 2 1190 LC-MS/MS Human DihdroxyTetrabenazine 0.2 to 250 ng/mL K EDTA 25 mg (API 6500) Plasma 2 LC-MS/MS Human 1191 Thalidomide (R & S) 2 to 600 ng / mL K EDTA 50 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 400 ER capsule 1192 Theophylline 50 to 20000 ng/mL K EDTA (Waters QPXE) Plasma 2 Fast/Fed LC-MS/MS Human 30 mg of 1193 Thiorphan 1 to 160 ng / mL K EDTA (Waters QPXE) Plasma 2 Racecadotril LC-MS/MS Human 1194 *Thromboxane B2 0.2 to 20 ng / mL Not applicable NA (Shimadzu 8040) Urine LC-MS/MS Human Ticagrelor 2.5 to 1500 ng / mL K EDTA 90 mg (Waters QPXE) Plasma 2 1195 LC-MS/MS Human Deshydroxyethoxy ticagrelor 1 to 300 ng / mL K EDTA - (Waters QPXE) Plasma 2 LC-MS/MS Human 1196 Tinidazole 0.5 to 25 µg / mL K EDTA 500 mg (Shimadzu 8045) Plasma 2 LC-MS/MS Human 1197 Tofacitinib 0.2 to 100 ng / mL K EDTA 5 mg (API 4000) Plasma 2 LC-MS/MS Human 1198 Tofacitinib 0.5 to 350 ng / mL K EDTA 10 mg (API 3200) Plasma 2 LC-MS/MS Human Sodium 1199 Tolterodine 20 to 10000 pg / mL 4mg (Waters QPXE) Plasma heparin

I N D I A D I N LC-MS/MS Human Sodium 1200 Tolterodine 20 to 10000 pg / mL 4 mg (Waters XEVO TQ-S) Plasma heparin LC-MS/MS Human Sodium 1201 Tolterodine 50 to 30000 pg / mL 4 mg (steady state) (Waters QPXE) Plasma heparin LC-MS/MS Human Tolterodine 50 to 13000 pg / mL Heparin 4 mg (Waters QPXE) Plasma 1202 5-Hydroxymethyl LC-MS/MS Human 20 to Heparin - tolterodine (Waters QPXE) Plasma 10000 pg / mL LC-MS/MS Human Tolterodine 20 to 7500 pg / mL Heparin 2mg (API 4000) Plasma 1203 5-hydroxymethyl LC-MS/MS Human 10 to 7520 pg / mL Heparin - Tolterodine (API 4000) Plasma LC-MS/MS Human Tolterodine 20 to 5000 pg / mL Heparin 2 mg (Waters QPXE) Plasma 1204 LC-MS/MS Human 5-hydroxymethyl Tolterodine 10 to 5000 pg / mL Heparin - (Waters QPXE) Plasma LC-MS/MS Human 1205 Tolvaptan 2 to 600 ng / mL K EDTA 30 mg (Waters QPXE) Plasma 2 LC-MS/MS Human 1206 Topiramate 50 to 4000 ng / mL Heparin 50 / 100 mg (API 3200) Plasma LC-MS/MS Human 1207 Topiramate 10 to 600 ng / mL Heparin 25 mg (API 3200) Plasma LC-MS/MS Human Sodium 1208 Topiramate 50 to 7000 ng / mL 200 mg (API 3200) Plasma heparin LC-MS/MS Human 10 mg / 1209 Torsemide 10 to 6000 ng / mL K EDTA (API 3200) Plasma 2 20 mg

Page 65 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 1210 Torsemide 25 to 15000 ng/mL K EDTA 50mg (Waters QPXE) Plasma 2 LC-MS/MS Human 1211 Tramadol 1 to 400 ng / mL Heparin 37.5 mg / 50 mg (Waters QPXE) Plasma LC-MS/MS Human Sodium Tramadol 2 to 400 ng / mL (Waters QPXE) Plasma heparin 1212 37.5 mg / 50 mg LC-MS/MS Human Sodium O-desmethyl tramadol 0.4 to 60 ng / mL (Waters QPXE) Plasma heparin LC-MS/MS Human 2 to 800 ng/mL Sodium Tramadol (Waters QPXE) Plasma heparin 1213 200 mg Yes LC-MS/MS Human Sodium O-desmethyl tramadol 0.4 to 120 ng/mL (Waters QPXE) Plasma heparin LC-MS/MS Human Trandolapril 0.1 to 30 ng / mL Heparin - (Waters QPXE) Plasma 1214 LC-MS/MS Human Trandolaprilat 0.2 to 31 ng / mL Heparin - (Waters QPXE) Plasma LC-MS/MS Human 1215 Trazodone 5 to 3000 ng / mL K EDTA 100 mg (API 3200) Plasma 2 LC-MS/MS Human 1216 Trazodone 5 to 3000 ng / mL K EDTA 100 mg (Shimadzu 8045) Plasma 2 LC-MS/MS Human 1217 Triamcinolone Acetonide 5 to 2500 pg / mL K EDTA 40 mg / mL (API 6500) Plasma 2 LC-MS/MS Human 1218 0.05 to 10 ng / mL CPD - I N D I A D I N (API 2000) Plasma LC-MS/MS Human 1219 Trifluoperazine 20 to 6000 pg / mL K EDTA 5 mg Yes (Thermo) Plasma 2 LC-MS/MS Human Trimebutine 0.1 to 30 ng / mL K EDTA 96 mg (API 3200) Plasma 2 1220 N-Desmethyl LC-MS/MS Human 1 to 400 ng / mL K EDTA - Trimebutine (API 3200) Plasma 2 LC-MS/MS Human 1221 Trimetazidine 0.4 to 150 ng / mL Heparin 35 mg (Waters QPXE) Plasma LC-MS/MS Human 35 mg mutiple 1222 Trimetazidine 0.4 to 250 ng / mL Heparin (Waters QPXE) Plasma dose LC-MS/MS Human Sodium 1223 Trimetazidine 1 to 400 ng/mL 50 mg Yes (Waters QPXE) Plasma heparin Human 1224 Trimethoprim HPLC-UV 0.025 to 2.5 µg / mL CPD 50 mg Plasma LC-MS/MS Human 1225 Trospium 25 to 12000 pg / mL K EDTA 20 mg (API 4000) Plasma 2 LC-MS/MS Human 1226 Trospium 25 to 8000 pg / mL K EDTA 30 mg (API 4000) Plasma 2 LC-MS/MS Human 1227 Trospium 10 to 2500 pg / mL K EDTA 60 mg (API 4000) Plasma 2 U Location : Canada LC-MS Human Ursodiol 100 to 12800 ng / mL K EDTA - (API 150) Plasma 3 Glycoursodeoxycholic LC-MS Human 1228 150 to 19200 ng / mL K EDTA - Acid (API 150) Plasma 3 Tauroursodeoxycholic LC-MS Human C A N D 100 to 12800 ng / mL K EDTA - Acid (API 150) Plasma 3

Page 66 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method V Location : Canada LC-MS/MS Human 1229 Valsartan 20 to 10240 ng / mL K EDTA 160 mg (API 3000) Plasma 2 LC-MS/MS Human 1230 Valsartan 10 to 5000 ng/mL K EDTA 80 mg (Waters) Plasma 2 LC-MS/MS Human Sodium Venlafaxine 2 to 192 ng / mL 150 mg (API 3000) Plasma heparin 1231 O- LC-MS/MS Human Sodium 4 to 384 ng / mL - Desmethylvenlafaxine (API 3000) Plasma heparin LC-MS/MS Human Sodium Venlafaxine 1 to 600 ng/mL 300 mg (Thermo) Plasma heparin 1232 Orthodesmethyl LC-MS/MS Human Sodium 2 to 800 ng/mL - Venlafaxine (Thermo) Plasma heparin LC-MS/MS Human Sodium Venlafaxine 1 to 256 ng / mL 75 mg (API 3000) Plasma heparin O- LC-MS/MS Human Sodium 2 to 512 ng / mL - Desmethylvenlafaxine (API 3000) Plasma heparin N- LC-MS/MS Human Sodium 1233 1 to 256 ng / mL - Desmethylvenlafaxine (API 3000) Plasma heparin N,O- LC-MS/MS Human Sodium 1 to 256 ng / mL - Didesmethylvenlafaxine (API 3000) Plasma heparin N,N,O- LC-MS/MS Human Sodium 1 to 256 ng / mL - Tridesmethylvenlafaxine (API 3000) Plasma heparin C A N D LC-MS/MS Human Not Venlafaxine 0.1 to 13 µg / mL - (API 300 or 3000) Urine applicable LC-MS/MS Human Not O-Desmethylvenlafaxine 0.2 to 25 µg / mL - (API 300 or 3000) Urine applicable LC-MS/MS Human Not 1234 N-Desmethylvenlafaxine 0.1 to 13 µg / mL - (API 300 or 3000) Urine applicable N,O- LC-MS/MS Human Not 0.2 to 25 µg / mL - Didesmethylvenlafaxine (API 300 or 3000) Urine applicable N,N,O- LC-MS/MS Human Not 0.1 to 13 µg / mL - Tridesmethylvenlafaxine (API 300 or 3000) Urine applicable HPLC Human Verapamil 2 to 256 ng / mL K EDTA - - Flurosence Plasma 3 1235 HPLC Human Norverapamil 2 to 256 ng / mL K EDTA - - Flurosence Plasma 3 LC-MS/MS Human Sodium Verapamil 2 to 300 ng / mL 240 mg (Thermo) Plasma heparin 1236 LC-MS/MS Human Sodium Norverapamil 2 to 175 ng / mL - (Thermo) Plasma heparin

Page 67 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method HPLC Human Verapamil (chiral) 1.6 to 102 ng / mL Heparin - - Flurosence Plasma 1237 HPLC Human Norverapamil (chiral) 1.61 to 102 ng / mL Heparin - - Flurosence Plasma LC-MS Human C A N A D A D A N A C 1238 Vigabatrin 0.2 to 25 µg / mL K EDTA - (API 150) Plasma 2 Location : India LC-MS/MS Human Valacyclovir 3 to 300 ng / mL Heparin 500 mg (API 2000) Plasma 1239 LC-MS/MS Human Acyclovir 40 to 4000 ng / mL Heparin - (API 2000) Plasma LC-MS/MS Human Valacyclovir 3 to 600 ng / mL Heparin 1000 mg (API 2000) Plasma 1240 LC-MS/MS Human Acyclovir 40 to 8000 ng / mL Heparin - (API 2000) Plasma LC-MS/MS Human Valganciclovir 2 to 600 ng / mL K EDTA 900 mg (API 3200) Plasma 2 1241 LC-MS/MS Human Ganciclovir 25 to 10000 ng / mL K EDTA - (API 3200) Plasma 2 LC-MS/MS Human Valganciclovir 2 to 320 ng / mL K EDTA 450 mg (API 3200) Plasma 2 1242 LC-MS/MS Human Ganciclovir 25 to 5000 ng / mL K EDTA - (API 3200) Plasma 2 LC-MS/MS Human Valganciclovir 2.5 to 750 ng/mL K EDTA 900 mg (Waters QPXE) Plasma 2 1243 LC-MS/MS Human Ganciclovir 40 to 12000 ng / mL K EDTA - (Waters QPXE) Plasma 2 LC-MS/MS Human 1244 valganciclovir 2 to 320 ng / mL K EDTA 450 mg (API 3200) Plasma 2 Human 1245 Valproic acid HPLC-UV 1 to 110 µg / mL Heparin 500 mg Plasma LC-MS/MS Human Sodium 1246 Valproic acid 0.25 to 25 µg/mL 200mg I N D I A D I N (Waters QPXE) Plasma heparin LC-MS/MS Human Sodium 1247 Valproic acid 1 to 80 µg / mL 500 mg (Waters QPXE) Plasma heparin LC-MS/MS Human 1248 Valsartan 20 to 2000 ng / mL Heparin 40 mg (API 3200) Plasma LC-MS/MS Human 1249 Valsartan 50 to 8000 ng / mL Heparin 160 mg (API 3200) Plasma LC-MS/MS Human 1250 Valsartan 50 to 8000 ng / mL K EDTA 160 mg (API 3200) Plasma 2 LC-MS/MS Human Sodium 1251 Valsartan 50 to 20000 ng / mL 320 mg (API 3200) Plasma heparin LC-MS/MS Human 1252 Valsartan 50 to 20000 ng / mL K EDTA 320 mg (API 3200) Plasma 2 LC-MS/MS Human Valsartan 50 to 20000 ng / mL K EDTA 320 mg (Thermo) Plasma 2 1253 LC-MS/MS Human Hydrochlorothiazide 1 to 300 ng / mL K EDTA 25 mg (Thermo) Plasma 2 LC-MS/MS Human Valsartan 12 to 5000 ng/mL K EDTA 80 mg (Thermo) Plasma 2 1254 LC-MS/MS Human Hydrochlorothiazide 1 to 150 ng/mL K EDTA 12.5 mg (Thermo) Plasma 2 LC-MS/MS Human 1255 Venetoclax 1 to 400 ng/mL K EDTA 100 mg fasting (Waters QPXE) Plasma 2

Page 68 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method LC-MS/MS Human 1256 Venetoclax 1 to 700 ng / mL K EDTA 100 mg Fast (Waters QPXE) Plasma 2 LC-MS/MS Human 1257 Venetoclax 2.5 to 1500 ng/mL K EDTA 100 mg Fed (Waters QPXE) Plasma 2 LC-MS/MS Human 1258 Venetoclax 4 to 2800 ng/mL K EDTA 100 mg Fed (Waters QPXE) Plasma 2 LC-MS/MS Human Sodium 1259 Venlafaxine 0.25 to 300 ng / mL 150 mg (Waters QPXE) Plasma heparin

LC-MS/MS Human Venlafaxine 1 to 600 ng / mL Sodium Heparin 150 mg /225 mg (Waters QPXE) Plasma 1260 LC-MS/MS Human O-Desmethyl Venlafaxine 2 to 800 ng / mL Sodium Heparin - (Waters QPXE) Plasma

LC-MS/MS Human Venlafaxine 0.5 to 200 ng / mL Heparin 75 mg (Thermo) Plasma 1261 LC-MS/MS Human O-Desmethylvenlafaxine 1 to 250 ng / mL Heparin - (Thermo) Plasma

HPLC Human Verapamil 2 to 250 ng / mL Heparin - - Flurosence Plasma 1262 HPLC Human Norverapamil 2 to 250 ng / mL Heparin - - Flurosence Plasma

LC-MS/MS Human Verapamil 4 to 300 ng / mL Heparin 240 mg (Waters QPXE) Plasma 1263 LC-MS/MS Human Norverapamil 2 to 177 ng / mL Heparin - (Waters QPXE) Plasma

LC-MS/MS Human Verapamil 4 to 300 ng / mL Heparin 240 mg (Waters QPXE) Plasma I N D I A D I N LC-MS/MS Human Norverapamil 2 to 177 ng / mL Heparin - (Waters QPXE) Plasma 1264 LC-MS/MS Human Trandolapril 0.05 to 15 ng / mL Heparin 4 mg (Waters QPXE) Plasma

LC-MS/MS Human Trandolaprilat 0.4 to 31 ng / mL Heparin - (Waters QPXE) Plasma

LC-MS/MS Human Sodium 1265 Vardenafil 0.2 to 80 ng / mL 20 mg (Waters QPXE) Plasma heparin

LC-MS/MS Human 1266 0.1 to 40 ng / mL K EDTA 10 mg (Waters QPXE) Plasma 2

LC-MS/MS Human 1267 Vilazodone 0.5 to 200 ng/mL K EDTA 40 mg (Waters QPXE) Plasma 2

LC-MS/MS Human Sodium 1268 Vildagliptin 1 to 500 ng/mL 50 mg (Waters QPXE) Plasma Heparin

LC-MS/MS Human Sodium 1269 Vildagliptin 2 to 1000 ng/mL 100mg stedy state (Waters QPXE) Plasma Heparin

Human Plasma LC-MS/MS 1270 *Vitamin D3 & Artificial 0.25 to 20 ng/mL K EDTA 60000 IU (Thermo) 2 Matrix

LC-MS/MS Human 1271 Voriconazole 1 to 700 ng / mL K EDTA 50 mg (API 3200) Plasma 2

LC-MS/MS Human 40mg/mL or 200 1272 Voriconazole 5 to 4000 ng / mL K EDTA (API 3200) Plasma 2 mg

Page 69 of 76 Lambda Therapeutic Research SMALL MOLECULES New / Sr. No. Drug Name Instrument Matrix Range Anticoagulant Dose Modified Method W Location : Canada

LC-MS/MS Human R-Warfarin 1 to 512 ng / mL K EDTA - (API 3000) Plasma 3 1273 LC-MS/MS Human S-Warfarin 1 to 512 ng / mL K3EDTA - C A N A D A (API 3000) Plasma Location : India

HPLC Human 1274 Warfarin 10 to 750 ng / mL Heparin 5 mg - Flurosence Plasma

HPLC Human

I N D I A D I N 1275 Warfarin 20 to 2500 ng / mL Heparin 10 mg - Flurosence Plasma Z Location : Canada LC-MS/MS Human 1276 0.125 to 64 ng / mL K EDTA 5 mg (API 3000) Plasma 2 LC-MS/MS Human 1277 Ziprasidone 0.5 to 256 ng / mL K EDTA 40 mg (API 3000) Plasma 2 LC-MS/MS Human 0.2 to 20 ng/mL K EDTA 5mg Nasal spray (Thermo) Plasma 2

C A N D 1278 LC-MS/MS Human N-desmethyl Zolmitriptan 0.1 to 10 ng/mL K EDTA 5mg Nasal spray (Thermo) Plasma 2 HPLC Human 1279 Zolpidem 1 to 512 ng / mL K EDTA 10 mg - Flurosence Plasma 3 Location : India HPLC Human 1280 Ziprasidone 1.5 to 200 ng / mL NA 40 mg - Flurosence Plasma LC-MS/MS Human Zolmitriptan 0.2 to 30 ng / mL Heparin 5 mg (Waters QPXE) Plasma 1281 LC-MS/MS Human N-desmethyl Zolmitriptan 0.2 to 20 ng / mL Heparin -

I N D I A D I N (Waters QPXE) Plasma LC-MS/MS Human 1282 Zolpidem 1 to 300 ng / mL K EDTA 10 mg (API 3200) Plasma 2 Human 1283 Zonisamide HPLC-UV 25 to 3000 ng / mL NA 100 mg Serum

*: Premium method

Page 70 of 76 Lambda Therapeutic Research NEW CHEMICAL ENTITIES (FULL NAME WITHHELD DUE TO CONFIDENTIALITY) Sr. No. Drug Name Instrument Matrix LLOQ Anticoagulant Location : Canada Rat Plasma LC-MS/MS New Chemical Entity - 1a or 0.5 ng / mL Lithium heparin (Thermo) Dog Plasma 1 Rat Plasma LC-MS/MS New Chemical Entity - 1b or 0.8 ng / mL Lithium heparin (Thermo) Dog Plasma LC-MS/MS Human 2 New Chemical Entity - 2 0.8 ng / mL Lithium heparin (Thermo) Plasma LC-MS/MS Dog cerebrospinal 3 New Chemical Entity - 3b 0.8 ng / mL Not applicable (Thermo) fluid HPLC - New Chemical Entity - 4 (±) Human Plasma 5 ng / mL K EDTA C A N D Flurosence 2 HPLC - 4 New Chemical Entity - 4a (±) Human Plasma 5 ng / mL K EDTA Flurosence 2 HPLC - New Chemical Entity - 4b (±) Human Plasma 5 ng / mL K EDTA Flurosence 2 LC-MS/MS 5 New Chemical Entity - 5 Human Plasma 2.94 ng/mL K EDTA (Thermo) 2 LC-MS/MS 6 New Chemical Entity - 6 Human Plasma 1.96 ng/mL Not applicable (Thermo) Location : India LC-MS/MS 7 New Chemical Entity-01 Human Plasma 5 ng / mL K EDTA (API 4000) 2 LC-MS/MS New Chemical Entity-02 Human Plasma 0.5 ng / mL K EDTA (API 4000) 2 8 N-Oxide of New Chemical Entity- LC-MS/MS Human Plasma 0.5 ng / mL K EDTA 02 (API 4000) 2 LC-MS/MS 9 New Chemical Entity-03 Human Plasma 5 ng / mL K EDTA (API 4000) 2 LC-MS/MS 10 New Chemical Entity-04 Human Plasma 10 ng /mL K EDTA (API 4000) 2 LC-MS/MS 11 New Chemical Entity-05 Human Plasma 1 ng /mL K EDTA & K EDTA (API 4000) 2 3

LC-MS/MS 12 New Chemical Entity-06 Monkey Plasma 50 ng / mL K EDTA (Waters QPXE) 2 I N D I A N D I I LC-MS/MS New Chemical Entity-07a Human Plasma 1 ng / mL K EDTA (API 4000) 2 13 LC-MS/MS New Chemical Entity-07b Human Plasma 10 ng / mL K EDTA (API 4000) 2 LC-MS/MS 14 New Chemical Entity-08 Human Plasma 2 ng / mL K EDTA (API 4000) 2 LC-MS/MS 15 *New Chemical Entity-09 Human Plasma 2 ng / mL K EDTA (Thermo) 2 LC-MS/MS

16 *New Chemical Entity-10 (Waters Human Plasma 20 ng / mL K2EDTA XEVO TQ-S) LC-MS/MS 17 New Chemical Entity-11 Human Plasma 0.2 to 100 ng / mL K EDTA (API 4000) 2 *: Premium Method

Page 71 of 76 Lambda Therapeutic Research IN-VITRO STUDIES

Sr. No. Drug Name Instrument Matrix Range Anticoagulant Location : India

*Doxorubicin (Encapsulated and LC-MS/MS Human 1 2500 to 250000 ng / mL K EDTA Total) (Liposomal) (Waters) Plasma 2

*Doxorubicin (Encapsulated and LC-MS/MS Human 2 0.5 to 25 µg / mL K EDTA Total) (Liposomal) (Waters QPXE) Plasma 2

LC-MS/MS Human 3 *Doxorubicin (Free) (Liposomal) 100 to 10000 ng / mL K EDTA (Waters) Plasma 2

LC-MS/MS Human 4 *Doxorubicin (Free) (Liposomal) 3 to 1800 ng / mL K EDTA (Waters QPXE) Plasma 2

*: Premium Method

Page 72 of 76 Lambda Therapeutic Research

IMMUNOGENICITY ASSESMENT

Sr. No. Molecules

1 Screening, Confirmatory assays for Antibodies against Darbepoetin (Bridging ELISA)

2 Neutralising assay for antibodies against Darbepoetin (Cell based Assay)

3 Screening, Confirmatory assays for Antibodies against Erythropoietin (Bridging ELISA)

4 Neutralising antibodies to Erythropoietin (Cell based Assay)

5 Screening, Confirmatory assays for Antibodies against Ranibizumab by (Bridging ELISA)

Screening, Confirmatory assays for Antibodies against Rituximab (Affinity Capture and Elution based 6 ELISA)

7 Screening, Confirmatory assays for Antibodies against Trastuzumab (Bridging ELISA)

8 Screening, Confirmatory assays for Antibodies against Denosumab (Bridging ELISA)

9 Screening, Confirmatory assays for Antibodies against Teriperatide (ELISA)

10 Screening, Confirmatory assays for Antibodies against PEG-GCSF (ECL-MSD)

11 Cell based assay for detection of neutralizing antibodies against PEG-GCSF

12 Screening, Confirmatory assays for Antibodies against GCSF (ECL-MSD)

13 Cell based assay for detection of neutralizing antibodies against GCSF

14 Screening, Confirmatory assays for Antibodies against Romiplostim (ELISA)

15 Cell based assay for detection of neutralizing antibodies against Teriperatide

16 Screening, Confirmatory assays for Antibodies against FSH (ELISA)

17 *Cell based assay for detection of neutralizing antibodies against FSH

*Elisa based method for determination and characterization of neutralizing antibodies against 18 Bevacizumab in normal human serum samples Elisa based method for Immunogenicity assessment of Bevacizumab in normal human serum 19 samples

*: Developed method available

Page 73 of 76 Lambda Therapeutic Research

PD MARKERS Sr. No PD Markers/Surrogate PD markers 1 3 Beta-D- Glucan 2 Absolute Neutrophil Counts (ANC) (Flow Cytometry) 3 ACTH (Adrenocorticotropic hormone) 4 Anti-Factor IIa activity of Enoxaparin (Colorimetric Method) 5 Anti-Factor Xa activity of Enoxaparin (Colorimetric Method) 6 Anti-Factor IIa activity of Low molecular weight heparin (Colorimetric Method) 7 Anti-Factor Xa activity of Low molecular weight heparin (Colorimetric Method) 8 Apolipoprotein A1 (Immunoturbidimetric) 9 Apolipoprotein B 10 BAP- Bone specific Alkalinephosphatase (ELISA) 11 Basophil Activation Test (Flow Cytometery) 12 Beta 2 Microglobulin (ELISA) 13 Clostridium Difficile Toxin-A & B 14 Cluster of Differentiation 34 - CD 34 (Flow Cytometery) 15 Cluster of Differentiation 19 - CD19 (Flow Cytometery) 16 CMV-IgM (Cytomegalovirus Antibody) 17 C-peptide 18 Corrected serum Calcium 19 Cortisol(Serum) 20 Direct- LDL-C (photometric) 21 Ecarin Clotting Time for Bivaluridin (Clot Based Assay) 22 Erythropoetin (ELISA) 23 Estradiol 24 Ferritin 25 Free T3 & Free T4 26 Fructosamine 27 Glucose (Glucose Oxidase Peroxidase Method) 28 Glycosylated Haemoglobin 29 Hep Test (Clot Based Assay) 30 High Sensitivity C-Reactive Protein (hs-CRP) 31 Human Serum Adiponectin-HMW (ELISA) 32 Human Serum Adiponectin-Total (ELISA) 33 Human Serum/Plasma Glucagon 34 IL-6 (Interleukin-6)

Page 74 of 76 Lambda Therapeutic Research

PD MARKERS Sr. No PD Markers/Surrogate PD markers 35 Insulin 36 Interferon Gamma Release Assay (IGRA) by ELISA 37 Leutinizing Hormone(LH) 38 Lipoprotein (a) 39 NEFA/FFA (Non Esterified Fatty Acids/Free Fatty Acid) 40 Osmotic Fragility of Red Blood Cells 41 Progesterone 42 PSA

43 Platelet Function (Platelet aggregation ) by Whole Blood using Impedence Aggregometry(Chrono-Log)

44 Reticulocyte Count (Flow Cytometry) 45 Rheumatoid Factor(RF/RA) 46 RLP[ Remnant Lipoprotein] cholesterol (ELISA) 47 Sputum Eosinophil & Neutrophil 48 Testosterone 49 TFPI [Tissue Factor Pathway Inhibitor] (ELISA) 50 TNF-alpha High Sensitivity (ELISA) 51 Transferrin saturation 52 TRAP(Tartrate Resistant Alkaline phosphatase) 53 Urine Alpha-GST (ELISA) 54 Urine Glucose

*Developed method available

Page 75 of 76 Lambda Therapeutic Research

EVALUATION OF EFFECTIVENESS OF HEALTHCARE HYGIENE PRODUCTS Validated Protocols

Sr. No Title

ASTM-E1174 - Standard Test Method for Evaluation of the Effectiveness of Health Care Personnel 1 Handwash Formulations.

2 ASTM-E1054- Standard Test Method for Evaluation of Inactivators of Antimicrobial Agents.

ASTM E1874 - Standard Test Method for Recovery of Microorganisms from Skin using the Cup Scrub 3 Technique.

4In-vitro assay for evaluating the efficacy of Oral Care Formulations

5Thiol production (BDCOH) assay for evaluating the effectiveness of Oral Care Formulations

6 EN-1276 Chemical disinfectants and antiseptics (under validation)

7 EN-13697 Chemical disinfectants and antiseptics (under validation)

A cosmetic study to assess the effectiveness of test toothpaste formulation compared to a standard 8 fluoride toothpaste and a commercially available toothpaste on plaque 1 and 12 hours after brushing.

9 Salivary sediment viability method

Examine the effects of oral care formulations on oral (S.mutans ATCC 25175) bacteria used of time-kill 10 assay

11 Plaque Biofilm method time kill assay

12 Method for quantification of Cetylpyridinium chloride(cpc) from clay surface

13 Zone of Inhibition Method to check the effectiveness of antibacterial effect of Mouth wash

Comparative evaluation of for viable spore count of Bacillus clausi after acid challenge and temperature 14 challenge.

To evaluate the efficacy of hand wash formulations, by measuring levels of residual bacterial count after 15 washing/rinsing, based on ASTM E2870-13 method on the palms of normal volunteers

Page 76 of 76

INDIA: Lambda Therapeutic Research Ltd. Lambda House, Survey No. 388, Nr. Silver Oak Club, Off. S. G. Highway, Gota, Ahmedabad – 382 481, India Fax +91-79-40202021 Web: www.lambda-cro.com

CANADA: Lambda Therapeutic Research Inc, 460 Comstock Road, Toronto, Ontario, Canada M1L 4S4 phone: +1416.752.3636 www.lambdacanada-cro.com

Follow us on:

www.lambda-cro.com